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ABSTRACT 
The level of sophistication associated with modern radiotherapy techniques such as 
Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc 
Therapy (VMAT) continues to increase, placing increasing demands on the current 
Quality Assurance (QA) procedures that ensure patient safety. There is therefore a 
significant need for real-time detectors that provide verification of IMRT and VMAT 
during the delivery of a patient’s cancer treatment. Current QA procedures typically 
involve a pre-treatment dosimetric verification to ensure that the linac is delivering the 
dose map as specified by the computerised radiotherapy treatment plan calculation. A 
transmission type detector consisting of a two dimensional (2D) array of silicon diodes, 
“Magic Plate” (MP), is one potential candidate that would allow for online dosimetry in 
real time, during the patient treatment. This is the focus of the studies presented in this 
thesis.  
The first part of this thesis is to demonstrate the potential performance characteristics of 
a silicon diode array called the Magic Plate (MP) quality assurance system when 
operated in dose mode (MPDM), as a dosimeter, i.e. on the patient couch embedded in a 
solid water phantom at several depths and different beam energies. These characteristics 
are then taken into account in the later chapters to compare with the reconstructed 2D 
and /or three dimensional (3D) dose in a phantom at several depths.  
The second part of this thesis demonstrates that for the two potential operational set-up 
conditions (i.e. different build up) of the Magic Plate when operated in transmission 
mode (MPTM) at different field sizes, treatment configurations and beam energies, the 





(both in field and out of field). A beam perturbation of < 0.5 % increase in the skin dose 
and < 0.5 % change in dose at depth in a solid water phantom is reported. This small 
change demonstrates that the MPTM is suitable as an instrument for real-time 
verification of VMAT and IMRT during patient treatment.  
The third part of this work is to describe the characterisation of the radiation response of 
MPTM. This mode of MP operation is designed to be used to sense the 2D energy 
fluence maps of the modulated radiation beam. For the MPTM investigation two 
potential operational set-up conditions have been studied: 
(a) The bare MP array sandwiched between black plastic sheets, 80 µm thick, here in 
referred to as “the bare MPTM”. 
 (b) The bare MP array with an additional 1 mm of solid water covering the entire array, 
here in referred as “MPTM with 1 mm build up”.  
In addition, the response of the MPTM was investigated for different field sizes and 
different treatment configurations ranging from 1×1 cm
2
 to 40×40 cm
2
 defined by the 
multi-leaf collimators (MLCs) only or MLCs and linac jaws. This study emphasises 
how having the MLCs fully retracted or matching the shape of the linac jaws influences 
the response of the MP operating in transmission mode. Moreover, to determine the 
significance of the different electron contamination and photon scattering conditions 
and the corresponding effect these conditions may have on the measured MPTM 
response.  
The last part of this thesis demonstrates that the 2D transmission response data can be 
used to reconstruct the dose in 2D or 3D in real time along rays projected from the 
photon source through each MP sensor element. Hence the dose can potentially be 






An algorithm has been developed, that predicts the dose in the patient/or and in the 
phantom based on the measured intensity of the X-ray distribution in the beam using 
MPTM. This can be checked against the planned dose and if they disagree the treatment 
can be stopped automatically and immediately. 
In transmission mode the MP is positioned in the block tray of a linac so that the central 
detector of the array lies on the central axis of the radiation beam. The MPTM response 
is proportional to the projected 2D dose map measured at a specific phantom depth, the 
“sweet depth”. A single factor, for several irradiation field sizes and depths, is derived 
to reconstruct the dose in the phantom along rays projected from the photon source 
through each MPTM detector element. The performance of the sensor system and 
reconstruction method for several square irradiation field sizes, as well as very 
asymmetric irradiation field geometries, is investigated with reconstruction in solid 
water phantom.  It is demonstrated that for all field sizes using the above method, the 
2D reconstructed and measured doses agree to within ± 2.48 % (2 standard deviation) 
for all in-field MP detector elements.  
Importantly also, is the direct confirmation that the sensor array, positioned upstream of 
the patient, does not significantly perturb the irradiation field depth dose profile, 
including the dose in the build-up region. The online monitoring and reconstruction may 
also be applicable to other complex forms of radiotherapy including Stereotactic 
Radiotherapy and Motion Adaptive Radiotherapy where real-time radiation treatment 
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For patients diagnosed with cancer, 52% would benefit from  radiotherapy to optimise 
their treatment outcome [1, 2]. Radiotherapy is a treatment that aims to deliver a 
sufficient radiation dose to the tumour to guarantee tumour control as long as the 
probability of serious side effects remains sufficiently low. As a result, the tumour 
control probability (TCP) has to be balanced against the normal tissue complication 
probability (NTCP). For some types of cancer, those probability curves are well defined 
and it is established that the outcome of a radiotherapy treatment depends on doses that 
do not vary by more than ± 5 % from the optimum. This accuracy requirement is 
generally extended to all treatments, though some studies highlight the need for higher 
accuracy in some situations [3, 4].  
Currently, the use of in vivo dosimetry is recommended for some complex treatment 
deliveries following recommendations by many national and international organisations 
[5, 6]. More complex treatment techniques such as IMRT and VMAT introduce new 
challenges and requirements. Increasing delivery precision from IMRT and VMAT is 
accompanied by increases in treatment complexity which raises the potential risk of 
accident due to a delivery error, hence online dosimeters used in vivo would be ideal. 
Therefore the need to provide real-time dosimetry devices with high spatial resolution, 





dosimeters in situ. Hence non-invasive dosimetry monitoring systems have become an 
attractive proposition to alert to any treatment delivery errors. QA systems currently 
available are too bulky or interfere detrimentally with the radiotherapy treatment 
delivery to be used during patient treatment [7, 8]. 
The Centre for Medical Radiation Physics (CMRP) at the University of Wollongong 
(UoW), Australia, has developed a 2D silicon diode array dosimeter called the Magic 
Plate (MP).The MP system is capable of providing real-time dosimetric and/or 
transmission radiation response information to the radiation oncologist and 
radiotherapist while the patient is being treated. The 2D array is different from other 
commercially available 2D arrays with its unique packaging design which exhibits 
advantages over conventional dosimeters. These benefits will be explored in this thesis. 
 
1.1 Thesis objectives 
This thesis demonstrates the real-time operation of an 11×11 semiconductor 2D diode 
array MP, which is specifically designed to be sensitive to the energy fluence without 
perturbing the radiation field incident on the patient. The array is therefore positioned 
between the linac radiation source and the patient, and utilised as a transmission 
detector during radiation treatment. 
 Real-time verification and 2D or 3D dose reconstruction on daily patient anatomy have 
the potential to improve treatment delivery, safety and accuracy during patient 
treatment. Recalculation of dose based on online fluence measurements with a 
transmission detector attached to the linac head is one possible implementation. This 
thesis provides a comprehensive analysis of the influence of the Magic Plate on 






Objective 1: To demonstrate the potential performance characteristics of the MP 
system when operated in dose mode (MPDM), i.e. in a phantom on the patient couch 
placed under the linear accelerator treatment beam. Objective 1 of this thesis is to repeat 
some of the work of Wong et al [9] at 6 MV (such as the field size dependence) and 
then extend this work to 10 and 18 MV photon beams to assess the operation of the MP 
in these significantly different radiation field environments (e.g. including neutrons 
presence on 18 MV photon beam). The research performed in relation to objective 1 is 
outlined in Chapter 4 and describes the following characterisation measurements  of the 
MPDM that were carried out such as: response to different field sizes, dose beam 
profiles derivation, the water equivalent depth (WED) for surface dosimetry and the 
response of the diode array for different frequency of the linac pulses.  
 
Objective 2: To demonstrate the performance characteristics of the MPTM system 
upstream of the patient. Of particular interest is to quantitatively study the effect of 
packaging of the MP (with and without 1 mm build-up/filtering material on the top of 
the MP) on response of the MPTM for different field sizes and photon beam energies. 
Any beam perturbation effects, leading to changes in the skin dose and/or the 
percentage depth dose (PDD) (both in and out of field) are examined.  In addition, the 
effect on the 3D dose distribution measured by the Delta
4®
 QA system was also 
investigated. The transmission factor for both of these MPTM setups in the central axis 
was performed. This is performed in Chapter 5.   
 
Objective 3: To describe the characterisation of the radiation response of the MPTM. 
This mode of MP operation is designed to be used to verify the dose from IMRT and 





modulated radiation beam. A demonstration of this concept is performed in Chapter 6. 
However, direct verification of a VMAT or IMRT plans not form a part of this thesis. 
Important parameters related to this concept are studied for the MPTM including 
linearity of response, reducibility, uniformity, the effect of forward scattered electrons 
from the jaws on the array detector response, the response of the array with different 
dose rates, energy response, and back scattering effect. 
 
Objective 4: To demonstrate how the 2D transmission response data can be used to 
reconstruct the dose in 2D or 3D in real-time along rays projected from the photon 
source through each sensor element. As it can be performed in real-time, dose can be 
reconstructed segment by segment or pulse by pulse for IMRT and/or VMAT 






CHAPTER 2  
 
                     Literature Review 
 
This chapter aims to provide an extensive background on modern QA detector 
technologies, specifically for the treatment of IMRT and VMAT. 
 
2.1 Cancer Data 
Cancer is defined as the uncontrolled malignant growth (cell division beyond normal 
limits) of a group of cells caused by a series of changes in the genome  [10, 11]. 
According to a study released by the Australian Institute of Health and Welfare, 
(Canberra) and the Australasian Association of Cancer Registries (AIHW & AACR, 
2015); 126,800 (69,790 males and 57,010 females) new cases of cancer were estimated 
in Australia in 2015, and cancer is the cause of approximately 3 in every 10 deaths 
registered in Australia [12]. This makes cancer the second most common cause of death 
behind cardiovascular disease. The five most common types of cancer diagnosed and 
reported were prostate cancer among males (with 17,250 cases diagnosed), bowel 
cancer ( 17,070 cases), breast cancer in females ( 15,740 cases), melanoma of the skin ( 
12,960 cases), and finally lung cancer (11,880 cases) [12]. However, the number of 
deaths has fallen for most cancer sites due to the development of treatments and the 






2.2 Review of Radiation Therapy 
Radiotherapy is a complex procedure that uses a dose of ionising radiation to the 
tumour. Beams may be composed of different particles, including; electrons, photons 
(X-rays) or protons  [13]. The use of X-rays delivered by linear accelerators dominates 
the delivery methods. 
 In practice, radiotherapy can be used alone or in combination with other treatments, 
such as chemotherapy or surgery, to treat cancers such as lung cancer and breast cancer 
[1]. The objective of optimal radiotherapy is to damage the DNA of tumour cells 
causing cell death and minimise the damage to the healthy normal tissue [13]. Research 
carried out by the Collaboration for Cancer Outcomes Research and Evaluation 
(CCORE) assessed that 52.3% of all cancer patients would benefit from radiation 
therapy treatment [14]. Hence, approximately one in every two cancer patients would 
benefit from radiation therapy referral.  
There are several methods used to deliver radiation to the patient. The most common 
type of radiotherapy is external beam radiation therapy (EBRT), which predominately 
uses medical linear accelerators [15, 16]. In this method the beam of radiation comes 
from outside the body, and is directed towards a target inside the body [17]. Other 
delivery methods include internal radiation therapy (otherwise known as brachytherapy 
[17]) and radioisotope therapy (or unsealed source radiotherapy) but these are outside 
the scope of this thesis.  
One significant enhancement  in EBRT came in the early 1970s with the use of X-ray 
transmission computed tomography (CT scanning) in clinical diagnostic radiology [18]. 
Since then CT scanning has been applied to radiotherapy planning to describe the 





been used in tumour localisation, and provides detailed information about surrounding 
healthy tissue [18].  
 The conventional approach of 3D conformal radiation therapy involves the 
combination of several irregularly shaped fields at different gantry angles. It can reduce 
toxicity to the neighbouring healthy tissue when delivering radiation to the deep seated 
tumours [16, 19, 20]. Irregularly shaped radiation beams were historically delivered by 
using blocking material. However the introduction of  MLCs which facilitates the use of 
fast field shaping enabled practical implementation of 3D conformal radiation therapy 
[1, 19]. Three-dimensional conformal radiation therapy (3D CRT) uses MLCs to define 
irregular shaped field boundaries, where multiple radiation beams can be used that each 
have been custom shaped to conform the dose to the tumour guided by the 3D CT 
images [19]. In 3D conformal radiation therapy the field shape covers the beam’s eye 
view projection of the target volume from each gantry angle and it represents a change 
from  traditional methods which did not spare normal structures adequately [19].     
IMRT represents a sub-set and new generation of 3D conformal radiation therapy [19, 
21]. Brahme et al (1982) published their paper which has been considered as the key 
theoretical article on IMRT [22, 23]. They introduced the problem of treatment planning 
as an inverse problem, contrasting it to forward planning which had been previously 
used. IMRT delivery increased the dose gradient between the tumour and the 
surrounding healthy organs [24].The historical development and modern practice of 
IMRT delivery methods was reviewed and studied in greater detail by Webb [23]. 
Radiotherapy delivery has thus become more precise, and the margin of error has been 
reduced [25]. However, there still remains problem that patient organs can move during 
the treatment delivery. The major challenge in the delivery of the desired dose by using 





thorax) due to respiration [26]. Radiation therapy delivery has been further developed to 
overcome these problems and they are addressed by a new technique called motion 
adaptive radiation therapy, where imaging systems determine the tumour position and 
the radiation beam is adapted to the dynamically changing tumour position [27, 28]. 
This allows the control of the irradiation of the tumour to be maximised without 
increasing treatment side effects. An even more recently available technique on linear 
accelerators is the use of real-time imaging for organ motion tracking by dynamic multi-
leaf collimator (DMLC) tracking. In DMLC tracking, each leaf that shapes the radiation 
beam has its position optimised in real-time to continuously align the radiation beam 
with the tumour. Several studies have made a significant step to minimising treatment 
time and reducing the radiation dose to the normal tissue due to respiratory motion by 
using the DMLC tracking technique. [27, 29-32]. Several methods exist to overcome 
organ motion (such as by the respiratory gating technique) that can lead to longer 
treatment times and are undesirable. Sawant et al (2008), Keall et al (2000), Falk et al 
(2010) and others have been focusing on many features of DMLC tracking such as 
tumour position, motion production, four-dimensional (4D) imaging, planning, and 
accurately targeting treatment. This advanced treatment needs a suitable QA dosimetry 
tool for routine clinical practice, one with an ability to imitate the moving organ in a 
tissue equivalent phantom. Several papers have been published on the dosimetric 
verification of DMLC technology and also for tracking movable organs [25, 27, 31, 33-
38].  
In vivo dosimetry refers to a process of direct radiation dose measurement in a patient 
which occurs either during diagnostic examination or radiation treatment. The process 





positioned upon the entrance or exit patient surface or invasively through implantation 
of the dosimeter at a point of interest.  
In radiotherapy in vivo dosimetry is performed noninvasively as a part of quality 
assurance programs. Indirect comparison between the dose that was prescribed and the 
dose that was delivered for a particular treatment field can be facilitated by in vivo QA 
programs. This provides additional protections against major setup faults and errors in 
calculation or transcription which were overlooked during the patient’s primary 
examinations [39-44]. In a perfect scenario, in vivo dosimetry protocols provide 
evidence that the treatment was conveyed correctly, in accordance with the user 
specified tolerances. 
The high accuracy maintained in dose delivery that is expected from complex and 
conformal radiotherapy treatments can be supported by in vivo dosimetry [45, 46]. 
Access to thermoluminescent detectors (TLDs) or other in vivo systems by clinics is 
highly recommended by the AAPM TG 40 (Comprehensive QA for radiation 
Oncology)[5] .Without increasing the duration of the treatment session, a clear and 
precise in vivo dosimetry program should be able to identify most faults. 
Patients undergoing radiotherapy treatments at multiple facilities experienced 120 
treatment faults that exceeded the 5% threshold, identified by in vivo dosimetry 
systems, in a review administrated by the International Atomic Energy Agency (IAEA) 
[6]. The conclusion of the review identified that in a recent case in Panama a well 
placed in vivo dosimetry program might have mitigated or prevented the overexposure 
of 28 patients. It was a recommendation of the report that adoption of in vivo dosimetry 
be encouraged in the departments of radiotherapy, however, appropriate planning and 





In vivo dosimeters used for performing measurements of entrance and exit dose are 
generally positioned upon the patient’s skin. The measurement of entrance dose enables 
detection of errors in delivery which may be attributed to human error or equipment 
malfunction. The exit dose allows for detecting additional dose delivery uncertainties 
caused by heterogeneities in tissue (e.g. air cavities, bone etc.). The measured and 
calculated doses are then compared for both cases. If the difference between these doses 
exceeds the user specified range, the result may be used to detect and identify numerous 
serious faults upon further investigation. Reports from other publications have also 
stated that faults in the calibration of some machines were identified using in vivo 
dosimetry[47]. The institution and the guidelines of the in vivo dosimetry program 
determines the accepted range between the measured and calculated dose, nevertheless, 
a ± 5% uncertainty limit has been suggested by some publications for all entrance dose 
measurements executed [42, 47-49]. 
 
2.2.1 Intensity modulated radiation therapy (IMRT) 
IMRT is an advanced radiation treatment delivery technique [9, 19]. IMRT is delivered 
as a sequence of many small beam segments per fixed gantry angle that enter the body 
from several gantry angles (different directions) [17]. With these multiple beams (or 
segments) the intensity of radiation of each field can be modulated to achieve a high 
dose to the tumour while sparing the surrounding healthy tissue. The sum of these 
multiple beams or segments can produce a non-uniform radiation field. The intensity of 
the radiation is modulated or more precisely the dose map is changed by using a MLC, 
which consists of individual leaves of a high atomic number material, such as tungsten, 
which can move in and out in real-time in the field to create a structure of complex field 





field, this requires a highly sophisticated computing application which can perform 
optimisations for a number of beam gantry angles in order to plan an optimum dose to 
the tumour. This is called ‘inverse treatment planning’. Many papers and books have 
studied inverse treatment planning in detail and many references to it can be found in 
the literature [50-55]. 
There are two techniques that are generally used to deliver static gantry IMRT dose 
distributions, “step and shoot” and “dynamic sliding window” deliveries. Both of these 
techniques deliver an IMRT beam with fixed (static) angles [56].  
In a step-and-shoot delivery, the beam of radiation is only delivering dose when the 
MLC leaves are stationary (fixed) (i.e. shoot). Whenever the leaves are changed from 
one segment to another, (i.e. step) the radiation beam is held off. On the other hand, in 
the dynamic sliding window delivery technique the radiation beam is on all the time 
when the leaves of the MLC are swept across the field [56, 57]. 
The safe clinical implementation of IMRT requires at least two systems before actual 
clinical use: The first one is the treatment planning computer system which can 
calculate the non-uniform fluence maps from multiple beam angles to deliver a high 
dose to the tumour while delivering a low dose to healthy organs. The second system is 
to deliver the non-uniform fluence as planned. Both of these systems must be tested and 
commissioned before clinical use and the QA programme should be performed for pre-
treatment, daily, monthly, and yearly verifications [58]. 
 
2.2.2 Volumetric modulated arc therapy (VMAT) 
The intensity modulated arc therapy (IMAT) technique was presented in a paper by Yu 
in 1995 [59]. In this technique the MLC can be used dynamically to shape and reshape 





being delivered to the patient. VMAT is similar to IMRT. However while IMRT is a 
static gantry delivery, in VMAT the gantry of the linear accelerator (linac)  rotates [58, 
60]. In VMAT the dose is generally delivered to the entire planning target volume 
(PTV) in a single or double rotation. Linear accelerators now have the capability to 
deliver VMAT, where MLC segments, dose rate, and gantry speed are varied 
simultaneously while the gantry is rotating. The two variables; gantry speed and dose 
rate are the enhancements that differentiates VMAT from IMAT and this significantly 
speeds up the treatment delivery. VMAT uses all angles that are available in the inverse 
plan, which can produce a better conformal dose distribution than IMRT [61, 62]. 
Studies have recommended that VMAT can be used as effectively as IMRT for different 
and complicated treatment sites, such as for head and neck treatments [60, 62, 63]. 
 The main advantage of VMAT compared to IMRT is that the former shortens the 
treatment time which may play a role in reducing both patient discomfort and intra-
fraction motion, and provide faster delivery than IMRT. One drawback of VMAT 
verification is that the dose verification is slightly more difficult, as there is one extra 
parameter; gantry rotation. In addition, dosimeters may display an angular dependence 
which must be corrected for, increasing the difficulty of verification techniques [62]. 
 
2.2.3 Stereotactic Radiotherapy/Radiosurgery 
Stereotactic radiotherapy has been under development for over 50 years; however, this 
form of treatment has only been used in radiation oncology for the past 15 years [64]. 
Grosu et al. state that stereotaxy is that method where a point is defined in the patient’s 
body by a 3D external coordinate system [64].  Stereotactic radiosurgery (SRS) is a 
single fraction of radiation therapy with a combination of a stereotactic apparatus and 





spread to other clinical sites due to its high geometrical precision and its ability to be 
applied to treat small tumours [64, 66].  
Stereotactic body radiation therapy (SBRT) is a very similar technique to SRS but is 
used for targets that are outside the brain and the spine. SBRT is most commonly used 
for targets in the lung, spine, liver, pancreas and kidney. In modern terminology, the 
term Stereotactic ablative radiation therapy (SABR)/SBRT is proposed to an external 
beam radiation therapy treatment that delivers a high dose of radiation with high 
geometric precision to an extra-cranial target. As this is performed with only one or few 
fractions and involves steep dose gradients, specialised planning and treatment delivery 
techniques are needed, with associated specific QA requirements [67].  A course of one 
to five fractions is typically delivered in SBRT[68].  
Recently, small irregular fields of X- rays have been shaped to irregular targets, with a 
high radiation dose delivered within a single session [66]. Therefore, accurate dosimetry 
is very important as the position and the dimensions of the field must be precisely 
matched and an accurate dose delivered to the target [69]. 
 
2.3 Current quality assurance and dosimetric verification 
 
2.3.1 Introduction 
The complexity of the IMRT delivery system requires the verification of the dose 
delivery [23]. Therefore, the successful clinical implementation of IMRT requires 
verifying the consistency between the dose calculated and the dose delivered to the 
patient [70]. Treatment plans generally are not implemented clinically until the 
calculated dose distribution is verified by an independent method. The treatment plan 





patient. Measurement of the dose to patient skin is viable but is labour intensive and 
increases dose to patient skin. Another way to verify the dose indirectly is to irradiate a 
phantom and compare the dose distribution results with those computed from the 
treatment planning system (TPS) for that particular phantom [71].  
The quantification of any major modifications between measurements and calculated 
dose distributions can be gained by superimposing TPS calculated doses and measured 
doses. This method is commonly employed to ascertain the agreement between the 
delivered dose distribution and the planned dose distribution [72] and weather there is 
any difference between dose maps in terms of measured and calculated dose, this 
difference can also be used to indicate the appropriateness between measured and 
calculated dose distributions [73]. These maps are sensitive to small spatial shifts that 
may be due to mistakes in experimental set up or calculation or delivery errors. Small 
shifts produce large dose differences between the calculated dose and the measured 
dose, especially in the steep dose gradient region where the dose changes rapidly [74].  
One important factor for dosimetric verification is the selection of the best dose 
measurement instruments. There are several types of detectors; for example, there are 
point dose measurement systems, such as: ionisation chambers, TLDs, and diode 
detectors which can be used clinically for point measurements. For IMRT, a point dose 
measurement cannot give adequate information for dose distributions as it is not able to 
verify the IMRT plan at multiple points or in a plane. As mentioned above, IMRT is a 
complicated technique where the dose drop-off is very large in small spatial 
displacement, especially at the edge of the target [19, 72]. Therefore, to precisely verify 
an IMRT plan in 2D or 3D the data would ideally be sampled with a high spatial 





2D or 3D dose verification techniques such as: film, detector arrays (for example 
Delta
4®
 system), and gel dosimetry.  
 
2.3.2 Point dose verification systems 
Main stream in vivo dosimetry systems currently available for megavoltage (MV) 
photon radiotherapy are restricted to point dose detector technologies such as diodes 
[44, 76] , TLDs [77] and metal oxide field effect transistors (MOSFETs) dosimeters 
[42, 46, 78]. These point dose measurement techniques while being very valid and 
useful, can be labour intensive and provide inadequate information with the dose only 
being determined at a single point [79]. Notwithstanding their limitations, these existing 
techniques are widely used in many facilities. 
 
2.3.2.1 Ionisation chamber (IC) 
Ionisation chambers are the standard and most commonly used dosimeter in 
radiotherapy and in diagnostic radiology for the determination of a point measurement 
of radiation dose [80]. An ionisation chamber measures the number of ion pairs 
generated in a volume of air (gas) due to beam interaction [17, 80, 81]. Ionisation 
chambers come in various shapes and sizes depending on specific requirements and 
purposes and include the free air ionisation chamber [82], thimble chamber [83], 
condenser chamber, farmer chamber, extrapolation chamber, parallel-plate chamber, 
and waterproof chamber [17]. For dose verifications, ionisation chambers are inserted 







Figure 2.1: The electric equilibrium in a free air chamber. 
 
When an X-ray beam is passing through air, interactions occur between the photons in 
the beam and the atoms of the gases. The interactions depend on the magnitude of 
energy that the photons possess. The interactions of photons with matter include; 
photoelectric effect, Compton effect, or pair production. Electrons are produced by one 
of these interactions, these high speed electrons generate further ionisations along their 
paths. An electric field within the chamber is produced by the application of a large 
voltage (100V– 400V) across the ion collection plates (cathode and anode). The positive 
charges are attracted to the negative plate (cathode) and the negative charges move to 
the positive plate (anode). This creates a current and the charge can be collected of 
either sign and measured by an electrometer [17] (as shown in Figure 2.1). Several 
papers discuss the conversion from ionisation to dose and the protocols that deal with 





Usually the ion chambers are not sealed, so an ion chambers response will be affected 
by atmospheric conditions such as temperature and pressure. Therefore, the density of 
air in the chamber volume depends on these atmospheric conditions. Thus, the density 
of the air in the chamber volume will increase as the temperature decreases or pressure 
increases. The chamber reading for a given exposure will increase as the temperature 
decreases or as the pressure increases. For this reason, corrections are important and 
TG-51 or TRS-398 recommendations (clinical reference dosimetry of high-energy 
photon and electron beams protocol or protocols for the dosimetry of high-energy 
photon and electron beams: a comparison of the IAEA TRS-398 and previous 
international codes of practice) should be performed [58, 85, 87]. 
The ionisation chamber has many advantages in clinical use, such as: it is accurate and 
precise, and recommended for beam calibration, with necessary the corrections well 
understood; it offers long term stability, relative ease of use and instant, direct readout 
[88]. The disadvantages with ionisation chambers are the necessity for positioning of 
the ionisation chamber in a high dose and low gradient region in IMRT dose 
distribution during creation of the phantom plan for verification. Furthermore, the 
corresponding phantom needs to be setup on the treatment couch for measuring the 
delivered dose. Both procedures are time consuming. It has also several disadvantages, 
such as: limitations in physical dimension due to the finite size of the air volume 
required for sufficient signal; its requirements for connecting cables, a high voltage 
power supply; and the necessity for many corrections for high energy beam dosimetry 
[15, 89]. For instance, when an ion chamber is used in IMRT where high dose gradients 
exist, the ionisation chamber tends to overestimate the penumbra width due to its large 
volume. Therefore, it does not accurately represent areas with high dose gradient fall-off 





dose [91-94]. Recently, the design of the ionisation chambers has been improved to 
make them as small as possible, however, these small chambers are still big compared 
to some solid state dosimeters [95].  
 
2.3.2.2 Thermoluminescence detectors (TLDs) 
Thermoluminescence has been used for almost 100 years [68, 77]. TLDs are small 
devices that are used to measure a dose delivered to a point [96]. They are constituted 
by phosphors, such as a lithium fluoride (LiF:Mg,Ti,Na) or calcium fluoride 
(CaF2:Mn,Dy) [17, 97]. TLDs operate by the solid-state phenomenon known as 
thermoluminescence. Thermoluminescence is the emission of light from an insulator or 
semiconductor when it is heated [96, 98]. When radiation interacts with the crystal it 
causes electrons in the crystal’s atoms to elevate to higher energy states, where they are 
trapped, due to the impurities in the crystal, until heated. When the crystal is heated the 
electrons will be dropped back to their ground state, liberating photons of energy equal 
to the energy difference between the ground state and the trapped state. These photons 
are counted using photomultiplier tubes, and the number of photons counted is 
proportional to the quantity of radiation striking the phosphor.  
The TLDs response can be affected by many factors, such as: time, previous thermal or 
radiation history, the nature of storage between exposure , readout, and the surrounding 
gas during the readout process [17, 88]. There are many TLD phosphors available and 
the most commonly used are lithium fluoride (LiF: Mg,Ti,Na), lithium borate (Li2B4O7 : 
Mn,Cu), and calcium fluoride (CaF2: Mn,Dy) [97, 99]. Lithium fluoride dosimeters are 
available in the form of powder, chips, and rods. TLD dosimetry for radiotherapy 
treatment has a wide range of applications [100]. Firstly, it can determine the dose in 





finally, it can be used to monitor special treatments; such as a total body irradiation. 
TLDs offer a lot of advantages and disadvantages in clinical use [101, 102]. Some of the 
advantages of TLDs are that they are generally small detectors and offer close tissue 
equivalence, which make them useful for different applications in medicine [17]. In 
addition, no cables are required during measurement (unlike ion chamber 
measurements). They are also reusable, cheap, and multiple measurements can be 
performed at the same time. However, they also have disadvantages such as: their small 
physical size may make them difficult to handle; they are less accurate than an 
ionisation chamber; a long time is necessary for annealing the material after exposure; 
they cannot provide real-time dosimetry and expensive readout equipment is required 
[81]. 
 
2.3.2.3 Semiconductor diode dosimetry 
Semiconductor materials are attractive as radiation detectors and have been studied for 
over 125 years [103]. The silicon semiconductor diode has been used as a radiation 
detector for over 30 years [46]. In medical radiation detection there are several types of 
semiconductor devices that can be used [68, 104]. Semiconductor diodes are more 
sensitive than ionisation chambers. This allows for the production of small size diodes 
that makes them very useful for measuring steep dose gradients in regions such as the 
beam penumbra. Most semiconductor devices are used as active radiation detectors, 
because they can allow real-time dose readout.  
A silicon diode is a p-n junction. Pure silicon is lightly doped with phosphorus to 
produce n-type semi-conductor material (called ‘donor’) or with boron to produce p-
type (called ‘acceptor’) semi-conductor material. Each donor impurity can contribute a 





carriers in n-type silicon are electrons, while ‘holes’ (acceptor atoms) are the minority 
carriers. In p-type silicon the reverse is true: ‘holes’ in the form of acceptor atoms are 
the majority carriers while donor atoms with their donor electrons are the minority 
carriers. Both n-type and p-type diodes are commercially available [46]. Silicon sections 
heavily doped with impurities of the opposite type are implanted on the surface region 
to create a p-n junction. Charge collection in a semiconductor diode is very different to 
that in ionisation chambers. Ionisation chambers require a high voltage supply; the 
intrinsic electric field across the p-n junction makes charge collection possible within 
the diode without application of an external bias. Many books and articles have 
discussed the principle operation of the silicon diode as a radiation detector [17, 68, 80, 
81, 103, 104].  
At the p-n junction, the majority carriers of each side diffuse to the opposite side, 
creating an electric field (built-in potential, ψ0), which stops extra diffusion of the 
majority carriers [105]. Diffusion of the majority carriers also leaves behind immobile 
negatively charged acceptors and positively charge donor ions in the p- type and n-type 
silicon respectively. This spatially charged region (p-n junction) is also known as the 
depletion region or depletion layer.  
 
When ionising radiation passes through the diode electron-hole pairs will be produced. 
The minority carriers (electron on p-type), (holes on n-type) will diffuse toward the p-n 
junction and will be swept up by the built-in potential towards the electrodes [105]. The 




















In 1984, Grusell and Rickner investigated radiation damage to diodes and the sensitivity 
of diodes [106]. They found that a diode’s sensitivity decreased with accumulated dose 
whatever the majority of doping material on the diode, whether an n-type diode or a p-
type diode, but that the n-type diode was much more affected by radiation damage. P-
silicon detectors remain more dose rate independent and show less change in response 
with radiation damage. In 1986, Grusel et al. investigated the effect of temperature on 
the diode signal, they concluded that the diode signal increased by a factor of 1~3% per 
10 C, which may overestimate the response, thus it should be taken into account when 
measuring radiation dose within the patient [107]. The specifications of diodes which 
are useful for radiation dosimetry have been investigated by Rikner and Grusell (1987); 
they confirmed their previous experiences in diode dosimetry [108].  
Task Group 62 (TG-62) (Diode in vivo dosimetry for patients receiving external beam 
radiation therapy) was formed to provide physicists and medical physicists information 
and guidelines for clinical use of in vivo dose verification using diodes [46]. Nilsson et 
al. (1988) investigated the factors affecting a diode’s response in radiation therapy 
[109]. The energy , angular, temperature, and dose rate dependency also required 
adequate characterisation [110]. A diode has a much higher atomic number (Z) than that 
of soft tissue. The effective atomic number of a silicon diode is approximately 14, while 
that of soft tissue is approximately 7. Due to this difference, the silicon diodes over-
respond at low photon energy (<150 KeV) due to an increased photoelectric effect 
contribution in this energy region [75, 111, 112]. Many researchers have suggested an 
epitaxial diode as it has great stability of sensitivity to radiation dose [113-115]. The 
CMRP-UoW epitaxial diode has been investigated and all the general aspects of 





Semiconductor devices are a suitable choice for medical radiation detection due to their 
many advantages, such as: compared to the ionisation chamber (IC), semiconductor 
devices have higher sensitivity (18,000 times than an IC of the same volume ) due to 
their higher density; the energy required to produce an ion pair is 10 times less than for 
gas in an IC (3.6 eV for silicon and 35 eV for gas); the small size of semiconductor 
devices satisfies the Bragg-Grey cavity theory conditions; they have a high spatial 
resolution allowing for pin-point dose measurements, can be used for various radiation 
fields, and provide good mechanical stability [105, 117]; and they can be operated in a 
passive mode like TLDs and in active mode (online) like an IC. Most semiconductor 
devices are based on silicon. The main factor which makes silicon diodes an excellent 
choice for radiation therapy application is the constancy of the silicon to water electron 
stopping power ratio in the mega voltage range (almost energy independent for electron 
energies in MV therapy) (as shown in Figure 2.3). However, they do have a number of 
disadvantages, including the higher atomic number of silicon as compared with water 
that gives rise to a large energy dependence (low energies) [104, 106]. 
 The mass absorption coefficient and the stopping power of the silicon contribute to the 
energy dependence for photon and electron beams. Most of the energy dependence in 
diodes designed for in-vivo use is due to the material surrounding the die, such as the 
electrode attachment, protective housing, and build-up [46]. Moreover diodes exhibit 
dose rate dependence due to charge recombination effect at high dose rates, and due to 
their construction they also show directional dependence, which has an  effect in some 
cases [46]. For photon beam in vivo dosimetry, the diode reading increases with 
increasing field size. For example, for a large field size (such as 40×40 cm
2
), the diode 
field size dependence can be up to 5% higher compared with the ionisation chamber 





For diodes with a small thickness of build-up (insufficient build-up) electron 
contamination is a contributing factor [46].  
 
2.3.2.4 MOSFET dosimetry 
Metal-oxide semiconductor field-effect transistor (MOSFET) dosimetry has been 
implemented in the field of medical radiation therapy including IMRT, stereotactic, 
brachytherapy (internal sealed source radiotherapy), and micro-beam radiation therapy 
[104]. The MOSFET was proposed and developed as a radiation dosimeter in 1978 by 
Andrew Holmes-Siedle and colleagues [118, 119]. 
The principal of operation of the MOSFET dosimeter is based on the creation of 
‘electron-hole’ pairs on the gate silicon oxide layer (SiO2) by ionising radiation 
followed by the build-up and accumulation of the positive charges on the Si-SiO2 
interface which causes a permanent shift on the threshold voltage of the MOSFET 
[120]. A MOSFET is very small in size [120-122], offers real time reading, is dose rate 
independent, and it is an integrator which can store the dose history. Hughes et al. 
(1988), Gladstone et al., in their 1991 and 1994 studies proposed the use of MOSFET as 
an in-vivo radiation dosimeter or as a surface dose dosimeter [122, 123]. Like any other 
semiconductor detector, a MOSFET is expected to have an over-response in low energy 
photons as a result of backscattered radiation or the packaging material which causes 
the release of secondary electrons [121, 124]. When using MOSFETs there are several 
points that should be taken into account such as: temperature dependence, dose 
response, limit of life because they lose signal with accumulated dose, sensitivity 
changing with bias voltage during irradiation, and MOSEFTs are not tissue equivalent 






2.3.2.5 Diamond detectors 
Diamond detectors have recently become available for dosimetry of megavoltage 
radiation [68, 126-128]. Diamond  (Z=6) detectors essentially offer approximate tissue 
equivalence (effective Z=7.42 for soft tissue), small physical size, real time 
measurement, and have small sensitive volume (1.4 mm
3
) which is useful for small field 
dosimetry [68, 94]. It is also an electrical insulator and insensitive to radiation damage. 
The small physical size of a diamond crystal detector gives a good spatial resolution, 
and could be a very useful bulk conductivity radiation dosimeter for medical and 
radiobiological work. Diamond detectors are also attractive because  the carbon water 
stopping power ratio remains approximately constant over the energy range of 1–20 
MeV, which implies a great advantage for diamond detectors over silicon diodes for 
electron dosimetry [127]. They have been successfully used for small field dosimetry 
and measuring in high dose gradients [129-131]. Diamond detectors are independent of 
photon beam quality for the clinical range [94]. The dose rate dependence of diamond 
detectors must be understood and also the pre-irradiation effects [69, 127, 132]. The 
reason for the application of diamond not being widespread compared with silicon is 
that artificial diamonds of suitable quality are not commonly available [126].  There has 
been work for the use of diamond for detection and clinical dosimetry [133, 134].   
Since all types discussed above provide point measurements only, a point detector 
cannot easily verify multiple points in a plane without repeated measurements. It is 
however common practice to verify 3D IMRT plans with single point dose 






2.3.3 Two dimensional dose verification systems 
The use of 2D array detectors designed to be placed on the treatment couch or attached 
to the treatment head for IMRT and VMAT QA, which shows the dose distribution 
immediately after the treatment delivery  are currently the most common verification 
systems in clinical use [138-141]. These dosimeters have advantages in terms of time 
saving, since the time required for data acquisition and analysis is shorter than for films 
or a single ionisation chamber. However, these 2D array detectors display the dose 
distribution only in a single plane Therefore, the dose measured by them cannot provide 
information about full 3D dose distribution. 
There are several types of dosimeters that can measure dose with high accuracy in a 2D 
plane and are considered as suitable tools for QA of IMRT dose verification.   
The 2D array detectors can provide a rapid method for dose verification and for daily 
IMRT QA. In general, IMRT QA verification 2D detector arrays for planar dose 
measurement can be divided into three design philosophies:  
(i) The first has a 2D detector array located on the linac couch, embedded in a 
phantom or mounted on the head of the linear accelerator in the absence of the patient.  
(ii) In the second the position of 2D detector array is between the MLC and the 
patient (transmission detector) for online and in vivo measurement during treatment 
delivery. 
(iii)  In the third, the 2D detector array is placed downstream of the patient, such as 
in the use of Electronic Portal Imaging Devices (EPID) or mounting the detector array 
on an EPID. 






2.3.3.1 Ionisation chamber array  
A pixel segmented ionisation chamber array  (MatriXX, Scanditronix Wellhofer) was 
designed  by the Torino University and the Instituto Nazionale di Fisica Nucleare 
(INFN) [142]. The basic dosimetric properties of the prototype were studied in 2003 by 
Amerio et al. and Herzen et al. (2007) to perform a 2D dose verification of radiation 
fields with complex shapes and with large gradients [139, 142]. The detector is a 32×32 
matrix of 1024 cylindrical ionisation chambers arranged in an area of 24×24 cm
2
. Each 
chamber is 4 mm in diameter and 5.5 mm in height and there is 7.5 mm from the centre 
of each detector to the next pitch. The sensitive volume of a single ionisation chamber is 
0.07 cm
3
. Amerio et al. reported good signal linearity with respect to dose and dose rate 
[142]. Moreover, the results have shown an excellent reproducibility with values 
remaining within 0.5% over one month of daily measurement [142]. Herzen et al. 
reproduced these results and extended this work to verification of 2D IMRT plans 
[139]. They compared the profiles in the cross plane direction that they measured using 
a pyramidal beam arrangement perpendicular to the chamber array to the calculated 
profiles and obtained a maximum deviation of 1% [139]. 
Poppe et al. (2006) undertook a study that examined two different of the 2D ionisation 
chambers array manufactured by “PTW” (PTW-Freiburg, Germany) for IMRT plan 
verification. These two detectors were version 1 (which consisted of 256 ionisation 
chambers in a 16×16 matrix) and version 2 (729 ionisation chambers in a 27×27 
matrix)[143]. 
The distribution of the array signals expected is calculated by convolution of the 
planned dose distribution. They have been found to demonstrate an excellent short-time 
reproducibility of 0.2%. The long-time reproducibility has been found to be within 1% 





verification of IMRT plan based on one field orientation. This was obtained by setting 
the gantry angle of the linac to 0
°
 with the 2D array positioned perpendicular to the 
beam axis [143].  
 
2.3.3.2 Film dosimetry 
In the realm of radiation therapy, films have been historically  a very important way of 
acquiring information about the human body and are also an attractive way of 
measuring the dose distribution and/or dose verification with high spatial resolution 
[144].  
There are two types of films: radiographic and radiochromic films. Radiographic films 
contains a radiation sensitive emulsion that coats a transparent polyester base [58]. The 
emulsion consists of silver halide crystals implanted in gelatine. When the emulsion is 
exposed to radiation, ionisation and excitation takes place in the silver halide which 
leads to the creation of a latent image. When the film is developed, the affected crystals 
are reduced to small grains of metallic silver, which cause the film to become opaque 
[68]. Extended dose range (EDR) radiographic film in an excellent dose range is 
available from Kodak (EDR2
®
) as a possible method for 2D dose verification of an 
IMRT delivery system. ) Radiographic film use has fallen dramatically due to need for 
dark room, and processing to obtain the image. 
Radiochromic external beam radiation (EBR) film (Gafchromic
® 
available from the 
International Specialty Products (ISP) Group) is self-developing, following absorption 
of radiation, without involving any latent thermal, optical or chemical development. It 
consists of a radiation sensitive monomer, which upon irradiation, polymerises to form 





density closer to tissue and offer a large range of doses up to 800 cGy when compared 
to radiographic films [145]. 
All films provide a 2D pixel intensity map that can be converted to a 2D dose map by 
using a calibration profile. Films also have some advantages such as: radiographic film 
has good spatial resolution [81]. The high resolution of radiographic film combined 
with modern film technology has an ability to provide a reasonably accurate and precise 
2D distribution from a single exposure.  
Films have an excellent spatial resolution, a large sensitive area, and are easy to handle 
Films are also useful tools to use for commissioning, for routine QA, and for dose 
verification [146], and there is a variety of commercially available types of film [81]. 
Nevertheless, the disadvantages are the dependence on film scanner readout values, 
time delay between irradiation and scanning and chemical processing. These problems 
make film dosimetry a very cumbersome procedure for routine treatment verification. 
Films also have some disadvantages such as: wet chemical processing where careful 
control is needed, their energy dependence for X-rays, their sensitivity to the 
environment, blindness to low energy neutrons, and it is acknowledged that absolute 
dosimetry is difficult  [17, 81, 147]. Films are also disadvantaged by the fact that they 
are not a real-time readout dosimeter, and results may not be ideal due to non-uniform 
commercial film scanners used for their readout [94, 148-150] .  
 
2.3.3.3 Electronic portal imaging device (EPID) 
The original purpose of an Electronic portal imaging devices (EPIDs) was as a 
replacement for port films. An EPID consists of a flat panel amorphous silicon detector 
array mounted on a retractable arm opposite the linac beam. They can be used for 





radiotherapy delivery [151, 152]. The use of the EPID has recently been extended to 
verify the fluence of IMRT delivery. Verification of the dose delivered to the target 
volume can be achieved with in vivo dosimetry [153], and several authors reported on 
the use of portal images for measuring 2D dose distributions [154, 155]. 
There are two approaches to EPID dosimetry and both of them are suitable for pre-
treatment verification and in vivo dosimetry [156]. The “forward approach,” is a method 
where the predicted dose or photon fluence calculated with TPS or an independent 
algorithm at the plane of the EPID is compared to the measured portal images [156]. In 
the “backward approach,” the portal images are used to reconstruct the dose within the 
patient or phantom [157, 158]. This back projection method enables the direct 
comparison of the calculated dose with the delivered dose distribution in the phantom or 
in the patient. Whereas the dose is verified in only one plane in the forward approach 
[156, 159]. 
 A new generation of EPIDs, based on amorphous silicon flat panel technology, can 
provide high quality verification images with as little as 2 cGy as compared with 7 cGy 
for film dose [160]. Electronic portal imaging devices show many advantages over the 
traditional use of film, for instance: ease of use, real time imaging display, and instant 
comparison with the planned treatment field. An EPID with a Si flat panel can provide 
very high resolution, high quality images, less handling, immediate image viewing, and 
less radiation to the patient. On the other hand, where an EPID is used as an IMRT 
dosimeter it is difficult to convert the image to dose and it requires a complicated 
procedure [151, 161]. Generally, the higher the beam energy used to obtain an image, 
the lower the contrast and resolution of the image. The beam used for cancer treatment 
(megavoltage) is of higher energy than the one used for regular diagnostic X-ray 





radiotherapy than for kilovoltage beams used in diagnostic radiography [57, 94, 144, 
162]. For this reason most patient setup imaging is now performed with kV x-ray 
sources and image detector arrays incorporated into the linac gantry (cf Varian OBI). 
 
2.3.3.4 MapCHECK (Sun Nuclear, Melbourne, FL) 
MapCHECK
®
 (from Sun Nuclear, Melbourne, Florida) is a 2D array of diodes that can 
be used for measuring the dose produced in a plane by a radiation beam. It consists of 
445 n-type diodes distributed over an area of 22×22 cm
2
. Diode spacing is 7.07 mm in 
the 10×10 cm
2
 central portal of the detector and increases to 14.14 mm outside this area 
[163]. These n-type diodes are proprietary designed and are very resistant to damage by 
radiation compared to n-types diodes commercially available before 2001. The diodes 
have a 2 cm build up region and 2.2 cm water equivalent backscatter region. The entire 
array of diodes is easily calibrated to be used for measurement of absolute dose. For 
IMRT QA, each beam is measured individually with the beam’s central axis oriented 
perpendicular to the plane of the diodes. The advantage of MapCHECK is that it 
provides an accurate means of treatment verification and is fast for IMRT QA [71]. The 
use of MapCHECK for routine quality assurance for IMRT fields has been found to be 
very efficient due to the time needed for various steps in the measurement [71, 104]. 
 In their work  Jursinic et al. (2003) found that for the long term (over a period of a 
month) reproducibility of MapCHECK measurements was quantified over a 261 day 
period of use and The relative standard deviation of these measurements was <0.05% 
[71]. These 2D array detectors mentioned above display the dose distribution only in a 
single plane. Therefore, the dose measured by them cannot provide information about 





2.3.4 Three dimensional dose verification systems 
There is a need for a practical 3D dosimetry system, suitable for clinical use, and with 
the accuracy and high resolution to allow comprehensive verification of the complex 
dose distributions typical of modern radiation therapy treatments. A full understanding 
of all 3D conformal radiotherapy generated dose distributions ideally includes 
volumetric verification, the verification of IMRT is further complicated by the fact that 
the radiation field is continuously changing size and shape (sliding window) or made up 
by multiple small beam segments (step and shoot). Thus, a detector with the possibility 
for integrating volumetric measurements is needed. Since an IMRT dose distribution 
often contains sharp dose gradients, good spatial resolution as well as independence of 
dose rate is desirable. Another crucial feature is that the detector response should be 
independent of incident radiation direction. This would enable a complete treatment to 
be evaluated in a single measurement, as opposed to measuring each beam separately.  
In external radiotherapy conventional dosimetry systems such as ion chambers, TLDs, 
diodes or film, are unable to satisfy all the above requirements. Volumetric 
measurements are not feasible without multiple detectors and/or repeated 
measurements. In the case of ion chambers, the sensitive volume is too large to obtain 
the necessary spatial resolution. Film can be arranged in a stack for 3D measurements, 
but suffers from lack of tissue equivalence when packed in this way and exhibits a 
dependence on the angular distribution of the radiation [164]. 
 
2.3.4.1 Gel dosimetry  
The biological effects of ionising radiation demand an increased interest in new 
techniques for determining the dose that is delivered to the internal structures [165]. 





verification in radiation therapy [166]. The use of gels with radiation sensitive material 
for dosimetry has occurred since the 1950s [165, 167]. At that time Day and Stein 
studied the chemical changes produced by radiation in aqueous solution and the use of 
changes for radiation dosimetry in the measurement of absorption of ionising radiation. 
For dosimetric applications, the system must be quasi-solid, give a chemical change that 
can be observed, and have the same average atomic number and electron density as 
body tissue (that is, the same as water). Gel dosimeters have been created from 
radiosensitive chemicals dissolved in gelatine material, that then polymerised as a 
function of the irradiation dose [94, 166]. 
Gel dosimetry can be divided into two types: Fricke-based gels[168] and polymer gels 
[68, 169, 170]. Gel dosimeters offer advantages such as: having near water equivalence 
and high spatial resolution. There are several methods to read out the gel dosimeters: for 
example: magnetic resonance imaging (MRI), X-ray computed tomography (CT), or 
ultrasound technique [171-174]. Gel dosimeters also exhibit some disadvantages such 
as: their high cost and problems that sometimes arise in obtaining access to an MRI 
scanner, difficulty in reproducing gels with equal radiation sensitivity in different 
batches, and the fact that the method is time consuming (a couple of measurement are 















Figure 2.4: The Delta
4®





 (ScandiDos, Uppsala, Sweden) dosimetry system is able to offer a real- 
time pre-treatment method for volumetric verification of 3D dose distributions for static 
angle and dynamic rotational delivery [176]. This device can be placed on the linac 
couch for dose treatment verification for both IMRT and VMAT delivery. Delta
4®
 
system is able to provide an effective means of measuring doses at multiple locations in 
the field. It consists of 1069 p-type diodes arranged in a matrix along two orthogonal 
planes. The p-type detectors have been shown to have little saturation of signal, 
especially at high levels of dose per pulse, compared with n-type detectors. Each p-type 




The detectors are spaced at 0.5 cm intervals in the central 6 × 6 cm
2
 area and at 1 cm 
intervals outside of this area, and they cover an area of 20 × 20 cm
2





are placed in an acrylic cylindrical phantom 22 cm in diameter and 40 cm in length (as 
shown in Figure 2.4). 
The Delta
4®
 system is comprised of a phantom with three removable detector planes 
that are arranged in orthogonal planes. The detectors are attached via multichannel 
readout circuitry to electrometers with the data displayed using customised software. 
The phantom has a cylindrical polymethyl methacrylate (PMMA) structure divided into 
quarters by the two detector planes. A main detector board forms one plane running 
along the diameter of the cylinder. Two wings sit on either side of the main board at 
right angles to form the second detector plane. The two planes are offset from the 
vertical; one at +50˚, one at -40˚. The asymmetric arrangement allows the user to 
change the angle at which the beam is incident to the board by 10˚. This design enables 
the user to avoid beam incidence angles that are parallel to the detector plane for most 
static gantry angles. The PMMA has markings in the horizontal and vertical directions 
for positioning the centre of the phantom. The markers are two straight lines spaced 1.5 
mm apart, between which the lasers in the treatment room can be aligned. For the 
Delta
4®




 system can be used in a gantry rotation mode for VMAT treatment delivery 
verification. As such it cannot be used for in vivo dosimetry [94, 176]. Bedford et al. 
found that the uniformity of response of the Delta
4®
 to different segment monitor units 
and dose rates was better than 0.5%. Also, the uniformity of angular response was 
around 0.5% over the range of gantry angles. For IMRT and VMAT, treatment plans 
were assessed. Even though the Delta
4®
 system has detectors in only two planes, it 
provides a novel interpolation algorithm that is capable of estimating doses at points 





2.3.4.2.1 Delta4® software tools: 
Part of the research work presented in this thesis involves a study of the impact of 
the MPTM with both a bare MP and a MP with an encapsulated by a 1 mm solid 
water build up layer. The impact on the 3D dose distribution in comparison to the 
open field configuration with no MPTM in place was investigated using the Delta4® 
system. A brief summary of standard operational procedures for the Delta4® system 
is therefore presented below. 
 
2.3.4.2.2 Daily Correction Factor  
A daily correction factor (DCF) are applied to measurements in order to account for 
differences in treatment conditions between the time of calibration and time of 
measurement, for instance changes in linac beam output. The DCF is determined by 
comparing the measured dose of all detectors in the central 6 × 6 cm2 of the detector 
plates to that of the planned dose in the same area. The DCF is calculated for a 
uniform, square field of 20 × 20 cm2 using a 6 MV beam potential. The relevant 
DCF has been applied to all measurements.  The DCF can be used to identify set up 
errors. If the DCF is vastly different from previously stable measurements, the 
source of the difference is more often than not a misalignment. Dramatic changes in 
DCF can also be indicative of errors with linac beam delivery.  
The software also provides a temperature correction that can be applied to 
measurements, as p-Si are known to have temperature dependence (as mentioned in 
section 2.3.2.3). The correction is calculated relative to the temperature at the time 
of absolute calibration. Prior to calculation of the DCF, the temperature is measured 





a correction applied internally. A more accurate temperature assessment could be 
achieved if the temperature was monitored from inside the phantom, as a surface 
measurement is not necessarily indicative of the heat transfer to the diodes during 
the measurement period [177, 178].  
 
2.3.4.2.3 Pass/Fail Criteria 
The software’s default pass/fail criterion was used in section 5.3.2. For dose 
deviation analysis, the field will pass if 80% of points have a measured dose within 
±3% of the calculated dose. For distance-to-agreement (DTA) analysis, the field will 
pass if 90% of the measured points agree with the calculated dose within a radius of 
3 mm. For gamma analysis, the field will pass if 90% of measured points have a 
gamma index ≤1. The maximum allowable dose and spatial deviation is ±3% and ±3 
mm respectively.  
 
2.3.4.2.4 3D Dose Distribution 
3D Dose Distribution is an optional feature of the Delta4® dosimetry system that 
allows the volumetric verification of treatment plans. A notable advantage of the 
feature is its ability to display the location of points that are failing the acceptance 
criteria. This allows the medical physicist to ascertain whether the discrepancy 
between measured and calculated dose are of clinical significance. This addresses 
some concerns that gamma analysis lacks specificity [179]. The 3D dose distribution 
is modelled by renormalising the TPS calculated depth dose to fit the measured dose 
points registered as the ray traverses the detector plate(s); this process is applied per-





al [180] has verified the accuracy of dose interpolation using ion chamber 
measurements. Calvo et al  found good agreement (between 0.3% and 2%) among 




The ArcCHECK (Sun Nuclear, Melbourne, USA), is a cylindrical diode array, 
containing of 1386 diodes in a helical shape with 1 cm inter-diode spacing, 1 cm pitch 
and 21 cm diameter. The central 10×10 cm of the ArcCHECK contains approximately 
221 detectors; the same as the MapCHECK 10×10 cm. Active detector size of each 
diode is 0.8×0.8 mm
2
. The system was developed to meet the need of rotational therapy 
QA. It is well suited for QA of VMAT and IMRT. It allows measurements at arbitrary 
gantry angles with sufficient spatial resolution even for the Novalis accelerator with leaf 
widths as small as 3 mm. [181] .  
The ArcCheck QA system can reconstruct the 3D dose distribution based on sensors 
inside a phantom placed on the patient couch. The ArcCHECK detectors are curved to 
form the surface of a cylinder inside a doughnut-shaped phantom [182], allowing the 
radiation beam to hit at least the central detectors perpendicularly at any gantry angle. 
 Dose reconstruction in the entire volume of the cylinder is based on the modification of 
the dose matrix calculated by the TPS. Without the import of TPS dose data, 
ArcCHECK is not able to present 3D dose grids. Therefore, the ArcCHECK method 







2.3.4.4 OCTAVIUS  (PTW, Freiburg, Germany) 
The Octavius
®
 4D system consists of a cylindrical, rotational phantom in which the 2D 
ionisation chamber array is inserted. The Detector 729 features 10 mm resolution, the 
central region of the Detector 1000 
SRS
 features 2.5 mm [185]. An external inclinometer 
mounted on the gantry provides constant feedback on the actual gantry angle and allows 
the control unit to rotate the phantom accordingly, keeping the 2D array perpendicular 
to the beam axis at all times. Thus, the orthogonal beam output can be measured from 
all angles and any possible directional dependence of the 2D array becomes irrelevant 
[186].  The OCTAVIUS 4D algorithm is based on dose measurements at a certain depth 
in the phantom and on PDDs that are used to reconstruct dose values along the ray lines 
that connect the relevant detectors and the focus of the beam. As a consequence, the 
commissioning of OCTAVIUS 4D is very simple and limited to PDD measurements 
and to the adjustment of the phantom’s density in the TPS [185]. 
 
2.3.5  Transmission detectors 
There is considerable need for real-time in vivo verification of the IMRT and the VMAT 
that can be achieved by a transmission-type detector placed in the photon beam 
downstream of the MLC during treatment. The idea of a 2D array transmission detector 
for real time in vivo QA in EBRT was first proposed by Paliwal et al. The transmission 
chamber was an off-the-shelf device called a Dose Area Product Meter (Gammex RMI, 
Inc., Middleton, WI 53562) [187] using the concept of dose area product to monitor the 
radiation beam in diagnostic applications for the measurement of patient exposure. The 
concept of a dose area product was further developed to allow online in vivo comparison 





compare it with pre-recorded data [8, 188]. 
Two dimensional dosimeter arrays have been used in radiation therapy to measure the 
complex dose distribution established by the IMRT and VMAT. These 2D arrays can 
measure the dose at multiple locations in the field. Many studies of several ion chamber 
arrays are available [140, 142, 189], diode detectors [71, 163], and EPIDs. In general 
most systems are not in real-time and still used for pretreatment verification as they 
perturb the beam too much to be left in during patient dose delivery. These detectors, 
with or without phantoms, are placed on the patient table or in a special gantry mount in 
the absence of the patient, or they can be arranged behind the patient. 
 There is a significant argument regarding the need and the possibility for the on-line 
verification of IMRT and VMAT using a transmission-type detector with high spatial 
resolution, mounted in the photon beam between the MLC and the patient. Such 
technology is not, commercially available. 
 
2.3.5.1 DAVID System (PTW-Freiburg, Germany) 
The DAVID
®
 system (PTW-Freiburg, Germany) is non-invasive enough to be able to 
perform QA measurement during patient treatment. The DAVID system is a flat, 
translucent multi-wire ionisation chamber to be placed in the second accessory holder of 
the linear accelerator. The DAVID system comprises a transparent flat ionisation 
chamber in order to minimise the interference with the light field of the treatment head, 
and multi wire transmission ionisation chamber (there are 37 individual wires that are 
positioned exactly below the associated leaf pair of the MLC) [8]. Its signal records the 
opening of this leaf pair during patient treatment. As it is at an upstream position in 





generated photon fluence. The system also has wireless connection with its software. 
The DAVID system has been developed for a standard Siemens linear accelerator. The 
transmission properties and characteristics of the DAVID chamber have been measured 
by Poppe (2010) [190].  
 
2.3.5.2  COMPASS (IBA Dosimetry, Germany) 
The COMPASS
®
 device from IBA Dosimetry, Germany) is a pixel segmented 
ionisation chamber. Its 2D array consists of 1600 air vented plane parallel ionisation 
chambers with a detector spacing of 6.5 mm, and an active volume of 0.02 cm
3
. The 
active area is which can measure fields of size 40 × 40 cm
2
 at the isocentre. The 
external dimension of this transmission device is 52 cm width, 49 cm length, 11 cm 
height, and 15 kg weight. Each chamber is 3.8 mm in diameter and 2 mm in height. The 
detector assembly can be attached onto the gantry in the wedge slot of a Varian linac 
2100iX which has a source to detector distance of 65 cm. Examinations of the influence 
of the transmission detector on the surface dose, and on a dose beyond dmax, have been 
carried out [191]. In their work Sankar et al. (2009) describe the influence of this new 
transmission detector consisting of a 2D ionisation chamber array on a 6 MV photon 
beam. They have found an increase in the surface dose for large field size and small 
source skin distances (SSDs), due to the increased surface dose for shorter SSDs. The 
impact of the COMPASS transmission detector on a 6 MV photon beam is an increase 
in dose particularly in the build-up region. Beyond dmax, the beam parameters of 
COMPASS detector and open fields were in good agreement. 
COMPASS QA systems can perform a full 3D collapsed cone convolution/ 





can determine the 3D dose distribution in the patient). COMPASS QA systems need to 
be commissioned with individual beam data in order to custom model for each unique 
linear accelerator.  
 
2.3.5.3  The Integral Quality Monitoring system (IQM) 
The integral quality monitor (IQM) utilises an area integrating energy fluence 
monitoring sensor (AIMS)  designed to be mounted between the final beam shaping 
device, the MLC and the patient. The system consists of spatially sensitive large area 
ionisation chamber with a gradient along the direction of the MLC motion in real time. 
The signal from the AIMS delivers a simple output for each beam segment, which is 
compared in real time to the expected value. The expected signal is calculated by 
IQM_CALC based on the field information derived from the TPS and is an independent 
of the treatment delivery system. The prototype ionisation chamber, with a physical area 
of 22 × 22 cm
2
, has been made of aluminum with the electrode separations varying 
linearly from 2 to 20 mm across the chamber.  The sensitive volume of the ion chamber 
was approximately 530 cm
3
. The chamber can monitor a radiation field that projects to a 
size of approximately 34×34 cm
2
 at the isocentre. A calculation method has been 
developed to predict AIMS signals based on an integration method, which takes into 
account different factors, such as the spatial response function of the chamber, field size 
factors, beam transmission through the secondary jaws, and MLC characteristics. Islam 
(2009) found out for a 10 × 10 cm
2
 field size, the chamber attenuates the beam intensity 
by 7% and 5% for 6 MV and 18 MV beams, respectively, without significantly 






2.3.5.4  Delta4® DiscoverTM (ScandiDose, Sweden) 
The Delta
4®
 Discover is a wireless head-mounted p-Si diode array detector, which is 
intended to be used during patient treatment. The Delta
4®
 Discover system is designed 
to monitor the dose that is delivered to the patient. The delivered dose is then abled to 
be compared with the planned dose automatically. The Delta
4®
 Discover detector 
system has a detector matrix consisting of 4040 detectors with a detector spacing of 2.5 
mm. The thickness of this device is 55 mm, and 10 kg weight. Each detector is 1 mm in 
diameter. It allows for an accurate dose and MLC leaf position detection. These 
detectors are positioned along the MLC leaves allowing detection of sub-millimeter 
positioning errors and dosage errors. 
Very recently published work showed that the Delta
4®
 Discover system contributes 1% 
to the skin dose and attenuates the beam by 1% [192]. 
 
2.3.5.5  Dolphin (IBA Dosimetry, Germany) 
Dolphin online treatment monitoring is based on a wireless ionisation chamber. It 
measures the real treatment fraction by fraction instead of pre-treatment beam. Its 2D 
array consists of 1513 air vented plane parallel ionisation chambers with a detector 
spacing of 5 mm in the inner detector area (centre to centre distance), and 10 mm in the 
outer area with  an active volume of 0.016 cm
3
. The size of this device is 24.3×24.3 cm
2
 
and with weight of 12 kg [193]. For transmission-type pixelated ionisation chambers 
such as the Dolphin device, to reconstruct the dose in a patient  requires complicated 
algorithms that take into account the perturbation properties of the transmission 
detector, which change with the irradiation field geometry. 





reconstruction and comparison with the TPS after each treatment fraction. Very recently 
with the Dolphin device inside the beam an increase in surface dose was observed 
maximum of +11%. Beyond dmax the impact of the Dolphin system on the PDDs was 
1%. Measurements showed that the transmission factor depends slightly on the field 
size (0.893- 0.921 for 5 ×5 cm
2 
to 30 × 30 cm
2
)[194].  
Although some of these QA delivery devices are available commercially, they are still 
rare in clinical practice for IMRT and VMAT delivery verification during patient daily 
treatment.  
 
2.4 Gamma Analysis 
Gamma analysis is a form of quantitative acceptance criteria assessment that considers 
dose difference and DTA. Its quantitative nature provides a more user-friendly way of 
comparing the agreement of calculated and measured dose distributions by providing a 
measure of disagreement in the regions that fail the acceptance criteria and an indication 
of calculation quality in regions that pass [195]. The -value is found according to 
Equations (2.1) and (2.3) below: 
 








Where r(𝑟𝑚 , 𝑟𝑐) = |𝑟𝑐 − 𝑟𝑚|, (2.2) 
 







Dc and Dm are the calculated and measured dose in positions rc and rm respectively. ΔDM 
and ΔdM are the acceptable dose difference and DTA criterion respectively. Dose 
difference refers to the variation between measured and calculated dose. DTA refers to 
the shortest distance between the point of interest corresponding to the measured dose 
and the closest point in the calculated distribution with the same dose. If the  -value 
has a magnitude greater than 1, the region fails the acceptance criteria. 
The  formula assumes that dose difference and DTA are of equivalent importance. In 
regions of low dose gradient the dose-difference calculation dominates. In contrast, the 
DTA is used in high-gradient regions where the dose-difference may be over-inflated 
i.e. a small spatial error (in calculation or measurement) can lead to a large dose-
difference [195]. 
There are no universal guidelines to follow when setting pass/fail criteria or the 
percentage of points evaluated in the analysis. Feygelman et al [182] surmises a trend 
towards error criteria being chosen on the basis of what can be “reasonably achieved” as 
opposed to being based on any strong scientific foundation. This is most likely due to 
the fact that  -analysis is yet to be put under rigorous scientific or clinical testing [182]. 
It is up to the clinic to apply their own judgment of what they deem to be acceptable, 
with different thresholds often applied to different anatomical regions. A survey 
conducted by Nelms and Simon [196] found that despite the lack of research into the 
technique, 3% /3 mm gamma criteria was the most common measure of calculation 
quality for 2D diode arrays. The 2009 AAPM TG119 report on IMRT commissioning  
used the same criteria [197]. 
Zhen et al [179] looked into the clinical impact of employing gamma analysis in IMRT 
QA, particularly the significance of the location of failing points in plans with high 





between passing rate and dose errors in anatomical regions of interest. Zhen et al [179] 
found there to be a weak correlation between the two, suggesting that the lack of 
information on location, magnitude and sign of dose errors places a significant limit on 
the ability of -analysis to predict clinically relevant errors. 
As suggested by Horsfield [198], the ease with which -analysis can highlight 
discrepancies between planned and measured dose distributions while still pertaining to 
an acceptable level of accuracy is advantageous in a clinical setting. It is ultimately up 
to the clinic to set high standards for IMRT QA. The popularity of -analysis instils 
confidence that these standards can be met through stringent acceptance thresholds. 
Thus 3%/3 mm acceptance criteria will be used when necessary throughout the course 
of this thesis. 
 
2.5 Skin and surface dose 
The skin dose is of interest as the skin is always irradiated during external beam 
radiation therapy, and yet, mainly due to voxel resolution constraints, the TPS is 
incapable of accurately predicting the dose within 1 mm or 2 mm of the patient’s 
surface. 
According to the International Commission on Radiological Protection (ICRP) [199] 
and the International Commission on Radiation Units and Measurements (ICRU) [200] 
the skin depth recommended for practical dose assessments is at 0.07 mm below the 
surface. Generally, this depth corresponds to the interface between the epidermis and 
dermis layers of the skin “Basal layer” [201]. 





skin dose is affected by the treatment technique, the accessories and immobilisation 
used during radiotherapy, such as thermoplastic masks, wedges, blocks and trays [202-
210].  
It has been found that mask material increased skin dose for 40% to 44% in cases of 
head and neck radiation therapy, while tray and blocks can contribute another 3% to 
4%. Furthermore, a decrease in the source to surface distance (SSD) also increases the 
skin dose [204]. 
 Kim et al, investigated the skin dose by changing the main clinical parameters, such as: 
energy, field size, SSD, blocks, physical wedges, dynamic wedges, and beam shaping 
with a MLC. They concluded that the skin dose increases for large field sizes of 40 × 40 
cm
2
 for energies of 8 MV and 18 MV, from 6% to 38% and from 5% to 44%, 
respectively. In addition, an acrylic block tray increased these values for large field size 
by ~19 % for both energies.  
Lee et al, investigated skin toxicity as a result of an increase in skin dose from multiple 
fields extended intensity modulated radiation therapy for head and neck cancer, and 
concluded that this reaction resulted from causes such as the immobilisation masks used 
during irradiation, or during the inverse treatment planning system. An 18% reduction 
of the skin dose has been observed if the skin is defined as sensitive area during inverse 
planning [206]. 
 Butson et al, agreed with previous authors that perspex blocking trays increased the 
skin dose of a 6 MV X-ray by about 22%, while an increase that occurred by shortening 
the SSD was much lower [207].  
Therefore an innovative method to find a suitable radiation detector for skin dose is 





several radiation detectors to measure the build-up region, skin, and surface dose for 
different radiation modalities [202-204, 211-222]. 
 A variety of dosimeter types can be used, such: a parallel-plate ionisation chamber, 
TLD, film, and MOSFET. The Attix chamber is regarded as a reference detector for in 
phantom build-up and surface dose measurements, whereas TLD, film, and MOSFET 
are less accurate relative detectors that do have potential as in vivo dosimeters due to 
their effective depth of measurement. On the other hand, the Attix chamber cannot be 
used for skin or in vivo dosimetry with a patient due to its size and high operational 
voltage, so other detectors are more convenient with patients for this aim [223].  
Each one of the relative detectors has its own advantages and disadvantages that may 
make it more favourable than the others in various applications. For instance, TLD is 
widely used for in vivo dosimetry due to its tissue equivalency and its lower cost, and it 
can also be used for skin dosimetry by using an extrapolation method [213]. However, it 
is not suitable for on-line measurements because they take a long time to analyse and 
get results. Moreover so many sources of errors may arise from annealing and reading 
procedures that can reduce its reliability as a detector [223].  Radiochromic film is also 
being used for skin dosimetry because  its effective depth is deeper than basal cells and 
it can be used with correction against an ionisation chamber for accurate dose 
estimation [217], or without correction, to get an approximate dose near basal cells 
[224]. However, it cannot be used online and radiochromic film calibration and readout 
procedures may introduce some uncertainties especially if the calibration and irradiated 
films were scanned after different periods of time [225]. Handling, storage, or 
environmental factors such as temperature, humidity, light exposure, or scanning factors 
such as film orientation, resolution and scanner light source, can introduce large 





results with radiochromic film. However, film shows excellent results for cavity 
measurements, but it underestimates the dose for the distal cavity (by 5 – 6%) as a result 
of self-build-up when the film is parallel to the beam direction [226]. Film dosimetery 
can give two dimensional dose maps with good resolution (~80 μm WED as for EBT2) 
[218, 227].  Rosenfeld et al, Butson et al, [211, 228], promoted MOSFET as a surface 
and skin dosimeter in radiation therapy. They found that the bare MOSFET is in 
excellent agreement with an Attix ionisation chamber on the build-up region, which 
makes it suitable for commissioning the build-up region and for measuring the skin dose 
with the patient. It has many advantages, such as its small size, simple reading circuit, 
low power operation, ability to store the dose history, and it can be used for online 
readout. The sources of uncertainties in MOSFET readings is different than the film, it 
is mainly associated with temperature, creep-up effect/instability and angular 
dependence. It is not affected by associated issues with cabling such as an ionisation 
chamber, as it’s an integrator based on charge build-up on the gate, it can work  and 
store signal even if there is no wire connected [228, 229]. 
 
2.6 Photon Beam Calculation – Convolution 
The ICRU defines the absorbed dose as that energy imparted by ionising radiation per 
unit mass [68, 230]. In the radiotherapy world, more accurate information about the 
absorbed dose that will be received by the patient’s body is very important to the 
provision of suitable treatment. For radiation treatment planning people rely on a 
predictive method to simulate the energy transport and deposit in the human anatomy 
[68, 231]. The TPS requires a dose calculation method, which conforms to correction 
based or model based methods [16, 232]. In the correction based methods, the dose can 





dose array and is manipulated taking into account patient contours and inhomogeneities 
(meaning regions with different tissue densities and composition, such as bone and air). 
In the second method (the model based methods), the dose can be determined from the 
transportation of radiation from the first principles through the patient. 
For photon beams, dose calculations of the patient were historically based on the 
correction based methods. The reason behind that is their simplicity [232]. In the 1970s 
the correction based dose method was proposed by Milan and Bentley [233].  
Due to the huge development of computers and model based algorithms such as various 
convolution superposition algorithms including the collapsed cone convolution 
algorithm, and the anisotropic analytical algorithm (AAA) have become standard in a 
clinical setting to calculate the dose distributions in the patient [234-236]. Monte Carlo 
methods are the ultimate model based approach. Monte Carlo methods are approaching 












Figure 2.5 illustrates photon interactions with the matter in a patient’s body. During the 
interaction some of the photon’s energy transfers to electrons, setting them in motion 
depositing dose mainly by collisional energy loss. The kinetic energy which is released 
in matter is called KERMA. When the electrons travel within the tissue, they will slow 
down due to multiple Coulomb collisions, producing ionisation along their pathway. 
After that, the  excitation of atoms can take place and the molecular bonds will be 
broken (biological damage) [239].  
The total energy released in the patient through this procedure is called the absorbed 
dose. On the other hand, other actions that take energy away from charged particles are 
referred to as the bremsstrahlung. ‘Bremsstrahlung’ comprises those photons created 
due to the deflection of electrons when approaching the nucleus of the atom. Delta rays 
(secondary electrons produced by electron-electron collision) can also take the energy 
away. Both braking radiation (bremsstrahlung) and scattered radiation can suffer 
multiple interactions in the same way as incident interactions [20, 238-242]. 
There are several kinds of convolution algorithms. However, all of them have two 
important components: Terma, and Kernel. ‘Terma’ is that energy imparted to the 
medium by the interactions of primary photons as discussed above (3D distribution of 
the total energy released per unit mass). On the other hand, ‘kernel’ is that energy 
deposited about the primary photon interaction site. 
In the literature, all convolution methods concentrate on the influence of the energy 
fluence that comes from the beam. To illustrate that, and in the case of homogeneous 
medium, the dose D( r), absorbed at a point r, from energy released at a point r` (Figure 






 D (r) = ∫ T (r`) A (r-r`) d
3
 r` (2.4) 
 
Where A (r-r`) is the convolution kernel, T(r) represents the TERMA. Also, TERMA is given 
by (2.5): 
 
 T(r`) = 
µ
𝜌






 is the mass attenuation coefficient and ψ (r`) is the primary energy fluence 
distribution in the phantom. 
In the Cartesian coordinate system this is the (fraction of energy absorbed in each cubic 
volume element ‘voxel’ situated at ‘x, y, z’ in a medium). Values in the kernel are the 
measurements of energy deposited at vectorial displacement from the interaction site as 
a fraction of terma at that site.  
 
Figure 2.6: Vector representation of the convolution scheme: vector r and r` show the 






The convolution method has been widely used to calculate photon dose in beams. The 
collapse cone convolution and an anisotropic analytical algorithm are commercially 
available. Many studies and articles have discussed these methods in the last past, from 
(1985 to 1990s) [232, 236, 242-245]. 
 
2.6.1 Convolution/ Superposition Technique 
The convolution/superposition technique has been used to calculate photon dose 
distributions [232, 236, 242-244]. It takes into account primary radiation and secondary 
radiation as well. It calculates the dose a convolution releases at each primary 
interaction site (location), which is called ‘TERMA’ (the total energy imparted or 
released in the medium by the interaction of primary photon), and the energy deposited 
about the primary photons interaction, which is called ’kernel’. Kernel explains the 
spread of energy due to a local scattering in the medium. This kernel is the same when 
exposing a homogeneous medium by using a mono-energetic beam, however a 
collection of weighted kernels are used to account for the energy spectrum for poly-
energetic photon beams. 
The description above is of what is known as a ‘superposition’ method. In the literature, 
kernel can be referred to a different technique based on the geometry of the beam that 
delivers the incident energy. For instance, it can refer to a dose spread array, a 
differential pencil beam, point kernel, and energy deposition kernel. There is also the 
‘planar kernel’, which describes both the forward and backward energy spread from 
primary interaction placed in a plane from the laterally oriented broad beam. 
Most TPSs these days are using this method for dose calculations. The reason for this is 
that this technique takes into account a lot of physics. Most implementations use 





has also some drawbacks, and the main one is it takes a long time to do dose 
calculations, and it needs empirical parameters that should be determined by dose 
measurement in tank water so it is not a pure model based algorithm [20]. The same for 
matching Monte Carlo if matched to water data. Lots of details about the convolution 
method and its types could can be found in the literature in depth [20, 58, 68, 236, 246]. 
One weakness is most superposition methods implement rectilinear scaling which 
slightly over estimates dose in lung as electrons do not follow rectilinear paths. 
 
The response of the MPDM using a 6 MV photon beam was investigated by Wong et al 
[9]. A preliminary characterisation of the array was performed, including radiation 
damage study, dose per pulse effect, percentage depth dose comparison with CC13 ion 
chamber and build up characteristics with a parallel plane ion chamber measurements, 
dose linearity, energy response and angular response. Post irradiated MP detectors 
showed a reproducibility of 2.1%. The MP dose per pulse response decreased at higher 
dose rates while at lower dose rates the MP appears to be dose rate independent. A good 
agreement of the percentage depth dose measurement of the MP with ion chamber depth 
dose measurements to within 0.7%.  
The MP was shown to have some angular dependency due to the anisotropy of the 
silicon diode with the maximum variation in response of 10.8% at a gantry angle of 
180
0
.  The angular dependence was within 3.5% for the gantry angles of ±75
0
. Field size 
dependence of the MP at isocenter was shown to agree with an ion chamber 
measurement to within 1.1%. In the beam perturbation study using MPTM, the 
transmission for the MP was 99% at 6 MV while the surface dose increased by 12.1% 
for a 30×30 cm
2






In summary, although methods are being developed to verify the quality of a treatment 
delivery, some cases are quite bulky and they are relatively expensive equipment, and 
not provide a comprehensive picture of the beam delivery. There is currently no 
complete mainstream method to verify the delivery of the plan, during patient treatment. 
The use of silicon diode arrays in QA holds much promise and have the potential to fill 
this gap in verification systems due to its desirable qualities, such as the real-time 
operation and feedback when compared to other methods e.g. films which are not real 
time, its high temporal response and strong radiation response, they have been selected 
to be used for the development of a quality assurance system in this thesis. 
It was important to verify in this thesis that the surface dose due to electron 
contamination from MPTM was not significantly increased. This was mainly performed 
by using an original Markus and Attix ion chambers in phantom under the MPTM as 
outlined in future sections of this work. 
The 2D transmission response data is collected in real-time. This data is then used to 
reconstruct the dose in 2D along rays projected from the photon source through each 
sensor element. As the data is collected in real-time, the dose, in principle, can be 
reconstructed segment by segment for IMRT or even pulse by pulse for VMAT. The 2D 
reconstruction could also be extend to 3D reconstruction, however this is beyond the 
scope of this thesis. It is extremely exciting for real-time QA of these increasingly 
complicated treatment regimes. The reconstruction methodology will also be of great 
interest to the wider oncology community as it is applicable to many other forms of 
radiotherapy including Stereotactic Radiosurgery, Stereotactic Radiotherapy, Image 
Guided Radiotherapy and Motion Adaptive Radiotherapy with dynamic multi leaf 
collimator tracking, where real-time radiation treatment monitoring through dose 





Transmission type detectors can provide a measure of the energy fluence and if they are 
real time systems that do not significantly attenuate the radiation beam have a distinct 
advantage over the current method as QA could in principle be performed during the 






CHAPTER 3  
 
                                Methodology 
The previous chapter reviewed the current technology used in IMRT and VMAT dose 
verification reported in the literature, and concluded with silicon diode detectors being a 
very attractive candidate for the development of an IMRT and VMAT QA system. This 
chapter goes on to describe the technology proposed for the dose verification in real-
time during treatment delivery. It describes the development from the single detector 
element to the 2D array of elements, the electronics system as well as other detectors 
that have been tested. 
 
3.1 Experimental setup  
 
3.1.1 Linear accelerator and field arrangements  
In this thesis, experiments were performed on a linear accelerator Varian model 
2100IX; (Varian Medical Systems, Palo Alto, CA), which operates at the energies of 6 
MV and 10 MV at the Illawarra Cancer Care Centre (ICCC), Wollongong Hospital, 
Wollongong and another medical linac model 2100iX; (Varian Medical Systems, Palo 
Alto, CA) producing 18 MV at St. George Hospital in Sydney. 
 Comprehensive detector characterisation (both in transmission mode and in dosimetry 
mode) included; beam perturbation study, IMRT dosimetry, VMAT dosimetry and 
verification of dose reconstruction methodology were carried out using the machines. 





delivery. Dose rates between 100 MU/min and 600 MU/min can be selected in 100 
MU/min increments. Up to 9999 MU can be delivered for any one treatment (i.e. in 
service mode). All the irradiation field sizes quoted refer to the field size defined at a 
source to surface distance (SSD) of 100 cm. Measurements undertaken for this thesis 
were performed with the radiation field defined by the linac jaws (an open field) and the 
MLCs; a highly non uniform irradiation field (C shape) and fields with several 
programmed MLC movements. The field size was changeable between the limits of 1 
× 1 cm2 and 40 × 40 cm2, unless otherwise stated.  
 
3.2 Epitaxial Diodes 
This kind of technology consists of a high quality tiny epitaxial film on the top of a 
heavily doped bulk silicon wafer, which behaves as a crystal seed for the tiepitaxial 
growth and later works as a supporting structure. “Epitaxial means layered upon” as 
shown in Figure 3.1. 
The epitaxial diode becomes an attractive option in the field of radiotherapy, and differs 
from conventional silicon detectors due to the thin epitaxial layer which works to be 
more “radiation hard” [247]. The capability to shrink the pixel area (detector sensitive 
area), allows a smaller detector thickness to be thinner compared to a silicon detector 
with a thickness of 300 µm. Also, thinner detectors would also reduce the required 
operational voltage [248].The epitaxial silicon diode has been designed and the 
characterisation of this device was reported earlier by Talamonti et al [249], and Bruzzi 
et al. [247].  The diodes used in the MP were grown by using the epitaxial growth 
technique [103]. The p-epitaxial layer is a 50 µm thick p-Si layer on the top of 375 µm 





characterisation of the individual epitaxial CMRP silicon diodes utilised have been 
reported elsewhere [9, 94, 250]. 
 
3.2.1The “Magic Plate”  
The Magic Plate (MP) incorporates an array of 11 × 11 silicon diodes (121 sensors), 
covering an area of 10 × 10 cm
2 
(as shown in Figure 3.2). Each sensor element was 
manufactured using epitaxial silicon detector technology. Figure 3.1 represents the single 
element structure of the 2 D array which is a diode manufactured by an epitaxial technology. 
The epitaxial layer is 50 µm thick, p-type (100 Ω cm) and grown on top of a 375 µm 
thick, very low resistivity (0.001 Ω cm) p-type substrate. The p-type substrate was 
chosen for its well-known radiation hardness and the epitaxial layer thickness minimises 
the radiation damage effects that influence the radiation response of the sensors while 
providing adequate sensitivity for the sensor application described in this thesis. The 
diodes were produced using ion implantation technology after which they were diced 
and embedded in a 0.64 mm thick Kapton
®
 carrier using the  ‘drop-in’ technology 
developed at the CMRP, UoW [251], so as to be spaced 10 mm apart. This technique is 
used to minimise the energy dependence and dose enhancement in a photon field due to 
high Z material typically used for packaging of silicon dies. The Kapton
®
 pigtails are 
then shielded with thin aluminium foil and grounded to minimise effects from external 
radio-frequency noise [252].  The physical size of a single diode is 1.5 × 1.5 × 0.05 mm
3
 













Figure 3.2: The 2 D array Magic plate (MP). The MP uses two 
SCSI-2 connectors, with 68 channels each connector, to interface 
with the readout electronics. This makes the MP modular, and can 






The MP has been designed to be used as a transmission detector (MPTM) that can be 
mounted on the linac head (accessory slot) in line with radiation beam (as shown in 
Figure 3.3).  In this case, MPTM can be used to verify the dose maps from IMRT and 
VMAT in real-time during treatment delivery and to measure the 2D fluence map of the 
modulated radiation beam. The MP can also be used in dose mode to measure 2D dose 




Figure 3.3: Magic Plate in transmission mode (MPTM) mounted in 
the accessory tray slot, just below the linac jaw of the medical 
linear accelerator on the head of a Varian linac. 
 
 
When the MP is used in transmission mode (MPTM), the MPTM array is sandwiched 
between a black plastic sheet (80 µm), to reduce light leaking to the detector, as a build-
up material and/or with an additional 1 mm of solid water covering the entire array, to 
remove scattered low energy electrons. Then, the whole assembly is clamped between 
two 6 mm acrylic Perspex
®





irradiation (TBI) tray, which can be attached onto the linac accessory slot (this is 58 cm 
on a Varian linac from the X-ray source). The field size on a MP is 1.72 times smaller 





Figure 3.4: (a) The MPDM was sandwiched between two pieces of 5 mm solid water 
plates that were designed to fit the Kapton
®
 substrate. (b) The 2D planar diode array 
detector placed in dose mode (MPDM) in a solid water phantom. 
 
 
When used as a 2D planar diode array in dose mode (MPDM) in a phantom (as shown 
in Figure 3.4 (a)), the MPDM was sandwiched between two pieces of 5 mm solid water 
plates that were designed to fit the Kapton
®
 substrate. The solid water plate’s width was 
1.5 cm. The two solid water plates serve three purposes: 
(i)  Shielding the detector from ambient light (optically light tight). 
(ii)  For mechanical strength, and protection of the MP diodes. 





This allows the MPDM to be used in combination with an IMRT phantom on the top of 
the linac couch (as shown in Figure 3.4(b)). A preliminary characterisation of this 
device in dose mode (MPDM) has been reported earlier by Wong et al. [94].  
The MP has been shown to possess suitable properties for use as a 2D radiation 
transmission detector for radiation therapy treatment verification during patient 
treatment. All MP measurements  were performed  in passive mode (no external bias 
applied at the electrodes) to minimise the variation of the leakage current and the 
consequent variation of the baseline of the signal which requires time consuming and 
frequent recalibration procedures. 
 
3.3 Electronics and software 
Each diode in the MP is read out individually by a multichannel fast data acquisition 
system (DAS) based on a charge to frequency converter chip named TERA06, designed 
by the Instituto Nazionale di Fisica Nucleare (INFN) – Turin Division and University of 
Turin microelectronics group. This was originally developed, for readout of pixelated 
ionisation or strip chambers for Hadron Therapy as described in detail elsewhere [253]. 
The device is capable of integrating the photo-induced charge in the detector with zero 
dead time over a range of acquisition times (for the experiments described in this thesis, 
this was set to 100 ms per frame) and for a fixed total acquisition time. The system 
provides the measure of the total charge by a digital value (16 bit) transmitted by a 
USB2.0 link; the information is stored on a computer and visualised on the screen in 
real-time (48 MB/sec transmission rate). The same readout electronics for the MP 
detector array were used in both transmission and dosimetry mode. Figure 3.5 (a) shows 
the layout of the Rad-X Doseview software which was utilised in order to acquire all 





see the real time response of up to 128 individual detectors as well as their respective 
integral response over the set time of acquisition. Alongside the realtime numerical data 
for individual detectors, the software allows for a viewing of an array of devices with a 
dynamic relative colour based scale as shown in Figure 3.5 (b). For further information 
about the readout system designed for the MP refer to [254, 255].  
The MPDM and MPTM measurements were performed in passive mode (no applied 
bias) for simplicity of operation and because for all the experiments described in this 
thesis, an adequate photogenerated response was measured, leading to an excellent 





Figure 3.5: (a) Rad-X Doseview Softwear with individual detector readout and (b) 
Rad-X Doseview Softwear for visualization of array readout 
 
 
3.4 Equalisation procedure 
The MP 2D array consisted of 121 detectors implanted on bulk p-type silicon substrate. 
The radiation response from each individual diode is different from the adjacent 





the integral dose between the 121 detectors readout channel will be slightly different. 




Figure 3.6: The equalisation procedure: the MP at a depth of 10 cm of a 30 
× 30 × 20 cm
3
 solid water phantom and exposed to a 20 × 20 cm
2
, (field 
size defined at an SSD of 100 cm). 
 
 
Figure 3.6 shows the experimental configuration which was carried out prior to any 
measurements by the MP detector array (MPTM and /or MPDM), a flat field correction 
was prepared by placing the 2 D array at a depth of 10 cm of a 30 × 30 × 20 cm
3
 solid 
water phantom and exposed to a 20 × 20 cm
2
, (field size defined at an SSD of 100 cm), 
and then irradiated for 20 seconds (200 MU) delivered at 600 MU/min dose rate. The 





any measurements to generate a flat beam. The flat field correction statistics of MP121 
response before and after the equalisation was applied. The differential response for 
each energy can be calculated as (3.1): 
 
 X (%) = 
𝑋𝑒𝑞(𝑖→𝑗)−𝑋𝑒𝑞(6,6)
𝑋𝑒𝑞(6,6)
 × 100 (3.1) 
 
where the Xeq (6, 6) is the integral response of the central pixel after equalisation as 
described in above, i= detector number (1) and j= detector number (121) .The variation 
in the response of all 121 detectors relative to the average response can be then 
calculated before and after flat field correction for each desirable beam energy.  
 
 
3.4.1 Ionisation chambers 
PTW original Markus parallel plate ionisation chamber along with four other ionisation 
chambers has been used in this thesis. The other four chambers are the Attix, Wellhöfer 
compact ionisation chamber (CC13), Farmer and PTW semiflex thimble ion chambers. 
Details about the experimental set-up will be explained for specific energy in details in 
future chapters. 
 
 3.4.1.1 Parallel plate ionisation chamber 
 
There are some limitations of the plane parallel chamber in surface dose measurements. 
For plane parallel chambers, the charge measured is produced by the electron fluence 
entering from the front window and that by the secondary electrons scattered from the 





Markus-type chambers (as indicated in Figure 3.7)  are known for their over-response 
due to their small guard ring [257, 258] and different methods have been developed to 
correct for this over-response [259]. To correct for the effect of electrons entering 
through the side wall, a factor to correct the chamber reading was derived by Velkley 
[260]. Gerbi and Khan [261] reported  that an accepted accuracy of ±2% was produced 
by the Velkley correction factor, but only for those chambers which have a distance of 
(5-11 mm ) between collecting edge and side wall, outside this range the formula did 
not predict accurate results. Gerbi and Khan modified the Velkley formula to take into 
account the effect of the distance between the collector edges to side wall. Rawlinson et 
al. [262] examined the design features of plane parallel chambers and found that the 
over response from the side walls is mostly dependent on the ratio of the electrode 
separation (s) to the diameter of wall (w), wall angle and wall density. They also 
extended the Velkley formula to account for the chamber wall diameter, size of the 
guard ring, separation of electrode and the material of chamber. The Velkley correction 
formula as modified by Rawlinson is as indicated in equations  (3.2),(3.3) and (3.4): 
 
 P (d,E)= P`(d,E.G) – ξ(d,E,G)                  (3.2) 
 
 ξ(d,E,G) = ξ(0,E,G) × e−4.0d/dmax              (3.3) 
 
 ξ(0,E,G)= c(E) × (s/w) × ρ
0.8    
                   (3.4) 
 
where P is the true percentage depth dose and P` is the measured percentage depth dose, 





mass density of the ionisation chamber wall, s/w is the ratio of electrode separation (s) 
to the diameter of wall (w). For 6 MV photon beam, dmax is 15 mm and c(E) = 27% (as 
per Rawlinson et al. [262]). 
In this thesis, all in-field dose measurements were therefore corrected using the Velkley 
correction as modified by Rawlinson to correct the over response of the Markus 
chamber measurements as mentioned earlier [260]. The chamber dimension used for the 















Another parallel plate ionisation chamber is the Attix chamber, which is an air filled 
parallel plate ionisation chamber made almost entirely of solid water with a flat plane 
towards the beam and an effective point at the surface of the air cavity (as shown in 
Figure 3.8). When enclosed in the recommended solid water phantom (design for Attix 
IC) perturbations of photon and electron beams by the chamber are negligible. It has a 
very thin window to allow the dose at the interface region to be measured. However, it 
does have some limitations, which include it’s very large size (6 cm diameter for 
Gammex RMI Model 449), so it cannot be used for fields that are smaller than its 
diameter (see Figure 13). The ion collector has a minimal thickness colloidal graphite 
coating on a 0.13 mm thick polyethylene disc. Therefore, its thickness allows 
measurements of dose build-up starting almost at the surface of a phantom.  
 
3.4.1.2 Thimble ionisation chamber 
 
One of the thimble ion chambers used to measure the output factors in this thesis is 
called a Farmer chamber (Model 2571). In 1955, Farmer designed a chamber which is 
stable and reliable for X-rays and gamma rays for all energies. In the newest design the 
thimble central electrode is of aluminium and the wall is made of pure graphite. The 
thimble insulator consists of polytrichlorofluorethylene (PTCE). The collecting volume 
of the ionisiation chamber is 0.6 cm
3
. It has three electrodes: the central electrode (the 
collector), the thimble wall, and the guard electrode. The role of the collector is to send 
the current to the electrometer (charge measuring device which is operated in high 








 dosimetry system 
The impact and the transmission factors of both the bare MPTM and for the MPTM 
with 1 mm build up on the open field 2D dose distribution was measured using Delta
4®
 
system to learn more about the dose difference of IMRT/VMAT beams with MP in 
place as compared to an open beam.  
 
3.4.3 Conclusion 
This chapter provides a description of the 2D detector array, the MP and the TERA 
DAQ system that was connected to the MPTM and MPDM which was used to sample 
the measured integrated charge and relay the data to the software suite.  Delta
4®
 was 
also introduced, with the dose calibration procedure presented, as it appears in further 
chapters in this thesis.  
The following chapter details the feasibility tests performed to characterise the use of 
the MPDM associate software system for use in IMRT and VMAT quality assurance 






CHAPTER 4                                                                                                                   
Radiation Response and Basic Characterisation 
of the “Magic Plate” when Operated in Dose      
Mode with Different Beam Energies 
 
This chapter demonstrates the potential performance characteristics of the MP system 
when operated in dose mode (MPDM), i.e. on the patient couch at several linear 
accelerator potential differences. 
 
4.1 Introduction 
Advances in modern radiotherapy techniques for the treatment of cancer continue to 
appear. A recent example is the introduction of VMAT which involves a complex 
combination of dose rate variation and beam shaping (to that of the target) while the 
treatment beam moves continuously around the patient [264]. The main driver for these 
advances is the desire to achieve better tumour control through dose escalation to the 
target together with tighter treatment margins. Such advances, need to be made without 






Implementation and commissioning of VMAT as well as routine QA of patient plans 
and linear accelerators requires an independent dosimetry system, preferably one 
capable of measuring a 2D dose distribution.  
The MP QA detector system includes a 2D silicon diode array, fast real-time readout 
system, and associated software which was first proposed by Rosenfeld from the CMRP 
at the UoW. The MP was designed to be placed on the treatment head of the linac as a 
transmission detector during the patient treatment (MPTM) as well as to function as a 
planar detector for dose distribution measurement in a solid water phantom for the 
dosimetric verification of IMRT and VMAT treatment deliveries. The MP has been 
previously described and characterised in dose mode (MPDM) to map a 2D dose 
distribution in a solid water phantom [9]. 
This chapter extends some of the work published by Wong et al [9]  that was carried out 
in dosimetry mode at 6 MV photon beam . In particular the field size dependence, beam 
profiles, and the response of the array with different frequency pulses have been 
measured for different beam energies such as 10 MV and 18 MV beams to assess the 
operation of the MP in these significantly different radiation field environments (e.g. 
including neutrons at 18 MV). 
 
4.2 Materials and methods 
The MP is designed to be operated in both transmission mode (MPTM) to sense the 
actual energy fluence during patient treatment and in dose mode (MPDM) to map the 
2D dose distribution at any depth on the solid water phantom. Details of the individual 
epitaxial diodes and characterisation of the array in dose mode are published in previous 
work [9, 250]. Measurements  were performed  in the passive mode (zero volts applied 





variation of the baseline of the signal which requires time consuming and frequent 
recalibration procedures. Prior to any measurements by the MP sensor array a flat field 
correction (equalisation procedure) was performed (see section 3.4). It should be noted 
that in all cases, irradiation field sizes quoted are referred to the field size defined at the 
SSD of 100 cm.  
 
4.2.1 Field size dependent surface doses and output factor measurements 
 
The potential performance of the 2D array in dose mode (MPDM) when measuring the 
linac radiation output as a function of the field size was investigated. Effectively this 
test assessed the scatter properties of the matrix of detectors, which depend on the 
internal design of the device.  
In this chapter output factor measurements and surface doses were carried out by 
delivering 100 MUs for squared field sizes ranging from 5 × 5 cm
2
 to 40 × 40 cm
2
. The 
MPDM was positioned in the phantom surface and in standard set-up (depth of dmax at 
100 cm SSD). Dose outputs were compared with ion chamber measurements taken at 
the same conditions using a Markus ion chamber (Model N23343 ), Attix parallel -plate 
(MRI,Model 449) ion chamber, Wellhöfer compact ionisation chamber (Model CC13), 
Farmer ionisation chamber (Model 2571) and the PTW semiflex thimble ion chamber 
(Model 31010).The ion chamber detectors were connected to a Unidos universal 
dosimeter (PTW, Freiburg, Germany) (Model 1300698- T10023) for 6 MV, 10 MV and  






4.2.2 Beam dose profile measurements 
The beam dose profiles were also measured at different depths (at the phantom surface 
and depth of dmax) in the solid water phantom by the MPDM. The MPDM were 
compared with those from the CC13 ionisation chamber and the PTW semiflex thimble 
ion chamber, at the same depth for field sizes ranging from 5×5 cm
2
 to 40 × 40 cm
2
 at 
an SSD of 100 cm using the beam energies previously mentioned. For each profile the 
MLCs were opened to match the linac jaws. The beam profiles were constructed by 
stepping the respective detectors laterally across the beam using the patient couch in 
centimetre steps for MP and millimetre steps for the ionisation chambers through each 
field. 
 
4.2.3 The response of the array with different frequency pulses 
The response of the array with different frequency pulses was measured by varying the 
pulse repetition frequency (PRF) of a Varian linear accelerator; the mean dose rate is 
changed while dose per pulse remains constant. The average dose rate as seen by the 
detector can be varied by either changing the dose per pulse or the pulse repetition rate 
of the linear accelerator. The dose per pulse was modified by changing the depth of the 
detector in the phantom. The MP diode array detector was placed at different depths on 
the solid water phantom at dmax and depth of 10 cm in a 10×10 cm
2
 beam at an SSD of 
100 cm and irradiated with 100 MU for 6 MV, 10 MV and 18 MV beams. The single 
diode of the array located on the central axis was used to evaluate the response of the 
2D detector array. The dose rate at dmax ranged from 100 cGy/min to 600 cGy/min but 

































(c) 18 MV 
 
Figure 4.1. Surface doses comparison between 2D MPDM and ion chambers 
(Markus and Attix ion chambers). The local percentage difference is also shown. 
Field size range between 5×5 cm
2
 and 40×40 cm
2
. Data were acquired at the 




Field size dependent surface dose measurement results of MP for 6 MV, 10 MV and 18 
MV beams at 100 cm SSD are shown in  
Figure 4.1(a , b and c) respectively. The Surface doses measured using the Markus ion 
chamber and Attix chamber were also included for comparison. The field size 
dependence of the 2D array central axis (CAX) diode values measured at source 





difference of the MP compared to the ion chambers measurements are related to the 
water equivalent depth (WED) of MP which is 500 µm. The increase in WED is mainly 
caused by the fact that the material above the sensitive volume is not water equivalent but 
silicon. So, the additional energy deposited in the sensitive volume scales with the density 
of the material (Silicon compare to water). More electrons back scattering due to higher 




Figure 4.2: Output factor comparison between 2D MPDM and ion chambers (Farmer 
and CC13 ion chambers). The local percentage difference is also shown. Field size 
range between 5×5 cm
2
 and 40×40 cm
2
. Data were acquired at dmax in standard set-up 







Output factor measurement results of MPDM for 6 MV photons at 100 cm SSD are 
shown in Figure 4.2. The output factor measured using the Farmer ion chamber and 
CC13 chamber were also included for comparison. The field size dependence of the 2D 
array CAX diode values measured at source detector distance (SDD) 101.5 cm (dmax) 
agreed well with both the Farmer chamber and CC13 ion chamber. Discrepancies are 




Figure 4.3:  Output factor comparison between 2D MPDM and ion chambers (CC13 
and Markus ion chambers). The local percentage difference is also shown. Field size 
range between 5×5 cm
2
 and 40×40 cm
2
. Data were acquired at dmax in standard set-up 






Figure 4.3 shows the field size dependence of the 2D array CAX diode values at SDD 
100 cm for a 10 MV beam. The output factor measured using the Markus ionisation 
chamber and CC13 chamber were also involved for comparison. MPDM measurements 
have been performed at depth of dmax (21 mm in case of 10 MV beam) agreed very well 




Figure 4.4: Output factor comparison between 2D MPDM and ion chambers (Thimble 
and Markus ion chambers). The local percentage difference is also shown. Field size 
range between 5×5 cm
2
 and 40×40 cm
2
. Data were acquired at dmax in standard set-up 
using solid water phantom. 18 MV beam was used for this study. 
 
Field size dependent measurement results of MPDM for 18 MV beam at 100 cm SSD 





chamber was also included for comparison. The output factors of the 2D array CAX 
diode values measured at SDD of 103 cm (dmax) fit very well with the thimble ion 
chamber within 0.57 % for all field sizes.  
 
4.3.2 Beam dose profile measurements 
 
 






(b) 10 MV 
 
(c) 18 MV 
Figure 4.5: Beam dose profiles measured at the phantom surface with MPDM. 6 MV, 
10 MV and 18 MV linac beams were used for this study. Error bars are not shown 






Figure 4.5(a-c) shows dose beam profiles measured of the MP at the phantom surface in 
absolute terms (independently converted to Gy) for 6 MV, 10 MV and 18 MV linac 
beams and SSD of 100 cm. Measurements were made with radiation fields from 5×5 
cm
2
 to 40×40 cm
2
 and fields defined by the linac jaws and the MLCs. The aim of these 
measurements is to study the behavior of the array at the surface. Comparison with 
some data in transmission mode will be useful to reconstruct the dose in the patient. 
 
 
(a) 6 MV 
 






(c) 18 MV 
Figure 4.6: Comparison between measured dose profiles using ion chambers (CC13 and 
PTW Thimble chambers) and measured doses using Magic Plate in solid water phantom 
(MPDM) at dmax. 6 MV, 10 MV and 18 MV were used for this study. Error bars are not 
shown for clarity purposes. 
 
 
Figure 4.6 (a-c) shows dose beam profiles measured of the MPDM (dots) at depth of 
dmax in absolute terms (individually converted to Gy) compared with dose beam profiles 
of ionisation chambers (lines) measured at the same depth for 6 MV, 10 MV and 18 MV 
linac beams and SSD of 100 cm. Measurements were made with radiation fields from 
5×5 cm
2
 to 40×40 cm
2
 and fields defined by the linac jaws and the MLCs. 
The 2D Array data fit very well the ion chamber profiles with a maximum percentage 
difference of 3% for all field sizes and for all beam energies tested, both in and out of 
the irradiation field. Furthermore, the MPDM detector measurements are accurate also 
in the penumbra region. This case is interesting because it shows some limitations of the 





spatial resolution of the MP detector elements easily accounts for the small differences 
observed between the data sets in the penumbra region of the beam profiles. It can be 
noted that for all field sizes the dose on the thin end of the profiles is not measured in 
the completed dataset. This is because the field edges actually fall between two adjacent 
detectors. This is due to the detector design having a 1 cm spacing of the MPDM. 
Nonetheless the agreement between the two datasets is very good with the 2D array data 
accurately matching the ion chamber profiles. Above results prove that MPDM is 
validated against the ion chambers and no perturbation of the field caused by MPDM in 
a solid water phantom. This demonstrates that the robustness of the 2D array when 
operated in dose mode. 
 
4.3.3 The response of the array with different frequency pulses 
In previous work the MPDM was irradiated with a 10 × 10 cm
2
 field size and showed 
decreased dose per pulse response at higher dose rates (dose per pulse >1 × 10
−4
 
Gy/pulse) due to the Auger recombination effect. However, at lower dose  rates typical 










(a) 6 MV (b) % STDEV (6 MV) 
  







(e) 18 MV (f) % STDEV (18 MV) 
 
Figure 4.7: The response of MPDM with changing dose rate with comparison with Farmer 
chamber and 0.125 CC chamber. The local percentage difference is also shown. The variation 
of the response of 2D MPDM at dmax with changing dose rate was also shown. 6 MV, 10 MV 




Figure 4.7 (a, c and e) shows the response of the array CAX diode value with different 
frequency pulses measured of the MPDM (black squares) at depth of dmax 
(independently normalised to 600 MU/Min) compared with normalised data from an 
ionisation chamber (red dots) measured at the same depth for 6 MV, 10 MV and 18 MV 
linac beams and SSD of 100 cm. Measurements were made with radiation field size of 
10×10 cm
2
 and fields defined by the linac jaws and the MLCs. The 2D Array data 
(CAX) diode value agreed very well with the ion chamber measurements with a 
maximum percentage difference within 2.5 % for 10×10 cm
2
 field size and for all beam 





Figure 4.7 (b, d and f) show a 2D presentation of the percentage standard deviation of 
all dose rates tested on the MPDM array which was within 1% (one standard deviation). 
 
  
(a) 6 MV (b) % STDEV (6 MV) 
 
 







(e) 18 MV (f) % STDEV (18 MV) 
 
Figure 4.8: The response of MPDM with changing dose rate with comparison with Farmer 
chamber and 0.125CC chamber. The local percentage difference is also shown .The variation 
of the response of 2D MPDM at depth of 10 cm with changing dose rate was also shown. 6 
MV, 10 MV and 18 MV were used for this study. The data has been normalised to the 600 
cGy/min response at each energy. 
 
 
The response of the 2D array (MPDM) (CAX) diode value with different frequency 
pulses measured of the MPDM (black squares) at a depth of 10 cm (independently 
normalised to 600 MU/Min) was investigated in  
Figure 4.8 (a, c and e). MPDM results compared with normalised data of ionisation 
chambers (red data points) measured at the same depth for 6 MV, 10 MV and 18MV 
linac beams and SSD of 100 cm. Measurements were performed with radiation field 
size of 10×10 cm
2
 and fields defined by the linac jaws and the MLCs. The 2D Array 
(CAX) diode data value agreed very well with the ion chamber measurements with a 
maximum percentage difference less than 2.8 % for 10×10 cm
2
 field size and for all 





Figure 4.8 (b, d and f) also show that a 2D presentation of the percentage standard 




In a phantom, the response of the silicon diode array (MPDM) is determined by a 
combination of photon interactions directly in the diode as well as energy depositions 
within the diode resulting from secondary electrons produced in the phantom that reach 
the diode. The primary component of the energy dependence observed using silicon 
diodes for dosimetry is due to the low energy component of the scattered photon 
radiation in the phantom combined with the increase in the photoelectric cross-section 
of silicon compared to water. Such energy dependence is therefore not critical here 
where the beam energy is 6 MV, 10 MV, and 18 MV. However for out-of-field (OOF) 
measurements it is expected to be more significant and therefore must be taken into 
consideration. 
At small field sizes (< 5×5), it is well known that the lack of electronic equilibrium a 
lower dose delivered per monitor unit, whereas for field sizes >10 × 10 cm
2
, electronic 
equilibrium is reached and so the dose delivered per monitor unit is constant. One of the 
main interests in using detectors such as MP for IMRT and VMAT dose verification is 
that the dimensions of the  detector is very small so they are usually regarded as an 
excellent choice for output factor measurements especially for small field sizes. It is 
well known that ionisation chamber measurements for field sizes less than 5×5 cm
2
 may 
not be accurate because of the volume averaging effect. This highlights one of the major 
advantages of the MP detector since the IMRT segment sizes in clinical treatments 





characteristics of the 2D array MPDM have been investigated. In Wong et al [9] the  
measurements performed using a 6 MV photon beam showed that the 2D array response 
(MPDM) was very reproducible, within 2.1 % and the system’s linearity to dose was 
also verified for the measured dose range of 0.05-10 Gy. Output factor comparison with 
ion chamber measurements was also very good. In this work output factors agreed very 
well with reference dataset for field sizes ranging from 5 × 5 cm
2
 to 40 × 40 cm
2
. The 
2D MPDM successfully detected centimeter positional movements of the linac 
secondary collimators. Moreover, dose profiles matched very well with ion chamber 
measurements. As pointed out in this chapter, the MP spacing of 1 cm may result in a 
limited sampling of the radiation beam. This may be an issue if high resolution for 
asymmetric profile edges are needed, e.g. in high dose gradient regions. However, this 
is an efficiency problem common to other planar detectors currently available.  
Promising devices for IMRT verification and in vivo dosimetry include EPIDs [151, 
161], Delta
4®
 [176], ArcCHECK [181-183, 266] and OCTAVIUS [267]. These 
detectors can provide very high resolution and highly efficient planar dose maps. 
However, further investigations are under way for the deployment of this technique into 
in vivo routine clinical practice [268, 269]. With the 2D MPDM the workload can be 
remarkably reduced when compared to conventional verification techniques. One of the 
attractive points of this class of devices is that dose distributions are acquired, shown 
and potentially processed in real-time. The data acquisition software provides a 
graphical environment where dose maps can be compared and evaluated pulse by pulse. 
Alternatively, measurements may be exported to any files format and loaded in other 
applications. MPDM sensor is very thin compared to other commercially available 
detectors and easy to use for daily radiotherapy plan verification. The experimental 





average time required to arrange the system in the standard measuring set-up was <5 
min which is similar to the setup time for a Delta





The radiation response of the MPDM was characterised. The 2D array of epitaxial 
silicon based detectors with “drop-in” packaging showed properties suitable to be used 
as a simplified multipurpose and non-perturbing 2D radiation detector for radiation 
therapy dosimetric verification. On the basis of the of tests performed in this chapter, 
one can conclude that the 2D array is a dosimetrically accurate and sensitive tool and 
that it can be a useful device for QA and verification of clinical radiotherapy beams. 








CHAPTER 5                                                                               
Beam Perturbation and Surface Dose 
Characteristics in 6 MV, 10 MV and 18 MV 
Photon Beam Energies 
This chapter describes and discusses the performance characteristics of the MP system 
when operated upstream of the patient in transmission mode (MPTM). The MPTM is an 
essential component of a real-time QA system designed for operation during 
radiotherapy treatment. Of particular interest is a quantitative study into the influence of 
the MP on the radiation beam quality at several field sizes, several treatment 
configurations and linear accelerator potential differences. The impact is measured 
through beam perturbation effects such as changes in the skin dose and/or PDD (both in 
and out of field).    
 
5.1 Introduction 
The Magic Plate has been previously reported in dose mode (MPDM) to map a 2D dose 
distribution in a phantom [9] and further investigation with different beam energies has 
been performed in the previous chapter. However, for the real-time QA system the MP 
is placed in the accessory slot on the head of the linac and must be operated as a 





incident radiation field, requiring a detailed study of its influence on the treatment 
beam. The surface dose in particular can be one of the limiting factors in treatment plans 
with high doses to a target and is the focus of this chapter [217]. Similar studies in the 
past have been completed for beam modifiers such as wedges, MLC and block trays 
[205, 270-272]. 
 Beam perturbation can be quantified by measuring changes in the PDD profiles 
particularly in the build-up region including surface dose, with the transmission MP 
placed in the beam. Ideally, such a device would have no significant impact on the 
treatment delivery, either to the target dose or surrounding normal tissues. Therefore, 
the main objective of this chapter is to quantitatively determine whether or not the 
presence of the MP upstream of the patient has a significant effect on the surface dose 
and PDD during patient treatment.  
 
5.2 Materials and methods 
For the MPTM investigation, two potential operational conditions were examined in 
this chapter: 
 (i)  The MP array sandwiched between black plastic sheets, 80 µm thick, here in 
referred as “bare MPTM” as shown in Figure 5.1(a). The role of the black plastic is to 
remove light from the background detector response. 
 (ii) The MP array with an additional 1 mm of solid water covering the entire array as 
shown in Figure 5.1(b). The role of the 1 mm solid water was to remove scattered low 
energy electrons. 
Condition (i) is designed for minimum attenuation of the primary linac beam; however 





electrons. To better sample the energy fluence, the 1 mm of solid water was introduced 
in condition (ii) to filter a large component of these contamination electrons. 
Experiments were performed on two Varian linear accelerators (Model 2100EX), one of 
which operated at the energies of 6 MV and 10 MV, and another which was operated at 
18 MV. Irradiation field sizes of 5 × 5 cm
2
 and 10 ×10 cm
2
 and a constant SSD of 100 
cm were used for both linac experiments.   
 
5.2.1 Surface dose and percentage depth dose measurements 
The surface dose and PDD for each set-up (i.e. (i) and (ii) above) were measured and 
compared to the corresponding surface dose and PDD with no MP in place (i.e. open 
field). These measurements were carried out both in-field (on the beam CAX) and out-
of-field (OOF) for different field sizes. Ionisation chamber measurements were 
normalised to the maximum dose at a depth of 15 mm for 6 MV, 21 mm for 10 MV and 
30 mm for 18 MV beam energies. With the MPTM mounted on the linac accessory slot, 
PDD up to a depth of 10 cm were measured on the CAX and OOF 11cm laterally to 
CAX as a function of the irradiation field size. For the OOF measurements, the solid 
water phantom and detector on the linac patient couch were moving laterally from the 
central axis position. The phantom size was 60 × 30 × 30 cm
3
 with the lateral movement 
in the direction of the 60 cm phantom length to maintain consistent scattering conditions 
(see Figure 5.3 (a and b)).  
The depth dose profile and surface dose were measured with Markus type (PTW, 
Freiburg, Germany) parallel plate ionisation chamber Model N23343. The chamber was 
connected via a tri-axial cable to a PTW UNIDOS model T10002-20713 electrometer 
with -300 V bias voltage applied. The Markus chamber is designed for the measurement 





due to  the large separation and their small guard ring [257, 258] and different methods 
have been developed to correct for this over-response [260-262, 273]. In this chapter, all 
measurements using the Markus ionisation chamber were corrected using the Velkley 
correction as modified by Rawlinson to correct the over-response of the Markus 
chamber. The chamber dimension used for the correction calculation was obtained from 
Chen et al.  [263]. A dose of 200 MU was used for all measurements.  
All measurements were performed with MPTM (Source to Detector Distance (SDD) of 
58 cm) for the two different set-up conditions mentioned above and without MP (open 
field) as shown in Figure 5.2 (a and b). All measurements were repeated at least three 
times in order to calculate the average value and standard deviation.  
The depth dose as a function of field size in the solid water phantom were carried out 
using the Markus chamber mentioned above with some data compared with that using 
an Attix chamber, RMI model 449 for the same measurements. 
 
5.2.2 The influence of the MPTM on the beam quality using Delta4® system 
In the second part of this chapter, the influence of both the bare MPTM and the MPTM 
with 1 mm build up on the open field 3D dose distribution (measured change as a 
percentage) was measured by the Delta
4®
 QA system. 






, the beam segments and 
modulated IMRT beam for a patient lung tumour with seven segments) were verified 
using a Delta
4®
 phantom both with and without the MP located in the beam. A daily 
calibration factor was determined using a standard 20×20 cm
2






5.2.3 The transmission factor measurements 
In the third part of this chapter, the transmission factor of the MP was investigated. The 
transmission factor was derived from any dose change measured at dmax and at a depth 
of 10 cm for radiation field sizes 10 × 10 cm
2
 and 5 × 5 cm
2 
and an SSD of 100 cm for 6 
MV, 10 MV and 18 MV photon fields. A Farmer ionisation chamber (Model 2571A) 
was used for 6 MV, 10 MV and an Attix chamber, Model 449 was used for the 18 MV. 
A Delta
4®
 system was also used to measure the transmission characteristics for 6 MV 
photon beam using different treatment configurations for both MP versions in 





Figure 5.1: MP with two possible setup conditions: (a) the bare MP array 
(sandwiched between black 80µm thick plastic sheets) and (b) the bare MP 







Figure 5.2: MPTM, mounted in the accessory tray slot just below the linac jaw of the 
medical linear accelerator with a prototype version of the MP readout system on the 
head of a Varian linac. MPTM with two possible setup conditions:  (a) the bare MP 
array (sandwiched between black 80µm thick plastic sheets only and (b) the bare MP 











Figure 5.3: The out-of-field (OOF) measurements for (a) MP mounted in transmission 
mode and (b) no MP in place (i.e. open field). The solid water phantom and ionisation 
chamber detector on the linac patient couch were moved laterally from the central axis 
(CAX) position. The phantom size was 60 × 30 × 30 cm
3
 with the lateral movement in 














Figure 5.4: Depth dose measurements at 6 MV.  Depth dose and dose difference 
distributions in a solid water phantom for a 6 MV linac field, SSD 100 cm, with and 
without MPTM for different field sizes on the CAX (a) 10 ×10 cm
2
, (c) 5 ×5 cm
2
; 
and OOF (b) field sizes 10 ×10 cm
2
, (d)5 ×5 cm
2
.The solid circles indicate that the 
response of ionisation chamber when MP was operated in transmission mode and the 










Figure 5.4 shows the depth dose profile of a 6 MV photon beam on the CAX and OOF 
for a 10 × 10 cm
2
 and 5 × 5 cm
2
 field size, respectively, with the bare MPTM (setup (i)) 
mounted in the linac accessory.  
Error bars (where visible) represent three standard deviations from the mean. The 
square symbols in each graph show the measured change (plotted separately) in the 
depth dose curve (DDC) caused by the MPTM in the beam.  
Figure 5.4(a, c) demonstrate that the perturbation effect of the radiation beam by MPTM 
is negligible.  The change in the surface dose with the MPTM placed in the beam was a 
reduction of 0.0751 cGy (0.2270 %) for 10×10 cm
2
 and an increase of 0.1553 cGy 
(0.6125 %) for 5×5 cm
2
 field sizes. For all depths investigated, the maximum measured 
change in the absolute dose was a reduction of less than 0.2839 cGy (0.1647 %) for 
10×10 cm
2
 and 0.2769 cGy (0.2363 %) for 5×5 cm
2
 field sizes. The majority of the 
change occurs within 5 mm of the surface.  The measured changes in the CAX dose at 
any depths with MPTM in a beam were less than 1% of the equivalent open field value. 
The similar experiments on the 6 MV beam using the MPTM with additional 1 mm 
build-up showed an increase of the surface dose 0.9776 cGy (2.9554 %) for 10×10 cm
2
 
and 0.1001 cGy (0.3910 %) for 5×5 cm
2
 field sizes. 
In the case of the OOF, the effect of the MPTM on radiation field perturbation is greater 
in terms of percentage change than for the equivalent CAX measurements. In addition, 
the majority of the change occurs within 10 mm below the phantom surface. With 
MPTM placed in the beam, the surface dose increased by 0.1076 cGy (1.4997 %) for 
the 10×10 cm
2
 and 0. 1051 cGy ( 6.2561 %) 5×5 cm
2
 field sizes as shown in Figure 5.4( 
b, d).  The equivalent using the MPTM with an additional 1 mm solid water build-up 
showed 0.8031 cGy (10.8580 %) for 10×10 cm
2
 and 0. 2914 cGy (16.9675 %) for  5×5 
cm
2









Figure 5.5: Depth dose measurements at 10 MV. Depth dose and dose difference 
distributions in a solid water phantom for 10 MV linac field , SSD 100 cm, with and 
without MPTM for different field sizes on the CAX (a) 10 ×10 cm
2
,(c) 5 ×5 cm
2
; and 
OOF(b) field sizes 10 ×10 cm
2
,(d) 5 ×5 cm
2
. The solid circles indicate that the response of 
ionisation chamber when MP was operated in transmission mode and the open circles 







Figure 5.5 shows the depth dose profile  of the 10 MV photon beam on the CAX and 
OOF for 10×10 cm
2
 and 5×5 cm
2
 field sizes with the bare MPTM (setup (i)) mounted in 
the linac accessory.  
Similar to the 6 MV X-ray beam, the perturbation effect of the bare MPTM is small. 
The change in the surface dose by the introduction of the MPTM was a reduction of 
0.3576 cGy (1.5604 %) for 10 cm x10 cm and 0. 1097 cGy (0.7140 %) for 5 × 5 cm
2
 
field sizes.  
From Figure 5.5 (a , c) one can see that for all depths investigated, the maximum 
measured change in absolute dose was less than - 0.9138 cGy (- 0.5778 %) and - 0.3045 
cGy (- 0.2322 %) for the 10×10 cm
2
 and 5×5 cm
2
 field size, respectively. The greatest 
dose change occurs within 7 mm of the surface. The perturbation effect of MPTM on 
the depth dose change in the CAX is less than 1% for all measured depths. A similar 
experiment with 1mm solid water build-up placed above the MPTM showed an increase  
of the surface dose by + 0.3280 cGy (+ 1.4345 %) and + 0.0552 cGy (+ 0.3576 %) for 
10×10 cm
2
 and 5×5 cm
2
 field size, respectively. 
In OOF, the perturbation effect of the MPTM on depth dose distribution is slightly 
higher than for the same dose in a CAX. Most dose change is within 10 mm from the 
surface. The surface dose with MPTM in the beam decreased slightly - 0.0938 cGy (-
1.2412 %) for 10×10 cm
2
 and increased +0.0702 cGy (+ 3.7167 %) for the 5×5 cm
2
 
field sizes. The equivalent experiments using the MPTM with an additional 1 mm build-
up showed an increase of the surface dose +0.5858 cGy (+7.5330 %) and +0. 3749 cGy 
(+20.2024 %) for 10×10 cm
2
 and 5×5 cm
2










Figure 5.6: Depth dose measurements at 18 MV. Depth dose and dose difference 
distributions in a solid water phantom for 18 MV linac field, SSD 100 cm, with and without 
MPTM for different field sizes  in CAX (a) 10 ×10 cm
2
,(c) 5 ×5 cm
2





. The solid circles indicate that the response of ionisation chamber 
when MP was operated in transmission mode and the open circles indicate the response of 






Figure 5.6 shows the depth dose profile  of an 18 MV photoneutron beam on the CAX 
and OOF for  10×10 cm
2
 and 5×5 cm
2
 field sizes with the bare MPTM (setup (i)) 
mounted in the linac accessory.  
As for 6 MV and 10 MV X-ray beams, the perturbation effect of the bare MPTM is 
small.  The change in the surface dose by the MPTM was - 1.8991 cGy (- 6.3814 %) for 
10 ×10 cm
2
 and - 0.8535 cGy (- 6.2781 %) for 5 ×5 cm
2
 field sizes.  
 From Figure 5.6 (a, c) one can see that for all depths investigated, the maximum 
measured change in absolute dose was less than + 0.4773 cGy (+ 0.3013 %) and + 
0.3947 cGy (+ 0.2025 %) for the 10×10 cm
2
 and 5×5 cm
2
 field sizes, respectively. The 
most dose change occurs within 10 mm from the surface. The perturbation effect of 
MPTM on depth dose change in the CAX is less than 1% for all measured depths. A 
similar experiment with 1mm solid water build-up placed above the MPTM showed an 
increase  of surface dose of -2.4356 cGy (-8.1842 %) and -1.0862 cGy (- 7.9895 %) for 
10×10 cm
2
 and 5×5 cm
2
 field size, respectively. 
In OOF, the perturbation effect of the MPTM on depth dose distribution is slightly 
higher than in a field. Most dose change is within 10 mm of the surface. The surface 
dose with MPTM in the beam slightly decreased by 0.3169 cGy (-3.4432 %) for 10 ×10 
cm
2
 and decreased by 0. 04476 cGy (-1.9931 %) for the 5×5 cm
2
 field sizes. The 
equivalent experiments using the MPTM with additional 1 mm build-up showed a 
decrease in  the surface dose of  0.1804 cGy (-1.9631 %) and an increase of 0. 08228 
cGy (+3.6623 %) for 10×10 cm
2
 and 5×5 cm
2










Table 5.1: Summary of the Percentage Depth Dose (PDD) measurements with different 
energies. The change in dose at the surface measured at the central axis (CAX) and out 
of field (OOF) with open fields and an MP field in position. Values measured using an 
original Markus chamber and compared with an Attix ionisation chamber for 6 MV, 10 
MV and 18 MV beam energy at the surface of the phantom. The values are in 
percentage relative to the maximum dose (dmax= 15 mm, 21 mm and 30 mm). The 










Original Markus ionisation chamber  Attix ionisation chamber 













































 10×10 - 0.0375 0.4888 0.0538 0.4015  0.0767 0.4610 0.0485 0.3563 
 
 5×5 0.0776 0.0500 0.0525 0.1457  0.0157 0.1505 0.0312 0.1473 
 
10 
  10×10 -0.1780 0.1640 -0.0469 0.2929  -0.2559 0.1444 -0.0483 0.2428 
   5×5 -0.0548 0.0276 0.0351 0.1874  -0.0720 0.0527 0.0221 0.1195 
 
18 
  10×10 …. …. …. ….  -0.9495 -1.2178 -0.1584 -0.0902 





Table 5.1 summarises the findings of the beam perturbation by MPTM at dmax for all the 
above- presented radiation fields. 
 
Table 5.2: Summary of the response (sensitivity) (two standard deviation) of the MP in 
transmission mode (MPTM). The absolute response (in nano-Coulombs per 100 MU) of 
the central detector (CAX) of the MPTM  located on the central axis of the 6 MV, 10 














Field Size (cm2) 
 
 









































The quantitative absolute response (in nC per 100 MU) of the bare MPTM and the 





 field sizes and beam energies of 6 MV, 10 MV and 18 MV. The data are 
presented in  
 
Table 5.2. As expected 1mm build up is increasing response of the diodes however 
signal is enough in both cases to reliably measure signal with accuracy better than 0.1% 
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(B) Field size 5×5 cm2 
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(C) Field size 10×10 cm2 
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(E) Modulated IMRT beam for  lung tumour 
Figure 5.7: Impact on the measured dose (in percentage difference) by Delta
4®
 phantom for a 
variety of treatment field configurations. All data shown is with MP in transmission mode (bare 
MPTM or MPTM with 1 mm build up) comparison with no MP in place (i.e. open field). 
 
 
5.3.2 The influence of the MPTM on the beam quality using Delta4®system 
Figure 5.7 shows the effect of having the MPTM system in place on the measured 2D 
dose mapping by the Delta
4®
 phantom diode array for a range of treatment field 
configurations. All data presented here is with the MP in transmission mode (the bare 
MPTM or MPTM with 1 mm build up) with the data compared to the open field 
configuration with no MPTM in place. The measured changes in percent difference 
across the entire Delta
4®
 detectors have been displayed in (Figure 5.7). In the case of the 
bare MPTM the measured change in-field in percent difference averaged over all 
Delta
4®
 detectors (two standard deviation) were ±3.24%, ±2.77%, ±1.97%, ±2.75% and 






, the beam segments and modulated IMRT 
field configurations, respectively for 6 MV photon beam. A similar experiment with 
1mm solid water build-up placed above the MPTM showed that the in-field measured 
change in percent difference (two standard deviation) were ±3.47%, ±0.62%, ±2.05%, 






, the beam segments and 





Gamma analysis was performed using 3% and 3mm criteria. By comparing the planned 
dose to the delivered dose a plan will fail the criteria if <90% of all data points have a 
gamma index ≤1. Gamma analysis criteria (±3% dose deviation, ≤3 mm distance to 
agreement and ≤ 1 gamma index) for both MPTM setups (i and ii) and open field for all 
configurations of delivered radiation fields was carried out based on comparison of 3D 
doses reconstructed by the Delta
4®
 system in comparison with 3D dose predicted by the 
TPS. The gamma index gave 100% (90%) pass criteria for all treatment configurations. 
Hence, showing this gamma threshold was not sensitive to the inclusion of the bare 
MPTM or MPTM with 1 mm build up. 
 
Table 5.3: Gamma analysis output of the Delta
4®
 system for a variety of field size 
configurations. All data shown is with MP in transmission mode (bare MPTM or 
MPTM with 1 mm build up) comparison with no MP in place (i.e. open field). Gamma 
analysis criteria used was ((80%) with ±3% dose deviation, (90%) with ≤3 mm distance 
to agreement and (90%) with index ≤ 1 gamma index). 
Field Size 
(cm2) 
Beam statistics Open field 
 
MPTM field-  
no build up 
 
 
MPTM field-  




83.7 % (80 %) 83.5 % (80 %) 88 % (80 %) 
Distance to 
agreement 
100 % (90 %) 100 % (90 %) 
 
100 % (90 %) 
 
Gamma index 





89.5 % (80%) 91.1 % (80 %) 93.4 % (80 %) 
Distance to     
agreement 
100 % (90 %) 100 % (90 %) 100 % (90 %) 
 
Gamma index 





97.8 % (80 %) 97.8 % (80 %) 97.6 % (80 %) 
Distance to 
agreement 
100 % (90 %) 100 % (90 %) 100 % (90 %) 
 
Gamma index 






Table 5.3 shows gamma analysis criteria (±3% dose deviation, ≤3 mm distance to 
agreement and ≤ 1 gamma index) for both MPTM setups (i and ii) and open field which 
was measured by the Delta
4®
 system compared with the TPS. The data indicated that 
both versions passed the standard clinical gamma analysis. The numbers outside of the 
brackets are the percentage of data points which fall within the criteria specified for 
each histogram (i.e. points with a dose deviation of less than 3%, points with a DTA of 
less than 3 mm and points with a gamma index of less than 1). The number inside the 
brackets is the tolerance that has been specified for that particular beam to "pass". Both 
the limits for each metric and the percentages can all be specified within software. By 
analysing this way, a measured beam will not fail if the vast majority of points pass, but 
a small number does not; this is actually quite helpful for beams which traverse the 
couch on an oblique angle. 
 
5.3.3 The transmission factor measurements 
The transmission factor related to the dose change at dmax and 10 cm depth in a solid 
water phantom for two field sizes (10x10 cm
2
 and 5x5 cm
2
) for 6 MV, 10 MV and 18 
MV energy beams were measured and are presented in Table 5.4. Transmission factors 
at dmax and a depth of 10 cm were all within 1.630 % of open field. This result increases 
the rigidity and potential life-time reliability of the MP system. In the case of 
transmission detectors, both the IQM system and the DAVID system attenuate a 6 MV 
photon beam by 7% while the COMPASS system reported a 3.3 % beam attenuation, 





 system attenuates the beam up by to 1% [7] 
whereas a maximum of 11% increase in the surface dose has been reported for the IBA 
Dolphin
TM





The transmission characteristics for 6 MV photon beam using different treatment 
configurations for both MPTM versions in comparison with the open field configuration 
was measured by Delta
4®
 system at isocentre by finding difference in signals measured 
by all corresponding diodes in a field . In the case of the bare MPTM the measured in-
field transmission factors (two standard deviation) were 0.9902 (±3.24%), 0.9931 







, the beam segments and modulated IMRT field configurations, 
respectively for 6 MV photon beam. 
 A similar experiment with 1mm solid water build-up placed above the MPTM showed 
that the in-field measured transmission factors (two standard deviation) were 0.9835 
(±3.46%), 0.9829 (±0.62%), 0.9850 (±2.04%), 0.9863 (±3.38%) and 0.9873 (±3.1%)  






, the beam segments and modulated IMRT beam 
configurations, respectively for 6 MV photon beam.  
These transmission characteristics measured are similar to those measured by an 













Table 5.4: The transmission factor (two standard deviations) at depth of dmax and at 
depth of 10 cm for 6 MV, 10 MV and 18 MV energy beams. The Farmer ionisation 





         At depth of maximum dose                      At depth of 10 cm 
Energy 
(MV) MPTM field- no 
build up 
MPTM field- with 
1mm build up 
  
 
MPTM field- no 
build up 
MPTM field- with 

































































































Two potential operational set-up conditions of the MPTM were considered to 
investigate the perturbation of the radiation field, the first with a Magic Plate covered by 
a thin 80 m layer of light protection plastic and the second with an additional 1mm 
solid water build-up on top of the MPTM. The 1mm solid water build-up was 
introduced to reduce the sensitivity of the MPTM response to contamination electrons 
from the source and scattered from the jaws, thus making correlation with the energy 
fluence less challenging.  
Results suggest that for the majority of the radiation fields studied, the electrons 
produced from the interaction of the 6 MV and the 10 MV photons with the jaws are 
scattered. Most of these electrons are peaked forward and located close to the jaw 
surfaces, minimising any contribution to the centre of the 10 × 10 cm
2





phantom surface. This is supported by the increase in the relative surface dose when 
adding a 1mm solid water slab above the MP which acts as a build-up for photons and 
an attenuator of scattered low energy electrons. However, in the case of a 5×5 cm
2
 field, 
the role of electrons scattered from the jaw to the centre of the field is significant. This 
is supported by a small change in the relative surface dose caused by the addition of the 
1mm slab above the MP. This effect is a combination of the attenuation of the low 
energy electrons scattered from the jaws and the generation of electrons from direct 
photon interactions within the 1mm solid water build-up.  
It was demonstrated that the OOF surface dose enhancement produced by a 1mm build-
up was greater than when the bare MPTM was used. This result is consistent with the 
CAX measurements and supports the radiation field perturbation interpretations on the 
CAX. The CAX and OOF dose with depth with the bare MPTM (Figure 5.4 to Figure 
5.6 ) in place shows that the MPTM has negligible effect otherwise for all investigated 
fields and photon energies. The depth dose distribution perturbation is less than 1% at 
any depth less than 10 cm in a solid water. Perturbation factors at dmax and at a depth of 
10 cm were found to be less than 1.63 % of the open field for all energies tested. The 
MPTM therefore produces very minimal distortion of the field and skin dose, both in 
field and OOF. Monte Carlo simulations are required for a detailed explanation of the 




The impact of the black plastic sheet and the 1mm of solid water on the changes in the 
skin dose and full PDD have been investigated. The results showed that in general, both 





detector. However, if the surface dose considered as an important factor to be 
considered for the cancer treatment, then the bare MPTM proved to be the best 
candidate as the increase to the surface dose was the least of the two systems tested. 
It has been demonstrated  that at 6 MV, 10 MV and 18 MV the MPTM in the beam 
minimally perturbs the radiation field both in a field and out of field, leading to a < 0.5 
% increase in dose at the surface relative to dose at dmax and <1% in depth of the 
phantom.  This change is minimal and within any dosimetry budgeted error, while 
potentially allowing for real-time verification of VMAT and IMRT during patient 
treatment. Further chapters will be directed to the conversion of the response of MPTM 






CHAPTER 6                                                
Characterisation of the Magic Plate in 
Transmission Mode (MPTM) 
This chapter describes the characterisation of the radiation response of a silicon diode 
array called the MP when operated in transmission mode (MPTM). This mode of MP 
operation is designed to be used to verify the dose from IMRT and VMAT treatment 
delivery, in real-time and during patient treatment delivery by measuring the equivalent 
of the 2D energy fluence map of the modulated radiation beam. 
 
6.1 Introduction 
Energy fluence measurements can be made and logged using the ionisation chamber 
upstream of the MLC. This combined with comparison of the measured and planned 
MLC leaf positions provides some level of in vivo QA [182]. However, there is no 
direct measurement of the 2D spatial distribution of the energy fluence downstream of 
the MLC yet upstream of the patient. 
There are other transmission detectors that have been presented in the literature; the 
IBA COMPASS detector [275], the Integral Quality Monitoring system (IQM) [188], 
the DAVID system [8, 276] and more recently the IBA dolphin online treatment 
monitoring. All these detectors are ionisation chamber based except the IBA dolphin 





the surface dose and some can only provide online treatment evaluation after each 
fraction; not in real-time [194]. 
The MP system is designed so as to be able to make measurements representative of the 
energy fluence from which the dose can be reconstructed and compared with the 
planned patient treatment dose. If this can be done in real-time, the feedback would lead 
to a very high level of QA in cancer treatment delivery.  
This chapter describes the performance characteristics of a 2D silicon detector array 
system that have been developed, when operated in transmission mode to monitor the 
fluence during patient treatment for real-time QA of megavoltage photon radiotherapy 
on a medical linear accelerator using three different energies 6 MV, 10 MV and 18 MV. 
Characterisation of this detector in transmission mode is essential and must be carried 
out prior to clinical use. 
 
6.2 Materials and methods 
The MP was utilised as a transmission detector by mounting it on the linear accelerator 
head (in the accessory slot) normal to the radiation beam as shown in Figure 3.3.  
In this chapter, the MPTM was sandwiched between black plastic sheets (80 m), to 
minimise light leaking on the detector. The MP detector array is located on the linac 
accessory slot, and is 58 cm from the linac X-ray source. The source to detector distance 
(SDD) of 58 cm indicates the position of MP when used as a transmission detector, 
attached to the linac’s accessory slot. Prior to any measurements by the MPTM detector 






6.2.1 Linearity measurement  
Measurements were performed in free air geometry at 58 cm SDD. A single diode 
located at the central axis was used to evaluate the response linearity of the MP for 
10×10 cm
2
 field size. The setup was irradiated with 6 MV photon beam from 1 to 800 
MUs delivered with 75 MU/min, 150 MU/min, 300 MU/min, 600 MU/min  repetition 
rates. 
 
6.2.2 MPTM Detector Reproducibility 
The reproducibility of the MPTM signals was investigated. The setup was field size 
20×20 cm
2
 and irradiated with 6 MV, 10 MV and 18 MV beam energies. The detector 
was irradiated six times with a constant number of MUs, in our case both 100 MU/min 
and 600 MU/min dose rates. The average response for each detector element across the 
entire 2D array was calculated and the percentage standard deviation obtained. The final 
result is then displayed as a response distribution.  
 
6.2.3 Effect of scattered electrons on the MPTM response 
To investigate the effect of the MLCs on the MPTM response a systematic study of 
square fields defined by the linac jaws with either the MLC fully retracted or matching 
the jaws has been studied. This investigation was carried out for field sizes ranging from 
1×1 cm
2
 to 40×40 cm
2
. The transmission mode measurements were performed in free 
air geometry with the MP positioned at 58 cm SDD. The MPTM was sandwiched 
between black plastic sheets, 80 µm thick or with a thin passive contamination electron 
filter (1 mm solid water). The SDD of 58 cm indicates that the position of the MP when 





linac utilised. For this study only the response of the diode located on the central axis of 
the linac beam was used.  
 
6.2.4 The response of the array with different frequency pulses 
For this setup, the MP was placed in transmission mode and the dose rate range used 
(100-600) MUs/min; 100 MUs were delivered.  The field size was 10 ×10 cm
2
 at 100 
cm SSD and MLC was matching the linac jaws. The setup was irradiated with 6 MV, 10 
MV and 18 MV beam energies. The total time required to deliver 100 MUs was 
recorded by the CMRP MP readout system.  
 
6.2.5 Energy response measurement 
To study the energy response of the MPTM, the 2D array was irradiated with energies 
of 6 MV, 10 MV and 18 MV and 100 MUs were delivered each time. Measurements 
were performed in transmission mode. All diodes across the array were used to evaluate 
the energy response of the MP for 40×40 cm
2
 field size. 
 
6.2.6 MP in transmission mode versus full scatter conditions 
The effect of back scattering from the patient and/or a phantom on the MPTM response 





 were analysed. The response from a single row of MPTM detectors passing 
through the central axis of the 6 MV radiation field with and without a phantom which 
centered at the isocentre in place was investigated. The phantom was used to mimic the 








6.3 Result  
 
6.3.1 Equalisation 
Figure 6.1 (a, b and c) shows the flat field correction statistics of MP121 response 
before and after the equalisation was applied (see section 3.4). The differential response 
is calculated according to Equation (3.1). 
 
   
(a)  (b)  (c)  
   
(d)  (e)  (f)  
Figure 6.1 : (a, b, c) The MP response before and after the equalisation applied for 
different energies (6 MV, 10 MV and 18 MV), (d, e, f) the differential response of 
MP121 after equalisation. MP was placed at depth of 10 cm on the solid water 
phantom, 100 SSD and 20×20 cm
2







The variation in the response of all 121 detectors relative to the average response was ± 
2.708 % (1 SD) and ± 0.151 % (1 SD), ± 2.710 % (1 SD) and ± 0.145 % (1 SD),  ± 
2.693 % (1 SD) and ± 0.1009 % (1 SD) before and after flat field correction for 6 MV, 
10 MV and 18MV  beam energies respectively. Figure 6.1 (d, e and f) shows also the 
differential response of the 2D MP121 after equalisation which was less than ± 0.6% for 
all beam energies mentioned above. 
 
6.3.2 Linearity measurement 
 
  
(a)  (b)  
  
(c)  (d)  
Figure 6.2 :  MPTM response linearity with different dose rate of the central pixel, 
for 6 MV photon beam and 10×10 cm
2





The response of the MPTM  array was found to be linear with clinically useful range of 
1 MU to 800 MU for 6 MV photon beam with different dose rate repetitions range from  
75 MU/Min to 600 MU/Min. The adjusted regression coefficient R
2
 found to be 1 and 
















Figure 6.3: The distribution of the percentage variation (the reproducibility) of all 
121 detectors across the 2D array signals when operated in transmission mode. Field 
size was 20×20 cm
2
 and irradiated with 6 MV, 10 MV and 18 MV beam energies. 






All the 121 pixels, in transmission mode, present a reproducibility better than 1.27% 
(2SD), 1.18 (2 SD) % and 0.40 (2SD) % for 6 MV, 10 MV and 18 MV beams 
respectively as shown in Figure 6.3. 
 
6.3.4 Effect of scattered electrons on the MPTM response 
Part of this chapter focuses on how having the MLCs fully retracted or matching the 
shape of the linac jaws impacts on the MPTM response with photon field size. Such 
information is important in the context of the intended use of the MP array when used in 










Figure 6.4 Normalised response of bare MPTM defined by the jaws only or jaws 
and MLCs for 6 MV, 10 MV and 18 MV beam energies: (a) MPTM with no build 
up and (b) MPTM with 1mm solid water. Lower panels: percentage change of the 
central detector response with field size when the MLCs are retracted compared to 
when the MLCs match the jaws. 
 
 
The 6 MV, 10 MV, and 18 MV radiation fields that were used here are made up of 
photons, electrons, positrons and photo-created neutrons (in the 18 MV case). All data 
has been normalised to the response of the MP detector in a 10×10 cm
2
 field size. The 
central detector response of the MPTM in the both cases (where the MLCs fully 
retracted and MLCs match the jaws) is seen to increase logarithmically with increasing 
field size. Significant differences (> 10%) are observed for both measurement scenarios 
for field sizes less than 2×2 cm
2





being higher than when the MLCs match the jaws in all cases. The position of the 
MLCs (being between the jaws and the MPTM) is the reason for the change in response 
of the MP detector that is observed. The consistent decrease in MPTM response when 
the MLCs are matching the jaws indicates that the MLCs effectively act to reduce the 
amount of scattered radiation (electrons, photons and where relevant, neutrons) that 
reaches the central detector of the MP.  It is envisaged that utilisation of the MLCs (as 
such is the case in IMRT and VMAT where numerous small fields are incorporated in 
the treatment plan) will have a positive impact on the ability of the MPTM to correctly 
reconstruct the dose and discussed more in (section 6.3.4) below. 
 
6.3.5 The response of the array with different frequency pulses 
 
 
Figure 6.5 : The response of MP in transmission mode with changing dose 
rate for 6 MV, 10 MV and 18 MV photon beam , field size 10×10 cm
2
 at 






The MP diode array detector was placed in transmission mode at 58 cm SSD in a 10×10 
cm
2
 beam and irradiated with 100 MU. Figure 6.5 shows the pulse repetition frequency 
and continuous dose rate of MP array when operated in transmission mode. This show 
the detectors and the readout system are not subject to the saturation effects over this 
dose rate range.  
The percentage standard deviation across the array of frequency pulses range from 100 
MU/min to 600 MU/min was 2.384%, 1.711% and 3.325% for 6 MV, 10 MV and 18 
MV respectively. 
 












Figure 6.6: (a, b, c) The distribution of the MPTM response of all 121 detectors 
across the array in different photon energies modes (6MV, 10MV and 18MV). Field 
size was 40×40 cm
2






Figure 6.6 presents the MPTM response with increasing beam energy (6 MV, 10 MV 
and 18 MV beams). The histogram data presented includes the response data for all 121 
diodes in the MP array. The field size was 40×40 cm
2
 at SSD 100 cm, with 100 MU 
delivered at each energy. The sensitivity of the MPTM increases by ~20% when the 
beam energy is increased from 6 MV to 10 MV, however remains almost constant 
(decrease of ~5%) when further increased to 18 MV. 
 
6.3.7 MP in transmission mode versus full scatter conditions 
The response from a single row of MPTM detectors passing through the central axis of 












Figure 6.7: Influence of back scatter on the MPTM response in 2×2 cm
2
 and in 
10×10 cm
2 
field sizes. MP was operated in transmission mode. 
 
 
The phantom was used to mimic a patient and the difference between the two 
measurements (with and without the phantom) in the case of the two field sizes studied 
is shown in Figure 6.7. The variation of the response of the MP detector array elements 
within the radiation field is less than 0.5%. For MP detector array elements outside the 
radiation field varied by less than 3.5%, which is indicative of the small contribution 
that backscattered photons from the phantom, make to the measured response for a 2×2 
cm
2
 field size.  
The MPTM is not design to measure water equivalent tissue dose but rather the MPTM 





energy fluence should be much higher than that scattered from the phantom (mimicking 
a patient) in the field, it was not obvious that this effect will be negligible for the 
MPTM detector array elements in out of the radiation field. The presented results 
quantify and clarify this point by demonstrating that placement of the phantom (patient) 












Figure 6.8 shows also the frequency distribution of the percentage variation across the 
array for the same field sizes when the phantom in place and without. The response of 
MP was not significantly affected by scattered radiation from the phantom for both 






6.4  Discussion and conclusion 
The radiation response and basic characterisation of the MPTM for QA during patient 
treatment delivery was carried out. Variation of the response between the diodes in a 
flat field was ± 0.151 %, ± 0.145 % and ± 0.1009 % after the equalisation technique for 
6 MV, 10 MV and 18 MV energy beam respectively. The dose and dose rate linearity of 
the MP in transmission mode was excellent. The effect of scattered electrons and 
photons from the jaws (and MLCs to a minor extent) which contribute to the central MP 
detector response is different in case of the bare MPTM compared to the case with 1mm 
build up. The 1 mm build-up acts as a passive filter to reduce the scattered low energy 
electron contribution to the MPTM response. The MLCs, when placed so as to match 
the jaws, reduced scatter response contribution from jaws to the central detector for all 
photon energies. The highest efficiency will be expected for the 6 MV photon beam as 
the average energy of scattered electrons is lowest. The effect is more pronounced for 
small fields of 2×2cm
2
 or less. The effect of the scattered electron contribution to the 
response of the MPTM vs field size should be taking into account when MPTM is used 
for photon energy fluence map measurements. 
The percentage variation of the response of in-field MPTM detector array elements for a 
field size of 2×2 cm
2
 and 10×10 cm
2
 with and without the phantom in place was less 
than 0.5%. For array elements outside the radiation field the variation was less than 
3.5%. These results indicate that the backscattered photons from the phantom, make a 
very small contribution to the measured response of the MPTM with field size, 
(particularly in-field). A significant contribution (>10%) would have to be taken into 





It was therefore concluded that this contribution could be ignored in the dose 
reconstruction process. Small contribution that backscattered photons from the 






CHAPTER 7                                                                                
2D Mapping of the 6 MV Photon Fluence and 
3D Dose Reconstruction during Radiotherapy 
Treatment 
This chapter discusses the development of an algorithm that predicts (reconstructs) the 
dose in a homogenous phantom based on the measured 2D fluence map during patient 
delivery and independently of the linac settings. This can be checked against the 




During radiotherapy treatment, reconstruction of the 2D and 3D dose maps for 
comparison with the treatment plan (TP) is significantly challenging. Commercially, 
radiosensitive film technology  can be used for such 2D dose mapping, however no 
comparison with the TP can be made in real time [68]. Electronic portal imaging 
devices, have recently been used for such 2D dose map reconstruction [151, 162, 277, 
278]. The reconstruction procedure however, is not clinically common and is complex 





where the beam attenuation and scatter conditions change continuously as the beam 
rotates around the patient.  
Some QA systems (e.g. ArcCheck and Delta
4®
) reconstruct the 3D dose distribution 
based on sensors inside a phantom placed on the patient couch. However, they require 
the dose distribution calculated by the TPS in the phantom as an input parameter in their 
software for comparison, which detracts from their independence as a QA device [183, 
184]. Independent tools that provide the 3D dose distribution are the OCTAVIUS
®
 4D 
(in a phantom only) and COMPASS transmission detector [185, 279]. New 





[192] and Dolphin [193]) are based on 2D diode or ionisation chamber arrays. These 
systems are advanced in vivo QA dosimetry devices capable of 3D dose reconstruction 
and comparison with TPS after each treatment fraction. The clinical impact of these 
systems, particularly their effect on the skin dose, perturbation of the radiation field and 
accuracy of 3D dose reconstruction, is important. Therefore, real-time, in vivo QA 
devices that are able to provide 3D dose reconstruction in a patient, while being both 
independent of the TPS and non-perturbing of the treatment beam are still required. 
This chapter aims to quantitatively demonstrate reconstruction of the real-time radiation 
dose from the irradiation response of the 11×11 silicon MP detector array operated in 
transmission mode. 
 
7.2 Materials and methods 
Figure 7.1 shows a schematic diagram of the linac with the relevant positions of the MP 
detector (MPTM and MPDM). When mounted in the accessory slot of the linac the 
MPTM (is 58 cm from the X-ray source) and the field size on a MP is 1.72 times 





For the MPTM investigation in this chapter two potential operational set-up conditions 
were studied , (i) The bare MPTM and (ii) the MPTM with 1mm buildup (see Chapter 
5). 
Prior to mounting on the linac head the MP for transmission operation flat field 
equalisation in a phantom of all MP detector elements and readout channels is 
performed (see section 3.4). 
 Figure 7.1 also illustrates the divergence of the radiation field with distance from the 
X-ray source, which obviously must be taken into account when reconstructing the dose 
at any given depth in the phantom from the response of the MPTM detector.   
 
7.2.1 Surface dose and buildup measurements  
The influence of the MPTM detector on the PDD profile and in particular the surface 
dose (both in-field and out-of-field) was first determined. With the MPTM mounted in 
the linac accessory slot, percentage depth dose curves were therefore measured both on 
the CAX and 11 cm OOF as a function of the irradiation field size to a depth of 100 
mm. The  CAX and OOF measurements were performed as described in chapter 5.2.1.  
 
7.2.2 MPTM response as a function of field size 
In the second part of this chapter the MPTM response was therefore investigated for 
different irradiation field sizes that ranging from 5×5 cm
2
 to 40×40 cm
2
. These 
measurements were performed with the radiation field defined by the linac jaws only or 
both the MLC and linac jaws in order to determine the significance of the known 
different electron contamination and photon scattering conditions and the corresponding 
effect these conditions may have on the response measured by the MPTM in the 





SDD which is the standard MPTM accessory position for the two different set-up 
conditions mentioned above.  
 
7.2.3 Dose reconstruction technique using MPTM response 
The radiation field incident on the patient is a complex mixture of Bremsstrahlung 
photons from the target modified by a flattening filter, scattered electrons from the linac 
jaws and MLC and electrons generated in air. All of these components, including their 
dependence on the radiation field size are taken into account by the dose simulation 
engine component of the linac beam model in the TPS. It is possible to convert the 
MPTM response to dose via beam modelling assuming that MPTM does not perturb the 
radiation field downstream. Such a method, is used for transmission-type  pixelated 
ionisation chambers e.g. Dolphin device, and requires complicated algorithms that take 
into account the perturbation properties of the transmission detector, which change with 
the irradiation field geometry.  
Assuming that the MPTM is effectively transparent to the radiation field it is reasonable 
to assume that a direct correlation may exist between MPTM response and the patient 
dose. Ideally this correlation would be independent of field size. In order to empirically 
determine whether a simple conversion factor exists to convert the MPTM detector 
response to dose in the phantom, the dependence of the central detector response, Rc, in 
the 11×11 MPTM detector matrix (also referred to as the (6,6) detector), on the 
irradiation field size was investigated for simple square fields and SSD 100 cm. The 
hypothesis here was that there exists a particular depth in the homogeneous solid water 
phantom for which the response of the (6,6) detector located at 58 cm SSD is 
proportional to the dose and is also independent of field size (i.e. proportionality 





ideally, is the same for all MPTM detector array elements (i,j) and their projected dose 
positions at the SwD. The relationship between the response of the MPTM to the 
projected dose at the SwD on a central axis can be defined as DSwD= α Rc, where α is a 
constant and ideally DSwD (i,j) = α Ri,j, where Ri,j is the response of detector element (i,j). 
It is then possible to find the relation between Ri,j and the dose at any depth, r, in the 
phantom along the projected ray from the centre of the source through the particular 
diode (i,j) using the PDD in water or scaled to the phantom material for a given field 
size. In this case dose at depth r given by (7.1): 
 
 Di,j(r) = DSwD (i, j)  
𝑃𝐷𝐷(𝑟)
𝑃𝐷𝐷 (𝑆𝑤𝐷) 





This approach to 3D dose reconstruction based on point dose information measured by a 





 4D [185] while the experimentally derived dose at SwD point can be 
considered as the dose measured by a “virtual diode”. In a megavoltage photon beams, 
the average energy decreases with increasing distance from the CAX. Such lateral 
energy variation has an influence on the attenuation and scattering properties of photon 
beams at a point located a significant distance away from the CAX and it has to be 
taken into account. This effect is known as off-axis softening and can be explained by 
selective attenuation of photons by the flattening filter. The effect leads to a reduction of 
the PDD at off-axis points. In this case, for non-central axis dose, the reconstruction is 
based on correction of the “virtual diode” reading using a tissue phantom ratio (TPR) 
and correction factor provided in the case of a flattening filter in Tailor et al [281] or 






The validity of this approach to dose reconstruction in a phantom is demonstrated by 
reconstructing the 2D dose at dmax and different depths based on the “virtual diode” 
response for different field sizes followed by comparison with the 2D dose map 
measured on the dmax plane with an ionisation chamber at the same reconstruction 
points. The depth dose measurements and related PDD(r) as a function of field size in 
the solid water phantom were carried out using a Markus chamber. This information is 
not known for a patient and will be part of future studies. Beam profiles and output 
factor measurements at a few depths were separately measured using a Wellhöfer 
Compact ionisation chamber (Model CC13) for each field size and used for dose 
reconstruction  comparison at dmax (i,j) in a phantom according to the equation (7.1). 
 
In addition to the 2D dose distributions reconstructed for several square field geometries 
and depths, an asymmetric multileaf collimator configuration within a 20×20 cm
2 
field 
size has also been reconstructed. In the asymmetric MLC configuration case, the 
reconstructed 2D dose map of the radiation field at dmax was quantitatively compared at 
the same reconstructed sampling points with the equivalent dose map exported from the 
Pinnacle
TM
 dose planning system as well as from directly measured dose profiles at the 








Figure 7.1: Schematic diagram of a typical linac with the various in situ operating 





7.3.1 Surface dose and buildup measurements  
The percentage depth dose profiles shown in Figure 7.2 were measured in the solid 
water phantom, with and without (open field) the MPTM detector array mounted on the 
linac accessory tray. Error bars (where visible) represent three standard deviations from 
the mean. At the phantom surface and on the CAX, the  change in the dose relative to 





 field size respectively.  In the case of the OOF measurements change in the 
measured surface dose relative to dmax with MPTM in position was + 0.054 % and + 
0.052 % for the 10×10 cm
2
 and 5×5 cm
2








Figure 7.2: Measured percentage dose profile  measured (Markus IC) as a function of depth in solid 
water phantom with and without bare MPTM in situ together with the difference between the two 




. A 6 MV photon beam was used 
for measurements in both field sizes. 
 
 
7.3.2 MPTM response as a function of field size 
Figure 7.3(a) shows the absolute response of the central detector of the MPTM (in nano-
Coulombs) located on the CAXs of the 6 MV radiation field, as a function of field size. 
Only the response of the diode located on the CAX of the linac beam was used for this 
chapter since for small field sizes only the central diode is fully exposed to the beam 
due to the divergence of the photon beam (illustrated in Figure 7.1).  
The MPTM was sandwiched between either two sheets of 80 µm thick black plastic 
(triangles) and 1 mm of solid water (dots). The observed decrease in absolute MPTM 
response when the MLC matches the linac jaws is due to the MLCs effectively 





linac. No such decrease is observed for the case where the MP detector is encapsulated 
by 1 mm of solid water, which indicates that the solid water attenuates the bulk of the 
above mentioned contamination electrons. For the case where the MLCs match the linac 
jaws, adding the 1 mm solid water leads to a consistent increase in the absolute response 
of the MP detector for all field sizes. Such an increase could be significant as it 
indicates that the MP response seems not to be dominated by the contamination 
electrons that make up the primary radiation field. The increase is analogous to that 
when approaching electronic equilibrium (the well-known build-up curve observed with 
MV photon fields). One would expect a decrease in the measured response if the 
response was dominated by the component related to contamination electrons and this 












Figure 7.3: (a) Response of MP in transmission mode (MPTM) with different field sizes. MP 
was sandwiched between two sheets of 80 µm thick black plastic or 1 mm of solid water. (b) 
Normalised response of MP in transmission mode together with a Farmer IC measured field 
factor for different irradiation field sizes. (c) Ratio of the measured (Markus chamber) dose at 
several depths and MPTM (with no build up) response for different irradiation field sizes. The 
data has been normalised to 1 for a 10×10 cm
2
 field size at each depth. (d) Ratio of the 
measured (Markus chamber) dose at several depths and MPTM (with 1 mm build up) response 
for different irradiation field sizes. The data has been normalised to 1 for a 10×10 cm
2
 field 
size at each depth. The 6 MV photon beam was used for all measured field sizes. 
 
 
The data in Figure 7.3 (b) has implications for the final intended application of the MP 
when used in transmission mode, which ideally, would be to measure the real-time 
energy fluence so as to be able to reconstruct the dose along rays defined by the line 
emanating from the photon source through each MP detector during a patient treatment. 
In this case, a decrease in the measured response with decreasing field size is to be 
expected. Ideally, the in-field response of the MP would scale with the linac output 
factor. The observed difference between the MP response and the Farmer chamber 





positioned in the accessory mount is in free air geometry. The response of MP is 
therefore significantly affected by the make-up of the primary radiation field which 
includes a significant proportion of low energy scattered electrons created in the linac 
head (jaws etc.) [283, 284] and the influence of the MLCs on the measured response as 
mentioned above.  As such, a scaling or correction (conversion) factor could be used in 
order to reconstruct the dose in vivo from the MP response. This is especially important 
for small field sizes as they are more commonly utilised in modern clinical radiotherapy 
treatments such as IMRT and VMAT etc. On the other hand, it may be possible to find a 
SwD where the MP response better mimics (proportional to) the dose as a function of 
field size. This has been investigated for the fields where the MLCs match the linac 
jaws for the MP detector array (with and without the build-up layer).  
 
7.3.3 Dose reconstruction technique using MPTM response 
Figure 7.3 (c) illustrates the procedure used to determine the Sweet Depth (SwD). The 
ratio of dose measured by the Markus ionisation chamber to the MPTM response, Rc, is 
plotted for 5 × 5 cm
2
 to 40 × 40 cm
2
 irradiation field sizes and normalised to the ratio at 
10×10 cm
2
 field size. This normalised ratio is plotted and produced for various 
measurement depths (between the surface and 15 mm). The Markus IC data used was 
taken with the MLCs matching the jaws and has been corrected for its well-known over 









Table 7.1: The ratio of the measured (Markus chamber) dose at several depths and 
MPTM (with no build up) response for different irradiation field sizes. The data has 
been normalised to 1 for a 10×10 cm
2
 field size at each depth. Ion chamber 




0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 15 mm 
5 0.896 1.058 1.107 1.107 1.113 1.120 1.144 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.130 0.999 0.960 0.955 0.946 0.940 0.921 
20 1.292 1.026 0.958 0.948 0.933 0.922 0.886 
30 1.595 1.099 0.978 0.962 0.936 0.919 0.863 
40 1.857 1.168 1.011 0.991 0.959 0.938 0.876 
 
 
Table 7.1 summaries the ratio of the measured (Markus chamber) dose at several depths 
and MPTM (with no build up) response for different irradiation field sizes. The data has 
been normalised to the deduced ratio for a 10x10 cm
2
 field size at each depth. 
Measurements were performed at SSD 100 cm and 6 MV photon field. One can 
conclude that 1 mm is almost the best candidate sweet depth that shows less dependent 
on field size.   
From Figure 7.3 (c) it follows that the SwD is 1 mm where the response is almost 
independent of field size (<5% for FSs <20 × 20 cm
2
) with the average conversion 
factor for these field sizes being α = 7.3 ± 0.22 x10
-3 
Gy/nC (one standard deviation). 
The 1 mm depth was therefore chosen as the sweet depth so as to best match the main 
application for the MPTM which is with IMRT and VMAT treatments that mostly use 
small field sizes (see Table 7.1).  
The data presented above utilised the response of the central detector (6,6) in the MP 





following results focus on extending the above data to make an assessment of all 121 
detector elements of the MPTM. For example, to reconstruct the dose at dmax for a 
10×10 cm
2
 and 100 MU delivered, the tissue-phantom-conversion factor (TPCF) for 
conversion of the “virtual diode (6,6)” response to dose at dmax (6,6) = 
𝑃𝐷𝐷(𝑟)
𝑃𝐷𝐷𝑆𝑤𝐷
    which 
is 2.361 and then the dose at dmax(6,6) is 2.361 × 7.3x10
-3
 Rc (Gy), where Rc (nC) is the 
MPTM response for the central diode. For different field sizes the TPCF will be 
different but is measured and well tabulated for each linac for the solid water phantom 
used. For non-central axis projections, corrections were considered but insignificant. 
The same conversion factor is then applied to all detector elements (i,j) to reconstruct 
the dose from the response of all in-field MP detector elements at the SwD.  
In the case of the MP with the 1 mm build-up layer Figure 7.3 (d) indicates that the 
SwD is between 1 mm and 2 mm. However, in this case, the field sizes over which the 
MP could be used increases to 30×30 cm
2
. Table 7.2 summaries all the measured dose 















Table 7.2: The ratio of the measured (Markus chamber) dose at several depths and 
MPTM (with 1 mm build up) response for different irradiation field sizes. The data has 
been normalised to 1 for a 10×10 cm
2
 field size at each depth. Ion chamber 




0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 15 mm 
5 0.826 0.974 1.020 1.020 1.026 1.032 1.053 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.165 1.030 0.990 0.985 0.976 0.970 0.950 
20 1.350 1.072 1.000 0.990 0.974 0.964 0.926 
30 1.685 1.162 1.034 1.017 0.990 0.972 0.912 
40 1.932 1.215 1.051 1.031 0.997 0.976 0.911 
 
 
All of the data presented above utilises the response of the central detector in the 
MPTM array (made up of 11×11 detector elements) operated in transmission mode. The 
following results focus on extending the above data to make an assessment of all 
detector 121 elements of the MPTM. Such an assessment is clinically very relevant as it 
is well-known that the contamination electron distribution, photon flux and photon 









 Figure 7.4: (a) 2D response map of the bare MPTM, field size 30×30 cm
2
 at SSD 100 
cm and (b) 2D dose map of MPDM, at 15 mm depth, field size 30×30 cm
2
 at SSD 100 
cm for a 6 MV photon field. 
 
Figure 7.4 (a and b) excellently illustrates the above point, showing the variation of the 
MPTM (the bare MP with no build up) response in the X-Y plane and the response of 
the MP operating in dose mode  at 15 mm depth in a 30×30×20 cm
3
 solid water 
phantom. For both plots a 6 MV photon field was used and the radiation field size 
defined at SSD100 cm was 30 × 30 cm
2
. The fraction of the field cross-section sampled 
by the MPDM is obviously a lot smaller (~10%) than that for MPTM (~40%) due to the 
divergence of the field with distance from the source. Regardless of this the trend 
observed in the MPTM 2D data which shows increase in response as one moves away 
from the centre of the field can also be observed in the MPDM plot.  
Equalization of MPTM is different to MPDM due to different nature of the response of 
the diodes in both modes. The response of the diode in MPTM is proportional to Ѱ 





coefficient in silicon. In a dosimetry mode the MPDM response is driven by secondary 
electrons and is proportional to DwS, where  Dw is the dose to water and S is a ratio of 
silicon -to-water stopping powers for electrons which is almost constant (within in 5%) 
for the electron energies of interest in this thesis work.   
Assuming that at depth of 10 cm the dose to water is uniform taking into account 
scattering radiation as well, equalization will therefore take into account any intrinsic 
difference in the charge collection or sensitive volume size of the diodes, which is 
important for the response in a transmission mode as well. However the effect of slight 
variation of photon energy of the beam out of the CAX on the response of the MPTM is 
not accounted in this equalization that potentially can lead to the error in dose derivation 
in a phantom based on the response of the MPTM.  
However good agreement in the beam profiles measured by IC and derived from the 
MPTM response including the penumbral region at different depths is confirmation of 
appropriateness of the current equalization procedure.  It is possibly due to the effect of 
softer photon fields on the edges of the radiation field which is contributing to   the 
response of the diode in the same way as in MPTM making equalization suitable for 
both MPMD and MPTN modes. Further confirmation of that should be investigated 
further using Monte Carlo simulations and comparison of the response of the MPDM 
and MPTM for the same beams including for 1mm buildup for MPTM. 
The noise in Figure 7.4 (a) and (b) is similarly, within ± 2%, with a tendency of the 
reduced response in a CAX in both cases. Relevant experimental data for MPTM with 1 
























Figure 7.5: Beam dose profiles measured at different depth with CC13 IC in comparison 
with reconstructed profiles from the bare MPTM response dose for all diodes in row 6 
of the MP array: a) depth dmax, c) depth 5cm, d) depth 10cm. The variation for each 
depth shown is for the in-field comparison only. (b) Frequency histogram of the 
variation of measured and reconstructed dose at depth of for in-field points for all field 
sizes tested. Reconstructed dose points can be compared with those experimentally 
measured for field sizes less than about 20×20 cm
2
 only as determined by the current 
size of the MPTM. Error bars are not shown for clarity purposes. 
 
 
Figure 7.5 (a) shows a comparison of the dose profile of the reconstructed point doses at 
dmax(i,j) from the measured Ri,j MPTM data with measured IC (CC13) data for several 
square field geometries along the centre of the field at this depth. To make this 
comparison a correction of the “virtual diode” response at non central axis at depth 1 
mm was taken into account as was mentioned earlier. The observed decrease in the 
reconstructed and measured dose at dmax at the centre of the field with decreasing field 
size corresponds perfectly to the well-known dose reduction (output field factor) since 
for each field size 100 MU was delivered by the linac corresponding  to 1 Gy delivered 
in the centre of a 10×10 cm
2
 field at dmax. 
   
Figure 7.5 (b) shows a frequency histogram of the percentage difference between the 
reconstructed point doses and the measured point doses for all in-field MPTM detector 
elements for all radiation field sizes investigated (over 230 measurement points). For all 
field sizes the in-field point doses reconstructed from MPTM response was shown to 
correlate extremely well to measured point doses with less than 1.24 % variation (1 





MPTM data has been used to reconstruct the dose at several depths in a phantom along 
the projected rays from the source through each MPTM detector element.  
Based on the same MPTM raw data, in  
Figure 7.5 (c) and (d) a comparison of the dose profiles of the reconstructed dose profile 
at a depth of 5 cm and 10 cm in the solid water phantom were shown. Measured IC 
(CC13) data for several square field geometries along the centre of the field (row 6) at 
these depths are shown for comparison. For all field sizes point doses reconstructed 
from MPTM response was shown to correlate extremely well to the measured point 
doses. Accurate 2D dose mapping in a phantom using MPDM was confirmed earlier, 






























Figure 7.6: a) Reconstructed and b) planned 2D dose map at depth dmax for a highly asymmetric 
radiation field geometry; (c-m) dose profiles along the lines indicated in (a) and (b) as  planned, 
reconstructed and measured by MPDM in the phantom at dmax .  
 
 
Figure 7.6  demonstrates the application of MPTM for dose reconstruction in the case of 
an asymmetric MLC leaf configuration.  
Figure 6 (a) shows the reconstructed dose map generated at dmax from all MPTM 
detector elements within the 20×20 cm
2
 irradiation field (defined at SSD of 100 cm). 
The equivalent dose map planned using the Pinnacle
TM
 TPS is shown in Figure 7.6 (b). 
 Figure 7.6 (c) -6(m) show profiles of the planned dose in the phantom (red solid lines), 
reconstructed dose in the phantom (blue dots) and measured dose with MPDM in the 
phantom (green squares) along the column numbers indicated in Figure 7.6 (a). The 
CC13 ionisation chamber was not used for 2D dose mapping in a solid water phantom 
for the case of a strongly asymmetric field (Figure 7.6) as the chamber is not suitable for 
small field dosimetry and in any case such 2D mapping would be a very time 
consuming process.  
For most dose profiles good agreement (better than 5%) between the MPDM and the 
planned dose is observed, except for column #7. The column #7 is between blocked and 
non-blocked fields and any small misalignment of MPDM along the leaf direction will 
lead to large discrepancy due to the present MPDM sensor element pitch, which is 10 
mm.  Prediction of the dose profile out of field using the same reconstruction algorithm 







The 6 MV primary radiation field used here is made up of photons, electrons and (to a 
much lesser extent) positrons [286]. The MP detectors are constructed of silicon and 
sense all charged particles traversing the sensitive volume of the detector, whereas their 
sensitivity to photons depends on the interaction cross section [287, 288]. The 
proportion of the three primary field components is well-known to change slightly with 
the field size defined by the linac jaws. Further, minor changes are expected depending 
on the configuration and position of MLC leaves relative to the jaw position due to 
changes in the scattering and shielding conditions resulting from the MLC leaves.  
When the MP is mounted in the block tray the response of the silicon detectors used in 
the MPTM will obviously be determined by the make-up of the primary field 
components. However, due to the active thickness of the silicon detectors being only 50 
µm, one might expect the corresponding response to be less sensitive to the photons (i.e. 
weighted more towards charged particles) within the primary radiation field. The 
electrons directly interact with the silicon detectors whereas the interactions cross 
section for photoelectric, Compton and pair production are not significant in the 
detector volume for clinically relevant (6 MV) photon spectra [288].  
The results obtained in this chapter, represent an exciting development toward real-time 
QA for IMRT and VMAT during treatment delivery using the MPTM.  
 MPTM measurements lead to direct dose derivation at any depth in a homogeneous 
phantom using a “virtual diode” response concept effectively placed in the build-up or 
pre-electronic equilibrium regions. The impact of MPTM on beam perturbation was 
investigated both in-field (central axis) and out-of-field (OOF) for square field sizes 5×5 
and 10×10 cm
2





All data presented demonstrated that the design of MPTM produced negligible 
perturbation of the radiation field reflected in less than 1% skin dose variation and less 
than 0.1% in dose variation below depth 1 cm in -field when MPTM is in a beam. This 
net decrease implies that the additional scatter dose created by having the MPTM 
detector array in beam is not significant.   
For OOF a similar decrease in dose at depth where electronic equilibrium exists was 
measured except at the phantom surface which showed a small increase in dose when 
the MP was placed in the beam. This difference however remains insignificant relative 
to the dose at dmax. While the out of field dose is small one needs to consider it over the 
full course of radiotherapy treatment and it should be minimised as much as possible, 
consistent with the well-known ALARA principle. The small change of the OOF dose 
measured can be attributed to a net increase electron contamination caused by the 
MPTM detector in the beam acting as an extended source.  
It is important to investigate this in more detail (i.e. whether the increase truly is due to 
an increase in electron contamination or a change in the average LET of the 
contamination electrons that traverse the MP detector). All data presented demonstrated 
that the design of MPTM produced negligible perturbation of the radiation field as 
reflected by the < 1% variation of in-field doses measured depth 1 cm when the MPTM 
is placed in the beam. 
The term “sweet depth” (SwD) and the “virtual diode” corresponding to that depth, 
were coined to describe the depth at which the ratio of the central axis MPTM response 
and absorbed dose at SwD in the phantom was approximately constant with field size.  
The SwD that has identified for a 6 MV photon field was found to be at 1 mm depth in 
the phantom for the bare MPTM detector on the central axis. Applying the same 





the dose measured by the “virtual diode” (i,j) and it has been demonstrated that the 2D 
reconstructed dose correlated to within less than ±2.48 % (2 standard deviations) of the 
measured by ionisation chamber 2D dose at dmax in the solid water phantom for all 
square field sizes investigated.  
The well-known effect of energy dependence of commercially packaged silicon diodes 
used for direct dosimetry in a phantom or on a patient is minimised in this method by 
using the transmission response of the MP to reconstruct the dose at any depth in a 
phantom. This has been achieved in the MP design by utilising the “drop in” packaging 
technology, developed at CMRP, which avoids any high Z materials, gold wire bonding 
and thick over layers in contrast to packaging in commercial diodes [289]. Additionally, 
the relative response of MPTM in free air geometry associated with silicon diode energy 
dependence is not changing with an MLC determined field size significantly due to 
minimal change in the photon spectra. This is in contrast to application of silicon diodes 
for direct dosimetry in a phantom, where the silicon diode response is affected by 
photon spectral changes with depth due to the contribution of lower energy scattered 
photons to the dose which increases with increasing depth. 
 The sweet depth could be further refined in the future depending on the desired 
precision and is certainly expected to be different for different linac operating 
conditions (e.g. 10 MV or 18 MV photon fields), which will be the focus of a future 
chapter. 
 Reconstruction of the dose under MLC blocked area using the same method as 
developed for in-field dose is not feasible because the dose under the blocked area is 
determined not only by the leakage through the MLC (as measured by the bare MPTM) 
but also by scattered photons from in-field . This dose depends on the size of the MLC 





easily determined by the response of the MPTM and can be incorporated into a dose 
reconstruction algorithm, similar to what was done in OCTAVIUS
®
 [8]. 
 An attempt was made to reconstruct the dose under MLC blocked regions using the 
same procedure for the in-field reconstructed dose, however differences between the 
reconstructed and measured doses were observed. This difference was 6 % in the case 
of the 5x5 cm
2
 square field at depth of dmax (but 5 mm outside of the field – see  
Figure 7.5 (a)) and up to 50 % (Figure 7.6) for the asymmetric MLC leaf configuration.  
It is clear in the profiles shown in Figure 7.6 (c) – Figure 7.6 (m) that for the 
asymmetric field case our simple analysis breaks down significantly when the MPTM 
detector array elements are blocked by the MLC leaves. A systematic study of the dose 
reconstruction under for fields partially blocked by the MLC leaves will be a part of 
future work.  
The proposed SwD method leads to the corresponding “virtual diode” at particular 
depth in a phantom gives rise to in-field dose reconstruction at any depth for any gantry 
angle during the treatment delivery and this allows application of the MPTM for 3D 
dose reconstruction in a phantom for comparison with TPS using algorithms such as 
those developed for OCTAVIUS
®
 4D [8]. However, OCTAVIUS
®
 4D can be used for 
pre-treatment QA only and requires a cylindrical phantom and a real 2D detector array 
and its synchronisation with a gantry angle. In comparison with existing transmission 
mode detectors placed on a linac head for dose verification during treatment; the MPTM 
is neither perturbing the beam nor increasing the skin dose. The “virtual diode” method 
also leads to a direct, experimentally based, derivation of the in-field depth dose 
distribution for any shape of MLC opening, i.e. independent of any beam model and /or 
TPS having to be utilised in one or another way as required by other transmission 





reconstruction under blocked fields, the separate beam model is required, and this will 
improve the overall 3D dose reconstruction for IMRT and VMAT.  
The proposed SwD method leads to the corresponding “virtual diode” depth allows 
immediate and simple application of the MPTM for 3D dose reconstruction. Using a 
homogeneous virtual solid water cylindrical phantom for IMRT or VMAT delivery, it 
has been shown by OCTAVIUS
®
 4D [185] that 3D reconstruction followed by 
comparison with TPS predicted 3D dose in the same phantom is possible.  
This virtual cylindrical phantom should be placed at SSD =100 cm, and other simple 
corrections should be performed for points not on the central axis of the “virtual 
diodes”. This is distinctly different to the slab phantom used in this thesis. In contrast, to 
the OCTAVIUS
®
 4D QA phantom, the proposed method does not require a physically 
cylindrical phantom with rotated 2D ionisation chamber arrays and their 
synchronisation with the linac gantry rotation. This makes the virtual phantom mode 
QA simple and robust. Due to “virtual diodes” (as opposed to the 2D ionisation 
chamber array inserted in a OCTAVIUS
®
 4D phantom) the proposed system does not 
have a “dead layer” on the surface of the phantom where the dose reconstruction is 
impossible due to the absence of detectors close to the surface (mechanical constraint). 
 Additionally, due to very fast and high dynamic range of the readout electronics, the 
dose reconstructed along the projected rays can be compared to the predicted dose by 
the TPS in pulse-by-pulse or integrated within 200 ms as in case of OCTAVIUS
®
 4D 
for each gantry angle for application during patient treatment. Another advantage is in 
the small size of the diodes in MPTM allowing more accurate reconstruction of the 
point dose along the projection. However, it has been recognised that better spatial 





MPTM is therefore a universal QA tool which could potentially be used for 2D dose 
reconstruction in phantom or for QA during patient treatment and is fully independent 
of the TPS.  
The MPTM combines the advantages of transmission detectors which allow dosimetry 
during the treatment with those of the OCTAVIUS
®
 4D QA tools that provides 
dosimetry based on direct dose measurements in a phantom. In the future is planned to 
extend the 2D dose reconstruction of MPTM to 3D similar to OCTAVIUS
®
.  
Additionally, the same MP can be used for 2D dose mapping mode in a phantom, which 




It has been demonstrated that in a 6 MV linac photon field that the MPTM in the beam 
minimally perturbs the radiation field leading to < 0.1 % increase (relative to dmax) in 
the skin dose to the patient, and does not significantly change the PDD (less than 1% for 
depths below 1.5 cm) for the investigated field sizes, while potentially allowing for real-
time verification of VMAT and IMRT treatments.  
The first stage of development of a dose reconstruction procedure based on the sensing 
of the energy fluence and identifying the Sweet Depth (SwD), and corresponding 
“virtual diode” depth, was successfully completed. Based on the reading of “virtual 
diode” response found empirically, which is in the same proportion for all field sizes 
measured at 1mm depth, the dose map can be reconstructed for each open field and 
compared with the prescribed dose from the TPS. In this chapter it has been 





reconstructed dose correlates with the directly measured dose at dmax to be within ± 2.48 
% (2 standard deviations) for all in-field MP detector elements. 
The small in-field variation measured demonstrates the robustness of the reconstruction 
method of using the MPTM in field data to reconstruct the dose along the projected rays 
from the source through each MPTM detector element at the given depth in the 
phantom. Similar results are obtained for in-field dose reconstruction in an asymmetric 
field.  The reconstructed dose methodology in its current form is more than adequate to 
detect gross errors of in-field IMRT or VMAT radiotherapy treatment during patient 
treatment in real time using in-field MPTM diodes only.  
Determination of which conversion factor to be used for each ray is selected based on 
absolute response of the MPTM diodes. Diodes which are in open fields have 
essentially higher and identical response than diodes under blocked fields.  It will 
provide an open field effective area and selection of the conversion factors for each 
diode in real time pulse by pulse by the fast data acquisition system (DAQ) system.  
Reconstructed in-field and blocked field projected doses for each gantry angle will 
allow 3D dose reconstruction.  
Straight forward application of MPTM for QA on a virtual cylindrical phantom utilising 
“virtual diodes” which have angular independent response for 3D dose reconstruction is 
possible without delay applying similar to existing OCTAVIUS
®







CHAPTER 8                                                                            
Dose Reconstruction in 10 MV and 18 MV 
Radiation Fields  
This chapter extends the work described in the previous chapter to different beam 
qualities commonly used in clinical radiotherapy, namely 10 MV and 18 MV radiation 
fields.  It is important to demonstrate that the MPTM can be used in these radiation 
fields as they differ significantly from 6 MV with the production threshold of 
photoneutrons being surpassed at 10 MV. The impact on the ability of the MPTM to 
operate as a transmission detector in terms of beam perturbation is discussed in the 
context of a QA system for VMAT and IMRT treatment modalities. The methods 
undertaken here are similar to those described in the previous chapter and MPTM 
measurements performed in real-time are used to reconstruct the dose for simple field 
geometries in a uniform phantom. 
 
8.1 Materials and methods 
The divergence of the radiation field with distance from the X-ray source must be taken 
into account when reconstructing the dose at any given depth in the solid water phantom 
from the response of the MPTM. At the position (i.e. in the accessory slot of the linac) 





than that at 102.1 cm SSD, and 1.77 times smaller than that at 103 cm SSD for 10 MV 
and 18 MV beam energies respectively.  
For the MPTM study two operational set-up conditions were tested (i) the bare MP 
array (sandwiched between black plastic sheets, 80 µm thick) (ii) the bare MP array 
with an additional 1 mm of solid water covering the entire array. 
 In addition, the two set-ups were chosen to determine the influence of the unavoidable 
contamination electron component within the linac radiation field on the ability to 
reconstruct the dose from the MPTM response under similar irradiation conditions. 
 
8.1.1 Surface dose and buildup measurements  
The effect of the two MPTM set-ups on the surface dose (both in-field and out-of-field) 
is of primary importance since it is at the surface where the maximum impact of the 
MPTM is expected. Depth dose curves were then measured on the CAX and OOF as a 
function of the irradiation field size to a depth of 10 cm as explained in previous 
chapter. All dose measurements were made with a Markus chamber and Attix ionisation 
chamber in a solid water phantom. The Markus chamber was connected via a triaxial 
cable to a PTW UNIDOS model T10002-20713 electrometer with -300 V bias voltage 
applied. Additionally, the Attix chamber was connected via a triaxial cable to a PTW 
UNIDOS model T10001-11678 electrometer with -300 V bias voltage applied. All 
measurements were repeated at least three times to calculate the average and standard 
deviation. All Markus ionisation measurements were corrected for over response for the 






8.1.2 MPTM response as a function of field size 
 In the second part of this chapter the MPTM response for different irradiation field 
sizes ranging from 5×5 cm
2
 to 40×40 cm
2
 was investigated similarly to that described in 
the previous chapter.  
 
8.1.3 Dose reconstruction technique using MPTM response 
All 10 MV dose measurements as a function of field size and depth in the solid water 
phantom were carried out using the same ionisation  chamber mentioned above under 
the same geometric conditions with the data compared with independent extrapolation 
chamber data (Far West Technology) [285].  
A Wellhöfer Compact ionisation chamber (model CC13) and the Farmer ionisation 
chamber (model NE 2571) were used for complimentary output factor measurements at 
depth of 2.1 cm (dmax) in the solid water phantom. 
The final part of the work presented in this chapter demonstrates the ability of all 121 
pixels of the MPTM (operating under set-up condition (i and ii) mentioned above) to 
reconstruct the 2D distribution of the dose delivered at any depth in the phantom.  
The 2D dose distribution of the radiation field at 2.1 cm depth (dmax) for a 10 MV 
photon field and at 3 cm depth (dmax) for 18 MV beam for field sizes ranging from 5×5 
cm
2
 to 40×40 cm
2
 at an SSD of 100 cm was separately measured using the MPDM in 
the solid water phantom as explained in details in chapter 4.  
As the MPTM is effectively transparent to the radiation field it is reasonable assume 
that a direct correlation may exist between MPTM response and the patient dose and 
this correlation would ideally be independent of field size. The MPTM response may 
then be used to reconstruct the 2D or 3D dose without using any information from the 






8.2.1 Surface dose and buildup measurements  
 
Figure 8.1 shows the  PDD profile for both the (a and c) in-field on the CAX and (b and 
d) OOF for a 10×10 cm
2
 and 5×5 cm
2
 field size respectively with the bare MPTM. 
  




 (c) 18 MV (CAX) (d) 18 MV (OOF) 
 
Figure 8.1: 10 MV and 18 MV percentage depth dose profiles measured using a Markus 
IC (10 MV) and Attix IC (18 MV) as a function of depth in solid water phantom with 





highlight the differences. (a) and (c) are for CAX and (b) and (d) are OOF. The field 
size was 10×10 cm
2
 and 5×5 cm
2
 as indicated. 
 
 
Error bars represent three standard deviations (3 SD) from the mean. The square 
symbols in each graph show the percentage deduced change (plotted separately) in the 
percentage depth dose curve caused by the MPTM. The influence of the bare MPTM is 
insignificant. At the phantom surface and on the CAX, the change in the dose relative to 
dmax with and without the MPTM in position was measured by an ionisation chamber to 
be less than 0.50% for all beam energies tested. In the OOF positions measured, the 
effect of the MPTM on PDD distribution at the phantom surface relative to dmax (21mm 
depth for 10 MV and 30 mm depth for 18 MV) was negligible, < 0.30% for all field 













Figure 8.2: 10 MV radiation field analysis with (a) Response of the MPTM with treatment field 
size; (b) Normalised response of the MPTM together with CC13 IC for different irradiation 
field sizes; (c) Ratio of the measured IC (Markus chamber) dose at several depths and MPTM 
(i.e. no build up) response for different irradiation field sizes. The data has been normalised to 
the 10×10 cm
2
 field size response at each depth; (d) Ratio of the measured IC (Markus 
chamber) dose at several depths and MPTM (with 1 mm build up) response for different 
irradiation field sizes. The data has been normalised to the 10×10 cm
2
 field size response at 












 Figure 8.3: 18 MV radiation field analysis with (a) Response of the MPTM with treatment field 
size; (b) Normalised response of the MPTM together with CC13 IC for different irradiation field 
sizes; (c) Ratio of the measured IC (Markus chamber) dose at several depths and MPTM (i.e. no 
build up) response for different irradiation field sizes. The data has been normalised to the 10×10 
cm
2
 field size response at each depth; (d) Ratio of the measured IC (Markus chamber) dose at 
several depths and MPTM (with 1 mm build up) response for different irradiation field sizes. The 
data has been normalised to the 10×10 cm
2





8.2.2 MPTM response as a function of field size 
Figure 8.2(a) and Figure 8.3(a) shows the absolute response of the central detector of 
the MPTM (in nC) located on the CAX of the 10 MV and 18 MV radiation field 
respectively, as a function of field size. The bare MP was sandwiched between either 
two sheets of 80 µm thick black plastic (triangles) or 1 mm of solid water (dots). 
 The observed small reduction in absolute MPTM response when the MLC positions 
were chosen to match those of the linac jaws is due to the MLCs shielding the MP from 
some contamination electrons created inside the head of the linac. No such decrease is 





which indicates that the solid water attenuates the bulk of the above mentioned 
contamination electrons.  
 
8.2.3 Dose reconstruction technique using MPTM response 
For the case where the MLCs match the linac jaws, adding the 1 mm solid water leads 
to a consistent increase in the absolute response of the MP detector for all field sizes. 
Such an increase could be significant as it indicates that the MPTM response seems not 
to be dominated by the contamination electrons that make up the primary radiation 
field, but rather the primary photons. This has important ramifications for the ability of 
the MP system to deduce the reconstructed dose for complex treatment fields as 
discussed below. 
The MPTM response data has implications for the final intended application of the MP 
when used in transmission mode, which ideally, would be to measure the real-time 
energy fluence so as to be able to reconstruct the dose along rays defined by the line 
emanating from the photon source through each MP detector during a patient treatment. 
A decrease in the measured MPTM response is expected with decreasing field size as it 
is well-known that the linac output monitor units (MUs) must be compensated 
(increased) as the irradiation field size is increased in order to maintain the delivery of a 
given prescribed dose to a target at a given source to target distance. The linac MU 
output factor is used to ensure the dose at dmax is independent of field size. Ideally the 
in-field response of the MPTM would scale with the linac output factor. 
The data in Figure 8.2(b) and Figure 8.3(b) are normalised to the response of the MP 
detector in a 10×10 cm
2
 field size in Figure 8.2(a) and Figure 8.3(a) respectively. The 





using both CC13 chamber for 10 MV and thimble IC for 18 MV at dmax measured with 
the MLCs retracted (crosses).  
The observed difference between the MP response and the OOF observed in  
Figure 8.1(b) and Figure 8.2(b) is to be anticipated as the MP (positioned in the block 
tray) is mounted in a free air geometry. The response of MPTM OOF significantly 
affected by the make-up of the primary radiation field at the position of the MPTM 
which will include a significant proportion of low energy scattered electrons created in 
the linac head [283, 284]. Likewise, the influence of the MLCs on the measured MPTM 
response is expected to be more significant OOF. 
For in-field elements of the MPTM array a simple conversion factor could be used in 
order to reconstruct the dose during patient treatment from the MPTM response. It may 
also be possible to find a SwD where the MPTM response is proportional to the dose as 
a function of field size, which could be different from that found for the 6 MV case. 
This has been investigated for the fields where the MLCs match the linac jaws for the 
MPTM detector array (with and without the build-up layer).  
Figure 8.2(c) and Figure 8.3 (c) show the dose measured by the Markus and Attix ICs at 
various depths divided by the MPTM response (without the 1 mm solid water cover). 
The dose values were obtained for irradiation field sizes between 5×5 cm
2
 and 40 × 40 
cm
2
. The Markus and Attix ICs data used were taken with the MLCs matching the jaws.  
Table 8.1and Table 8.3 show the ratio of the measured (Markus &Attix chambers) dose 
at several depths and the bare MPTM (without build up) response for different 
irradiation field sizes. 
If one focuses on using the MPTM in the block tray position for small field irradiation 





SwD appears to be between 1 and 2 mm, but only if the application is restricted to field 




Table 8.2 and Table 8.4 show the ratio of the measured (Markus &Attix chambers) dose 
at several depths and MPTM (with 1mm build up) response for different irradiation 
field sizes. In this case the MPTM with the 1 mm build-up layer as shown in Figure 
8.2(d) and Figure 8.3(d) indicate that the SwD is 2 mm. The data also indicates that the 







Figure 8.4: (a) 2D response map of MPTM, field size 40×40 cm
2
 at SSD 100 cm and (b) 
2D dose map of MPDM, at 21 mm depth, field size 40×40 cm
2
 at SSD 100 cm for a 10 








Figure 8.5: (a) 2D response map of MPTM, field size 40×40 cm
2
 at SSD 100 cm and (b) 
2D dose map of MPDM, at 30 mm depth, field size 40×40 cm
2
 at SSD 100 cm for an 18 
MV photon field. 
 
Figure 8.4 and Figure 8.5 illustrates the above point very well, showing the variation of 
the MPTM response (in nC) in the X-Y plane for a 40×40 cm
2
 field size at SSD100 
together with the response (in nC) of the MP operating in dose mode at 21mm and 30 
mm depths for 10 MV photon and 18 MV beams respectively (MPDM-dmax), in a 
30×30×20 cm
3
 solid water phantom. The trend observed in the MPTM 2D data can also 
observed in the MPDM plot even though the field cross-section sampled by the MPDM 








(a) 5×5 cm2 (b) 10×10 cm2 
  







(e) 40×40 cm2  
Figure 8.6: The beam dose profiles measured by the MPDM were compared with those from 
the CC13 IC and reconstructed doses at dmax 21 mm in case of 10 MV. The SwD used was 1mm 
(bare MPTM with no build up). 
 
 
Figure 8.6 shows a comparison of the dose profile of the measured MPDM, 
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build 
up) with measured IC (CC13) data for several square field geometries along the centre 
of the field at 21mm depth for 10 MV photon beam. The observed offset in the profiles 
is due to the field factor as 100 MU was delivered at each position and the graphs are 
displayed in term of measured dose in Gray (Gy). Excellent agreement exists between 
the two sets of data for all of the field sizes, both in field and out of the irradiation field 
with all MPDM data. The percentage difference between the reconstructed dose and the 
measured dose at the central row (row no.6) for all in field MP detector elements for all 
field sizes was less than 3%, however, for 20×20 cm
2
 field size was 9 % at the edge of 







(a) 5×5 cm2 (b) 10×10 cm2 
 
 








Figure 8.7 shows a comparison of the dose profile of the measured MPDM, 
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build 
up) with measured IC (CC13) data for several square field geometries along the centre 
of the field at 21mm depth for 10 MV photon beam. The SwD depth of 2 mm was 
investigated as well. Results show that the same percentage difference indicated in Fig 5 








(e) 40×40 cm2 
 
 
Figure 8.7: The beam dose profiles measured by the MPDM were compared with those from the 
CC13 IC and reconstructed doses at dmax 21 mm in case of 10 MV. The SwD used was 2 mm 









(a) 10×10 cm2 (b) 20×20 cm2 
 
Figure 8.8: The 10×10 cm
2
 and 20×20 cm
2
 beam dose profiles measured by the 
MPDM were compared with those from the CC13 IC and reconstructed doses at 
dmax (21 mm in case of 10 MV). The SwD used was 1 mm in this case and the 




Figure 8.8 shows a comparison of the dose profile of the measured MPDM, 
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with no build 
up and MLC was retracted) with measured IC (CC13) data for 10×10 cm
2
 and 20×20 
cm
2
 field geometries along the centre of the field at 21mm depth for 10 MV photon 
beam. A SwD depth of 1 mm was utilized in this case. The percentage difference 
between the reconstructed dose and the measured dose at the central row (row no.6) for 
10×10 cm
2 
field sizes was less than 4%, and less than 8% for 20×20 cm
2






(a) 5×5 cm2 (b) 10×10 cm2 
  




(e) 40×40 cm2  
 Figure 8.9: The beam dose profiles measured by the MPDM were compared with 





The SwD that used was 1 mm for field sizes < 10×10 cm
2
 and 5 mm for field sizes 
> 10×10 cm
2
. The MPTM with 1 mm build up was used here. 
 
 
Figure 8.9 shows a comparison of the dose profile of the measured MPDM, 
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with 1mm 
build up) with measured IC (CC13) data for several square field geometries along the 
centre of the field at 21mm depth for 10 MV photon beam. It has been taken into 
account correction of the “virtual diode” response off the central axis at depth 1 mm for 
field sizes < 10×10 cm
2
 and 5 mm for field sizes > 10×10 cm
2
 by implementing an 
additional coefficient to α, which is an inverse distance squared ratio geometry based 
correction coefficient. The percentage difference between the reconstructed dose and 
the measured dose at the central row for all in field MP detector elements for all field 
sizes was less than 3%. However, for 20×20 cm
2














(c) ) 15×15 cm
2








 (f) 40×40 cm
2
 
Figure 8.10: Beam dose profiles measured at a depth of dmax (30 mm for 18 MV field) with the 
PTW thimble IC in comparison with both the measured MPDM and reconstructed profiles from 
the MPTM response dose for all diodes in row-6 of the MP array. The SwD that was used was 1 
mm for field sizes < 10×10 cm
2
 and 6 mm for field sizes > 10×10 cm
2
. The MPTM with no build 
up was used here. 
 
 
Figure 8.10 shows a comparison of the dose profile of the measured MPDM, 





up) along with the measured IC (PTW thimble) data for several square field geometries 























 (f) 40×40 cm
2
 
Figure 8.11: Beam dose profiles measured at depth of dmax (30 mm for 18 MV beam 
energy) with the PTW thimble IC in comparison with both the measured MPDM and 
reconstructed profiles from the MPTM response using all diodes in row-6 of the MP 
array.  The SwD that used was 2 mm for field sizes < 10×10 cm
2
 and 15 mm for field 
sizes > 10×10 cm
2
. The MPTM with 1mm build up was used here. 
 
 
Figure 8.11 shows a comparison of the dose profile of the measured MPDM, 
reconstructed point doses at dmax(i,j) from the measured Ri,j MPTM data (with 1mm 
build up) with measured IC (PTW thimble ) data for several square field geometries 
along the centre of the field at 30 mm depth for 18 MV beam. The correction of the 
“virtual diode” response on the non-central axis has been taken into account by 
implementing a coefficient additional to α which is an inverse distance square ratio 
geometry based correction coefficient. 
Similarly, for the MPTM (no build up device) the correction of the “virtual diode” 
response has been taken into account on the non-central axis at a depth of 1 mm for 
field sizes < 10×10 cm
2
 and 6 mm for field sizes > 10×10 cm
2
 and at a depth of 2 mm 
for field sizes < 10×10 cm
2
 and 15 mm for field sizes > 10×10 cm
2





1mm build up) by implementing a coefficient additional to the α which is an inverse 
distance square ratio geometry based correction coefficient. 
 
 
Table 8.1: Ratio of the (Markus chamber) dose and MPTM (no build up) response for 
different irradiation field sizes, measured at several depths. The data has been 
normalised to that for the 10×10 cm
2
 field size at each depth. Ion chamber 





0 mm 1mm 2 mm 3 mm 4 mm 5mm 10mm 15mm 21mm 25mm 30mm 100mm 
5 0.922 1.138 1.220 1.242 1.263 1.275 1.315 1.337 1.350 1.355 1.356 1.315 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.114 0.980 0.928 0.910 0.899 0.892 0.866 0.854 0.847 0.845 0.844 0.858 
20 1.265 1.022 0.928 0.899 0.879 0.866 0.82 0.803 0.792 0.789 0.787 0.808 
30 1.523 1.113 0.927 0.905 0.874 0.854 0.788 0.760 0.746 0.743 0.742 0.770 
40 1.705 1.186 0.987 0.927 0.890 0.866 0.793 0.764 0.750 0.747 0.746 0.775 
 
 
Table 8.2: Ratio of the (Markus chamber) dose and MPTM (1 mm build up) response 
for different irradiation field sizes, measured at several depths. The data has been 
normalised to that for the 10×10 cm
2
 field size at each depth. Ion chamber 





0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 10mm 15mm 21mm 25mm 30mm 100mm 
5 0.815 1.006 1.078 1.098 1.116 1.127 1.181 1.181 1.193 1.197 1.1989 1.162 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.218 1.072 1.014 0.995 0.982 0.975 0.934 0.934 0.926 0.924 0.923 0.937 
20 1.415 1.143 1.039 1.006 0.983 0.969 0.898 0.898 0.886 0.883 0.881 0.904 
30 1.760 1.287 1.072 1.047 1.011 0.987 0.878 0.878 0.862 0.859 0.857 0.890 







 Table 8.3: Ratio of the (Attix chamber) dose and MPTM (no build up) response for 
different irradiation field sizes, measured at several depths. The data has been 
normalised to that for the 10×10 cm
2
 field size at each depth. Ion chamber 





0 mm 1mm 2mm 3mm 4mm 5mm 6mm 15mm 21mm 30mm 33mm 35mm 
5 0.642 1.010 1.174 1.229 1.270 1.295 1.316 1.413 1.446 1.476 1.483 1.487 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.389 1.172 1.080 1.046 1.022 1.010 0.995 0.933 0.915 0.899 0.894 0.892 
20 1.695 1.321 1.160 1.102 1.058 1.038 1.011 0.904 0.875 0.849 0.844 0.841 
30 2.166 1.556 1.292 1.197 1.126 1.091 1.051 0.887 0.847 0.813 0.807 0.803 
40 2.467 1.703 1.369 1.253 1.1678 1.125 1.076 0.892 0.848 0.814 0.806 0.803 
 
 
Table 8.4: Ratio of the (Attix chamber) dose and MPTM (1 mm build up) response for 
different irradiation field sizes, measured at several depths. The data has been 
normalised to that for the 10×10 cm
2
 field size at each depth. Ion chamber 





0 mm 1 mm 2 mm 3 mm 4 mm 5 mm 6 mm 15mm 21mm 30mm 33mm 35mm 
5 0.537 0.845 0.982 1.028 1.062 1.083 1.1003 1.182 1.209 1.235 1.240 1.243 
10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
15 1.462 1.233 1.137 1.101 1.075 1.063 1.047 0.982 0.963 0.946 0.941 0.939 
20 1.811 1.411 1.239 1.177 1.131 1.109 1.080 0.966 0.934 0.907 0.901 0.898 
30 2.361 1.695 1.408 1.305 1.227 1.189 1.145 0.967 0.923 0.886 0.879 0.875 








Two versions of the MPTM were investigated with the intention of demonstrating the 
optimization of the trade-off between primary radiation field attenuation/scattering and 
best response repress 
entation of the energy fluence.  
The results showed that in general, both versions of the MPTM detector array could 
potentially be used as a 2D transmission detector, however, the MPTM with 1mm build 
up proved to be the best candidate for 10 MV and 18 MV beams. For the same field 
sizes the OOF dose was measured to be insignificant compared to the in-field dose but 
slightly increased at the surface with increasing irradiation field dimensions. The small 
change (<1%) of the in-field surface dose measured can be attributed to a net increase 
electron contamination caused by the MPTM detector acting as an extended source 
when in its operating position within the block tray.  
The best correlation between the measured MPTM 2D response (representative of the 
2D energy fluence) and the 2D dose was coined as the SwD and was characterised for 
both the versions of the MPTM array. The sweet depth that has been identified for a 10 
MV photon and 18 MV fields indicates that the MPTM response data correlates with 
the 2D energy fluence distribution of the modulated radiation beam and the 
reconstructed dose at a given depth within a homogeneous phantom for IMRT treatment 
delivery verification. For all field sizes investigated the deduced in-field 2D dose plan 
correlated very well with the actual in-field 2D dose plan measured in the solid water 
phantom. The sweet depth may be further refined in the future if better precision is 
desired, and is certainly expected to be different for different linac operating conditions 







The new real-time method with the potential to monitor the patient dose during 
treatment has been demonstrated using the MPTM. It has been demonstrated in a 10 
MV and 18 MV linac fields that the MPTM minimally perturbs the radiation field 
leading to < 1 % increase in the skin dose to the patient. The dose can then be 
reconstructed along rays projected from the photon source through each MPTM detector 
element and compared with the prescribed dose from the TPS system. This potentially 






CHAPTER 9                                                           
Conclusion and Future Work 
Over the last 15 years, more sophisticated methods for tailoring the radiation 
distribution to conform to the target and avoid healthy tissue irradiation have come into 
routine clinical use. Methods such as IMRT, VMAT and SABR rely on collimating the 
radiation beam to millimeter accuracy using over 100 independently controllable 
tungsten leaves which are driven by servo-motors to multiple positions at precise times 
during the treatment to shape the radiation beam correctly and thus better optimise 
clinical radiation treatment. 
A sophisticated computer algorithm calculates all the treatment parameters to optimise 
the dose distribution in the patient. A single patient treatment plan may contain 
thousands of treatment parameters defining all of these variables. This complexity 
makes it imperative that processes are in place to check and verify that the parameters 
are correct and that the X-ray equipment delivers the dose accurately.  
As there is a significant need for online detectors to be used during patient treatment a 
2D detector array “Magic Plate” was developed by the CMRP to measure 2D radiation 
dose distributions. 
In this thesis, the MP detector, developed for verification of complex radiotherapy 
treatment plans, was investigated in terms of its operational performance in many 
different irradiation geometries and irradiation beam qualities. An algorithm was 





the linear accelerator during a patient treatment so that it can continuously record a 2D 
map of the radiation dose being delivered for comparison with the intended dose plan.   
Traditionally most verification of a patient treatment plan occurs before the patient 
commences treatment and relies on measuring doses at multiple points in a phantom 
(effectively a plastic dummy patient). This is an intensive task and a significant 
workload for clinical physicists. The assumption is then that all of the subsequent 
patient treatments execute as planned and without differing from the pre-treatment 
verification test. This is generally, a reasonable assumption due to the high levels of QA 
that are applied to all systems involved. However, there is always a very small 
probability that mechanical, electronic, human or data corruption issues could lead to 
inaccurate treatment delivery in subsequent patient treatments. There are many layers of 
safeguards already in place to reduce this risk but the concept of measuring the radiation 
dose distribution every day as it is delivered to the patient is elegant and appealing.    
Using the method developed, the MP detector sits in the radiation path, in transmission 
mode, (MPTM) before the X-ray beam hits the patient and records millisecond by 
millisecond a 2D map of the intensity of X-rays directed at the patient. Because of its 
very thin design there is almost no perturbation to the X-ray beam due to the presence 
of the detector.  
In this thesis, an algorithm has been developed that predicts the dose in the patient 
based on the measured intensity of the X-ray distribution in the beam using MPTM. 
This can be checked against the intended plan and if they disagree the treatment can be 
stopped automatically and immediately. This requires additional interfacing, hardware 
and software decision systems that are not addressed in this thesis. 
The result is a method that could be used to ensure patient treatment safety and accuracy 





improved quality and safety with increased efficiency and automation. Incorporation of 
this system (MPTM system) into an automated daily dose data log could provide a 
higher level of assurance with minimal workload impact for clinicians. 
In transmission mode, two MP operational set-ups were presented in this thesis (the 
bare MPTM and the MPTM with 1mm build up). This thesis involved the assessment of 
the potential of the MP sensor array for small and large X-ray field transmission and 
dosimetry measurements on a medical linac.  
The 2D array of epitaxial silicon based detectors with “drop-in” packaging showed 
properties suitable to be used as a simplified multipurpose and non-perturbing 2D 
radiation detector for radiation therapy dosimetric verification (MPDM) (i.e. in 
dosimetry mode). The broad range of tests performed in this thesis, concluded that the 
2D array is a dosimetrically accurate and sensitive tool and that it can be a useful device 
for QA and verification of clinical radiotherapy beams.  
The output factor of the treatment field and beam profiles in a solid water phantom at 
different depths and different treatment configurations were measured and compared 
with different types of ionisation chambers. Discrepancies are within 1% for all 
measured field sizes and beam energies. The MP measurements were able to be 
extended to smaller field sizes less than 5×5 cm
2
 since the active volume of the MP 
sensors are much smaller than the ionisation chamber. This highlights one of the major 
advantages of the MP detector since the intra-fraction treatment field sizes in clinical 
treatment continue to decrease. The 2D MPDM successfully detected centimeter 
positional movements of the linac secondary collimators. Furthermore, dose profiles 
matched very well with ion chamber measurements. Both in and out of the irradiation 





energies tested has been reported in this thesis. Furthermore, the MPDM detector 
measurements are accurate also in the penumbra region. 
The basic characterisation of the MPTM was performed, including equalisation, 
response linearity, reproducibility, energy response, the response of the array with 
different dose rates, the response of the array as a function of field size, transmission 
factors, and attenuation of the beam by MP, back scattering effect. Discrepancy of the 
response between the diodes in a flat field was ± 0.15 %, ± 0.14 % and ± 0.10 % after 
the equalisation technique for 6 MV, 10 MV and 18 MV energy beam respectively. The 
response linearity of MPTM was excellent (R
2 
=1). The effect of the backscattered 
photons from the phantom to the response of the MPTM vs field size was investigated. 
The percentage variation of the response of in-field MPTM detector array elements for a 
field size of 2×2 cm
2
 and 10×10 cm
2
 with and without the phantom in place was less 
than 0.5%. For array elements outside the radiation field the variation was less than 
3.5%. These results indicate that the backscattered photons from the phantom, make a 
very small contribution to the measured response of the MPTM with field size, 
(particularly in-field). A significant contribution (>10%) would have to be taken into 
consideration in the dose reconstruction procedure. It was therefore concluded that this 
contribution could be ignored in the dose reconstruction process. Small contribution that 
backscattered photons from the phantom, make to the measured response as a function 
of field size. 
The performance characteristics of the MPTM system upstream of the patient were 
demonstrated. Of particular interest is a quantitative study into the influence of the 
MPTM on the radiation beam quality at several field sizes and linear accelerator 
potential differences. The impact is measured through beam perturbation effects such as 





surface dose relative to dmax was measured to be less than 0.5 % for the 6 MV, 10 MV 
and 18 MV energy beams. Therefore, MPTM does not provide a significant increase in 
skin dose to the patient and the PDDs showed an excellent agreement with and without 
MPTM for 6 MV, 10 MV and 18 MV energy beams. Compared to the transmission 
detectors, both the IQM system and the DAVID system attenuate a 6 MV photon beam 
by 7% while the COMPASS system reported a 3.3 % beam attenuation, which are both 





 system attenuates the beam up by to 1% whereas a maximum of 
11% increase in the surface dose has been reported for the IBA Dolphin
TM
 detector.  
Transmission factors measured for both set ups (with different build up) with 6 MV, 10 
MV and 18 MV at a depth of dmax and a depth of 10 cm were all within 1.6 % of open 
field (see section 5.3.3). The effect of both the bare MPTM and the MPTM with 1 mm 
build up on 3D dose distribution in comparison to the open field investigated using the 
Delta
4®
 system and both the MPTM versions passed standard clinical gamma analysis 
criteria. The results indicate that both versions may be suitable for the new real-time 
megavoltage photon treatment delivery QA system under development. However, the 
bare MPTM appears to be the slightly better suited of the two MP versions as it 
minimally perturbs the radiation field and does not lead to any significant increase in 
skin dose to the patient. However, if the surface dose considered as an important factor 
to be considered for the cancer treatment, then the bare MPTM proved to be the best 
candidate as the increase to the surface dose was the least of the two systems tested. 
The photon irradiation response of a 2D solid state transmission detector array mounted 
in a linac block tray is used to reconstruct the projected 2D dose map in a homogenous 





detector elements. A unique diode response-to-dose scaling factor, applied to all 
detectors, is utilised in the reconstruction to demonstrate that quantitatively real-time 
QA during radiotherapy treatment is feasible.   
The development of a dose reconstruction procedure based on the sensing of the energy 
fluence and establishing the sweet depth was successfully completed.  The sweet depth 
that has been identified for different MV photon beams proves that the MPTM response 
data can be used to both correlate with the 2D energy fluence distribution of the 
modulated radiation beam and proportional to the dose at a given depth within a 
phantom. It has been found that the MPTM response is proportional to the projected 2D 
dose map measured at a specific phantom depth, the “sweet depth”. A single factor, for 
several irradiation field sizes and depths, is derived to reconstruct the dose in the 
phantom along rays projected from the photon source through each MPTM detector 
element. It has been demonstrated that for all field sizes using the above method, the 2D 
reconstructed and measured doses agree to within ± 2.48 % (i.e. 6 MV photon beam) (2 
standard deviation) for all in-field MP detector elements.  
Currently several QA devices working in transmission mode for real-time dose 
verification during the patient treatment are available. One of them is Delta
4AT
 
transmission device from Delta 
4
 family products [290]. However this device should be 
used in conjunction with Delta 
4
 pre-treatment QA device and should be first calibrated 
for each particular plan delivery for which 3D dose delivery verified by Delta 
4
. This 
makes device expensive and not independent.  
Recently IBA Dosimetry introduced the transmission device Dolphin which is based on 
array of 1513 ionisation chambers with pitch of 5 mm [193] . The device measures 
photon energy fluence which is used to reconstruct 3D dose in a patient or phantom 





Another transmission QA device is IQM based on transmission wedge type ionization 
chamber which is placed on a linac head [291]. The device is measuring the area dose 
product in real-time during the patient treatment. It is assumed that response of the 
wedge ionization chamber is unique for particular MLC opening size and position. 
While the device provides control of the correctness of MLC opening driven by the TPS 
is not reconstructing the 3D dose independently of the machine.  
All mentioned above transmission devices are not ideally transmitting radiation and 
have different degrees of beam perturbation and increasing the skin dose to the patient.  
The proposed MPTM is very thin and does not perturb the beam, providing 
transmission of 1.6   % of the open field for all beam energies tested and no significant 
skin dose increase < 0.5 %.  
The proposed method of the response of the MPTM to dose in the patient is independent 
of the machine and TPS and is based on a virtual diode (sweet point) response and PDD 
for particular photon energy. It makes this device convenient for independent QA 
during the patient treatment. 
The advantage of MPTM compared to the EPID based system is that the algorithm does 
not need to cater for patient perturbation of the beam or patient motion effects.  
The reconstruction methodology will also be of great interest to the wider oncology 
community as it is applicable to many other forms of radiotherapy including 
Stereotactic Radiosurgery, Stereotactic Radiotherapy, Image Guided Radiotherapy and 
Motion Adaptive Radiotherapy with dynamic multi leaf collimator tracking, where real 
time radiation treatment monitoring through dose reconstruction is very important.  
Future work will be directed to the application of the MPTM for 3D dose reconstruction 
in a phantom for patient relevant plans and its comparison with the TPS and other 
devices such as Delta
4®
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